

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

England & Wales · Charity number 1182637

Details

Other names	CCLG, CCLG: The Children & Young People's Cancer Association, CHILDREN'S CANCER AND LEUKAEMIA GROUP, TEENAGERS AND YOUNG ADULTS WITH CANCER, TYAC
Status	Registered
Legal form	CIO
Registered	2019-03-26
Register	View on the Charity Commission register

Contact

Address	Childrens Cancer & Leukaemia Group Century House 24 De Montfort Street Leicester LE1 7GB
Phone	03330507654
Email	info@cclg.org.uk
Website	www.cclg.org.uk

Activities

Objects: FOR THE PUBLIC BENEFIT, THE RELIEF OF SICKNESS AND SUFFERING OF CHILDREN, TEENAGERS AND YOUNG ADULTS WITH CANCER AND ADVANCEMENT OF EDUCATION IN THE FIELD OF CHILDREN, TEENAGERS AND YOUNG ADULTS WITH CANCER, IN PARTICULAR BUT NOT EXCLUSIVELY BY:(1) THE RELIEF OF SICKNESS AND PROMOTION AND PROTECTION OF GOOD HEALTH BY SUPPORTING RESEARCH INTO THE NATURE, CAUSES, DIAGNOSIS, TREATMENT AND SOCIAL CONSEQUENCES OF CANCER IN CHILDREN, TEENAGERS AND YOUNG ADULTS, AND TO PUBLISH THE USEFUL RESULTS OF SUCH RESEARCH(2) THE RELIEF OF SUFFERING OF CHILDREN, TEENAGERS AND YOUNG ADULTS WITH CANCER AND THEIR FAMILIES AND CARERS, THROUGH THE PROVISION OF INFORMATION AND SUPPORT SERVICES TO THEM(3) THE ADVANCEMENT OF THE EDUCATION OF THE PUBLIC IN ALL AREAS RELATING TO CANCER IN CHILDREN, TEENAGERS AND YOUNG ADULTS(4) THE ADVANCEMENT OF EDUCATION AND CLINICAL PRACTICE BY THE DISSEMINATION OF KNOWLEDGE OF THE LATEST RESEARCH AND BEST PRACTICE AMONGST PROFESSIONALS AND PRACTITIONERS ENGAGED IN THE TREATMENT, CARE AND SUPPORT OF CHILDREN, TEENAGERS AND YOUNG ADULTS WITH CANCER

Activities: We fund and support innovative world-class research and collaborate, both nationally and internationally, to drive forward improvements in childhood cancer. Our award-winning information resources help lessen the anxiety, stress and loneliness commonly felt by families, giving support throughout the cancer journey.

Classification

- **How:** Makes Grants To Organisations, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Children/young People, The General Public/mankind

Geography

- Ireland
- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£4,924,431	£5,417,783	£2,795,200	24
2023-12-31	£9,823,023	£7,651,658	£3,288,552	22
2022-12-31	£8,311,775	£7,773,935	£2,460,897	22
2021-12-31	£5,669,635	£5,400,515	£1,923,057	18
2020-12-31	£3,890,756	£4,048,123	£1,653,937	18

Trustees

Name	Role	Appointed
David Oxnam	Chair	2019-02-01
Andrew Donnelly		2025-09-11
Catherine Anderson		2025-09-11
Dr Angela Polanco		2025-06-13
Dr Angelo Ercia		2025-09-11
Dr Bushra Khawaja		2025-09-11
Dr Hollie Ann Chandler Shears		2025-09-11
Dr Sarah Curtis		2021-04-14
Natalie Sara Agboeze		2025-09-11
Ngozi Yvonne Ayanru		2025-09-11
RACHEL WILCOX		2019-02-01

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

England & Wales - Charity number 1182637

Accounts

Charity Registration No. 1182637 (England and Wales)

Charity Registration No. SC049948 (Scotland)

Company Registration No. CE016951 (England and Wales)

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION
TRUSTEES' REPORT AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2024

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees	David Oxnam (Chair of Board of Trustees) Rachel Wilcox Sarah Curtis Dr Angela Polanco (Appointed 13 June 2025)
Chief Executive	Ashley Ball-Gamble
Charity number	1182637 (England and Wales) SC049948 (Scotland)
Company number	CE016951
Operating name	CCLG
Principal address	Century House 24 De Montfort Street Leicester LE1 7GB
Auditor	Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT
Bankers	HSBC Bank Plc 2-6 Gallowtree Gate Leicester LE1 1DA Scottish Widows Bank Plc PO Box 12757 67 Morrison Street Edinburgh EH3 8YJ CAF Bank Ltd 25 Kings Avenue Kings Hill Kent ME19 4JQ

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
CONTENTS**

	Page
Trustees' report	1 - 12
Independent auditor's report	13 - 15
Statement of financial activities	16
Balance sheet	17
Statement of cash flows	18
Notes to the financial statements	19 - 33

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees of The Children's Cancer and Leukaemia Group, trading as CCLG: The Children & Young People's Cancer Association (CCLG), are pleased to present their annual report and financial statements for the year ended 31 December 2024.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

OBJECTIVES AND ACTIVITIES

The objectives of CCLG as defined in the constitution are:

For the public benefit, the relief of sickness and suffering of children, teenagers and young adults with cancer and advancement of education in the field of children, teenagers and young adults with cancer, in particular but not exclusively by:

1. The relief of sickness and promotion and protection of good health by supporting research into the nature, causes, diagnosis, treatment and social consequences of cancer in children, teenagers and young adults, and to publish the useful results of such research.
2. The relief of suffering of children, teenagers and young adults with cancer and their families and carers, through the provision of information and support services to them.
3. The advancement of the education of the public in all areas relating to cancer in children, teenagers and young adults.
4. The advancement of education and clinical practice by the dissemination of knowledge of the latest research and best practice amongst professionals and practitioners engaged in the treatment, care and support of children, teenagers and young adults with cancer.

The main beneficiaries of the work carried out by the charity are children, teenagers and young adults with cancer and their families in the United Kingdom and elsewhere in the world.

Expert clinical work

CCLG is the UK and Ireland's professional association for all those involved in the treatment, care and research of children and young people (aged 0-25) with cancer. At the end of 2024, our membership had grown to more than 1,800 members. We also operate 'Teenagers and Young Adults with Cancer' (TYAC), a specific membership group for those working with young people aged 13-25 with a cancer diagnosis, which had over 470 members at the end of the year.

We bring together the experts in children and young people's cancer through our professional membership, creating a powerful national network driving progress. Together, we shape better treatment and care—developing guidelines, sharing expertise, offering advice, leading groundbreaking research, and creating essential resources and education for professionals. Our collective expertise sets the standard, advising, influencing, and advocating for excellence locally, nationally, and globally.

We carry out a wide range of activities to support our professional members, including:

- **Special Interest Groups and Member Networks:** Our Special Interest Groups (SIGs) bring together networks of members around specific cancer types, professions or disciplines, and key aspects of treatment and care. Our SIGs develop treatment guidelines, produce good practice guidance and resources to help professionals develop in their careers, develop and run educational opportunities for professionals, create new research projects, undertake quality improvement initiatives, provide networks for sharing best practice and new ideas, and lots more, with the ultimate aim of ensuring the best possible treatment and care for all children and young people.
- **Clinical treatment guidelines:** We develop national clinical treatment guidelines ensuring safe, consistent and standardised care for children with cancer. Where possible, children with cancer are

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

treated on clinical trials. However, the nature of research means that there will not always be open trials for some childhood cancers and using treatment guidelines is vital for ensuring equality of access to what is regarded by national experts as the best possible treatment currently available. CCLG members regularly review guidance and recommendations to cover all of the major children's cancers, including leukaemia. Our guidelines are written by national experts in the field of each tumour type, usually by members of the relevant CCLG Special Interest Group. Guidance and recommendations draw on evidence from international research and treatment protocols, and the aim is to ensure guidance is consistent with the standard of care internationally.

- **Education and professional development:** CCLG develops expert resources to support children and young people's cancer professionals in their careers, as well as providing professional education through meetings, conferences and webinars. We support the next generation of professionals including through our Paediatric Oncology Trainees Group and Early Career Researcher Network.
- **Our member website:** is a vital hub for professionals, providing a wealth of resources and educational opportunities, complemented by our online member community, allowing networking and good practice sharing opportunities beyond group meetings and events.
- **Professional voice for children, teenagers and young adults:** We advise governments and other bodies and ensure that we are represented on important groups or in consultations, for example in the area of NHS commissioning of children's cancer services or the development of NICE quality standards and guidance.

Our members are dedicated to ensuring that children and young people have a greater chance of survival and a better life after treatment.

Information and guidance

We support children and young people with cancer and their families in a variety of different ways:

- We provide trusted information and guidance for children and young people with cancer, their families, and everyone supporting them. Our expertise helps them navigate the challenges of cancer and its impact, offering reassurance and clarity when it's needed most.
- Our free booklets and factsheets, along with videos and our website, are a comprehensive resource for children and young people facing cancer, along with their families. Written by experts, including those with lived experience of children and young people's cancer, our information is reviewed regularly and accredited to the PIF Tick certification, so users can be assured it is trustworthy, and produced using strict quality criteria.
- Our free quarterly magazine, Contact, offers help, support and information for families of children, teenagers and young adults with cancer.
- Our online community provides a 'safe space' for parents of children with cancer to come together and share experiences, ask for advice, and, uniquely, ask expert questions of our professional membership.
- Our website is a comprehensive resource of childhood cancer information, providing a wide range of up-to-date expert information, personal stories and more.

Research

The incredible progress in treating cancer in children and young people is built on decades of dedicated research and clinical trials. Over the last 40 years, this research has transformed survival rates, with more than 80% of children now being cured. CCLG has been at the heart of this progress, driving research and collaboration to improve outcomes.

But there is still more to do. Some cancers remain difficult to treat, and many existing treatments cause long-term and life-changing side effects. We need more research to improve survival rates, develop kinder treatments, and ensure the best possible quality of life for children and young people after cancer.

At CCLG, we fund and support research across the entire cancer pathway—from diagnosis and treatment to patient experience and survivorship. We make sure research meets the real needs of children and young people with cancer, their families, and those who care for them. In 2022, we identified the top 10 priorities for childhood cancer research, shaped by the voices of children, young people, parents, and professionals.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Collaboration is at the heart of what we do. We work with leading researchers and organisations to drive forward impactful studies, ensuring the best projects and brightest minds receive funding. We partner with other charities to maximise investment in research and use our expertise to support smaller charities in funding high-quality studies with real impact.

We lead the UK Children's and Teenage, Young Adult & Germ Cell Tumour Cancer Clinical Research Groups, shaping and overseeing clinical research across the UK. Our Special Interest Groups bring together experts to share knowledge and plan future research.

We create opportunities for discovery. We organise and support scientific meetings, ensuring vital research is shared, discussed, and developed. We empower our professional membership to be actively involved in shaping research. Our Early Career Research Network and dedicated funding for nurses, allied health professionals, and early-career researchers ensure the next generation of childhood cancer experts can continue to push boundaries and drive progress.

Our research strategy sets out our vision for the future of children and young people's cancer research—because every child deserves the best possible chance.

We work to share information about research, including results and outcomes, with the public, including through our popular research blog and a series of webinars on a variety of research topics.

Since 2017, CCLG has been a member of the Association of Medical Research Charities, demonstrating our commitment to funding high-quality, world class research and confirming the high standard of the processes we use to select and fund research.

Policy and advocacy

We use our expertise and influence to make things better. By campaigning and advocating for children and young people with cancer, their families, and the professionals who support them, we're driving change where it matters most.

Working alongside politicians, governments, the NHS, and other organisations, we're pushing for progress and shaping a brighter future for young lives.

We combine our professional membership's expertise along with the voice of lived experience to develop position statements and policy ideas, shape campaigns, and respond to consultations from governments, the NHS, and other bodies about plans, policies, research or services for children and young people with cancer.

We also work in partnership with other organisations to ensure that children and young people's cancer has a strong, unified voice. We are a founding member of the Children and Young People's Cancer Coalition and our Chief Executive is the current Chair. We also contribute to wider policy work where it affects children and young people with cancer, including through our membership of Cancer 52 (the alliance for rare and less common cancers), the Association of Medical Research Charities, the Wales Cancer Alliance, and the One Cancer Voice coalition. Our Chief Executive was invited to be part of the Government's Children and Young People's Cancer Taskforce, working with the Department of Health and Social Care to drive forward improvements in the treatment and care of children, teenagers and young adults with cancer. This work was paused following the change in Government in May 2024, but re-started in early 2025 to support the development of the Government's forthcoming National Cancer Plan.

Early diagnosis

Early diagnosis saves lives. Spotting cancer in children and young people early means better outcomes, fewer long-term effects, and the best chance of survival. That's why we're dedicated to making sure children and young people with symptoms of cancer get a diagnosis as quickly as possible.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

We raise awareness of the signs and symptoms, empowering families and communities to act sooner. For healthcare professionals, we provide tools and resources to support informed decisions about tests and scans. Together, we're working to ensure every child and young person gets the timely diagnosis they need.

We have information about the signs and symptoms of cancer in children and young people, and information and resources for healthcare professionals about diagnosing cancer in children and young people.

During the year we continued to focus on research to generate a new evidence base on how cancer presents in children and young people, as well as the routes to diagnosis, to inform a new national campaign, Child Cancer Smart, which will launch in 2025. Child Cancer Smart will raise awareness of the signs and symptoms of children's cancer, and provide tools for GPs and other healthcare professionals to support them to make timely and accurate referrals.

We measure our success in achieving our objectives in a number of ways:

- Analytics around our health information provision, including the number of information products distributed, website and social media analytics, and user-provided feedback, are used to measure our work in supporting patients and their families.
- The number of members and retention of members, attendance at and written feedback from education days, meetings and conferences, and informal member feedback, are some basic measures used to ascertain how we are supporting the community of professionals we serve through our professional association activities.
- The number of research projects funded and their value, and the outcome of research projects including peer-reviewed papers in scientific journals, and the number of projects that led to further funding from ourselves or another research funder.
- We have now begun developing our new strategic plan, set to launch in 2026. As part of this work, we will consider how we better measure and report on our impact.

ACHIEVEMENTS AND PERFORMANCE

Around 1,800 children (aged 0-14) and a further 2,300 teenagers and young adults (aged 15-25) are diagnosed with cancer each year in the UK. Although overall five-year survival for cancer in children and young people is now over 80%, for some cancers there have not been such dramatic improvements in survival, and even where treatment is successful, many survivors have to contend with life-long and life-limiting side effects. We continue to work towards the four main goals set out in our strategic plan, launched in 2018, and the goals of the TYAC strategic plan, launched in 2019, as detailed below. Highlights of our achievements during the year are set out under each of these strategic goals.

Providing leadership and expertise for the treatment and care of children and young people with cancer

As the UK and Ireland's professional association for those working in the field of paediatric oncology and haematology, CCLG is a leading voice for children's cancer, liaising with community groups, the government and the NHS to influence policies. We use our expertise to improve treatment and care and meet the needs of patients and families. Highlights for 2024 include:

- Our Annual Conference continues to be the key professional event in children's, teenage and young adult cancer. This year we welcomed a record 600+ delegates to our two-day event, providing a unique opportunity for medical, healthcare and research professionals to come together and share news and discoveries.
- The conference featured our second annual Member Excellence Awards ceremony, celebrating the outstanding contribution of members to the work of CCLG and children and young people with cancer. The conference also showcased research, awarding prestigious CCLG Research Awards in a variety of categories recognising world-class, pioneering projects that are helping to break through boundaries and drive forward change in the treatment and care of young cancer patients.
- We held a variety of other educational and networking meetings, virtually and in-person, including a two-day course on neuroblastoma.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

- We continued to produce and update a number of clinical treatment guidelines, ensuring standardised, high quality and evidence-based treatment for all children, particularly in diseases where there is currently no open clinical trial
- Our online member community, CCLG Connect, continued to go from strength to strength, providing a space for members to connect with each other, participate in group activities, share best-practice and research outputs, ask questions and disseminate useful resources.
- Our strategic partnership with Young Lives vs Cancer continued, providing benefits to both organisations. The Chief Nurse role at CCLG is funded by Young Lives vs Cancer, working to provide clinical and health system insight and intelligence to the latter and enhance support for nursing and allied health professionals within CCLG.
- In 2022, in partnership with Young Lives vs Cancer, the Ellen MacArthur Cancer Trust, and Teenage Cancer Trust, we commissioned a ground-breaking piece of research that will build a new evidence base looking at the psychosocial needs of young cancer patients and how the current system supports them. Dartington Service Design Lab, a charity which improves children's outcomes through research, systems thinking and co-design approaches, was commissioned as the research partner. This year, we published the findings of this research and as a result, the four charities launched the North Star, a vision informed by the report that sets out what needs to be accomplished.
 - Every child and young person facing cancer receives care that's tailored to them. They feel informed and in control, and along with their families can make knowledgeable decisions about their care and future. They feel empowered every step of the way, facing no gaps in support or barriers to access. They have everything they need from the beginning of their cancer journey, during treatment and for as long as they need it afterwards.

Following this, CCLG, Young Lives vs Cancer and the Ellen MacArthur Cancer Trust, formed a Collective Impact Collaborative, a collaboration between the charities that will continue to build on the findings of the research and work towards systemic change that will see the North Star come to fruition.

- We launched further modules of our e-learning programme to support the development of multiprofessionals in the early years of a career in children or teenage and young adult cancer services. The full set of nine units will form a foundation course called 'An introduction to cancer in a child, teenager and young adult' and the remaining units will all be available by the end of 2025. The aim is to improve options and access to foundation level learning in a timely way, in a format where learners can choose their own schedule of learning.
- We launched a revised career and education framework for long-term follow-up nurses, representing a significant review of competencies and career progression for highly specialised nursing working in this field. This sits alongside a number of significant career and education support resources and service development and delivery resources published by CCLG and widely used across NHS children and young people's cancer services.
- We launched two new member Special Interest Groups to bring together expert CCLG members with an interest in a particular area of work. Our Physical Activity and Exercise SIG focuses on the benefits of physical activity and exercise for young cancer patients and is working to develop evidence-based guidelines to improve participation in this area. Our 16-18 SIG is focused on the particular challenges faced by this age group as they make the transition for specialist children's cancer services into either teenage and young adult services or adult services.
- We continued to support a number of National Advisory Panels, groups of national experts in particular childhood cancers, to provide expert advice and treatment guidance for difficult-to-treat cases across the UK.
- We launched a number of new opportunities for our professional members to take up national leadership roles that both support their professional development as well as make contributions to key areas of CCLG activity. These include two nursing secondment roles to undertake reviews of key CCLG resources that are widely used by nursing teams across NHS services in the UK, and two Guideline Fellowships that will support our programme of developing clinical treatment guidelines and best practice guidelines for children and young people with cancer.

Improving diagnosis times by increasing awareness

The significance of a delayed diagnosis presents a challenge for primary health care professionals, who are required to triage symptoms that may point to a cancer diagnosis and make appropriate onward referrals.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Many symptoms associated with cancer are non-specific and are seen every day in general practice, whilst a cancer diagnosis is seen infrequently.

Delays in the diagnostic pathway may well lead to more advanced disease at presentation, with subsequent greater risk of death, greater morbidity, and inevitably, distrust of the medical system. There is evidence that tumours presenting in childhood in the UK are larger, at a more advanced stage and require more therapy than those presenting in other parts of Europe. We work to improve diagnosis times for children and young people with cancer. In 2024:

- We continued our programme of research looking at how childhood cancer presents and the pathways to diagnosis, part of our Child Cancer Smart project. This will culminate in a large public awareness campaign, as well as the development of tools for professionals, which will launch in 2025. The aim of Child Cancer Smart is to raise awareness of the signs and symptoms of childhood cancer, and reduce the time taken for diagnosis.
- The Child Cancer Diagnosis Study, a research project funded by the National Institute for Health Research (NIHR) and CCLG, and jointly run by CCLG and The University of Nottingham, moved to the analysis stage, with the outcomes due to be published in 2025. This innovative, nationwide research will give us, for the first time, an accurate picture of the routes to diagnosis and where we can develop interventions to drive improvements.
- We published a paper calling for more research into population screening and targeted surveillance for children's and young people's cancer. The paper calls for prioritisation of research which investigates population screening and targeted surveillance for childhood cancer. Population screening would identify at-risk children, and targeted surveillance would identify changes and enable diagnosis as soon as they develop cancer. Earlier diagnosis could then improve survival rates and quality of life for young people with cancer.
- We played a leading role in running the second Teenage and Young Adult Cancer Awareness Month in April. This collaboration is an opportunity for charities and the young people we support to come together and raise awareness of the unique challenges facing this age group. The theme for this year was 'empowerment', focusing on supporting young people to take control of their healthcare. More than 20 charities took part in the collaboration.

Strengthening our expert information portfolio to support more families of a child with cancer

Looking after a child with cancer can be a scary and lonely experience for families. Our goal is to deliver the right information at the right time and make a positive difference to their daily lives. We continue to be the leading provider of expert-written, award-winning and quality-assured information about all aspects of childhood cancer, from diagnosis to life when treatment has finished. In 2024:

- We continued to provide free information booklets and leaflets to hospitals and directly to families during the year. A number of new publications were produced, and further existing publications were reviewed and revised.
- We produced four issues of our popular magazine, Contact. Feedback on the new format and design, launched in 2021, continues to be overwhelmingly positive, and Contact continues to support families across the UK and around the world.
- We continued our series of online 'research talks' aimed at parents of children with cancer (and the general public), which aim to explore the world of childhood cancer research in an accessible way, with each episode in the series featuring a talk from an expert speaker, as well as the opportunity for attendees to ask questions. Recordings of the webinars are made available on our YouTube channel for those unable to attend the live events.
- Our closed Facebook group for parents and carers of children with cancer, which allows members to seek advice and support from those with similar experiences, and, uniquely, 'ask the experts' through posting questions answered by our clinical membership community, continued to grow, reaching almost 1700 members.
- We successfully passed our annual reassessment for the Patient Information Forum (PIF) PIFTick accreditation for our health information. This quality standard is awarded following rigorous assessment of our information production processes, and demonstrates our commitment to reliable, expert, high-quality health information.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Supporting and funding world-class research

Our aim is to both support and fund world-class research, deepen understanding and foster collaborations across the children and young people's cancer community. Our Research Strategy outlines our plans to fund and support innovative world-class research into childhood cancer and recognises the importance of collaboration, both nationally and internationally, to achieve improvements.

We fund research directly, and work with partner charities to support them to fund the best possible research, using our well-established research funding expertise, experience and infrastructure.

In total, between our own research funding and that of the partners we work with, 29 new research projects totalling around £3.4 million were funded in 2024. Grants awarded cover a wide range of cancer types, projects focusing on different parts of the cancer experience, and covering a range of different types of research.

- Our partnership with The Little Princess Trust continues to go from strength to strength. We support The Little Princess Trust to fund the best quality research, with a focus on finding better, kinder treatments. We provide specialist advice and expertise, as well as run and manage their research-funding programme on their behalf. This partnership helps to minimise duplication, and share expertise meaning that ultimately more money is spent directly on research. During the year, the Little Princess Trust awarded CCLG around £2.3 million to fund innovative new research proposals.
- We funded a series of biological studies pilot grants, in partnership with the VIVO Biobank, to provide pilot funding for early career researchers to undertake innovative projects that will advance our understanding of children's cancers.
- We funded a series of nursing and allied health professional research grants for the first time, supporting key professionals to get involved in research, explore research careers, and undertaken research projects that will focus on the care and experience of children and young people with cancer.
- Other grants awarded in the year include those for research projects focused on late effects, or the long-term consequences of cancer treatment, to improve our understanding of the impact of cancer once treatment ends, and how we can better support survivors.
- We announced a joint research funding call with the Bone Cancer Research Trust, to co-fund a number of research projects into primary bone cancers. This collaboration will allow us to make a significantly larger investment than either organisation would be able to do in isolation, leading to a bigger impact for those diagnosed with bone cancers.
- Following the closure of the National Cancer Research Institute (NCRI) in 2023, we continued to support the vital children, teenage and young adult work previously undertaken by the NCRI, providing a national strategic resource for the development of future clinical research.
- We continued to publish our research blog, aiming to make research understandable and accessible to all those in the childhood cancer community and beyond, including parents, professionals and the general public. The blog shares research concepts and specific projects in an accessible way, raising awareness of both the research we undertake and of cancer research more generally.
- We hosted another Research Discovery Day; to offer valuable insight into the research we fund to families and supporters. Among the attendees were parents of children diagnosed with cancer, survivors and CCLG fundraisers, who were able to hear experts talk about how they're working to improve the future for children with cancer.
- Following the publication of the Top 10 Priorities in Children's Cancer Research, the result of a James Lind Alliance Priority Setting Partnership funded by CCLG and The Little Princess Trust, we commissioned a 'mapping exercise' to understand the landscape of children's cancer research funding in the UK, collecting data on which of the Top 10 Priorities are being addressed and where there are gaps, to help us plan future research investment and ensure all of the priorities are addressed.
- During the year, we began developing our new Research Strategy, which will be published in 2025. We have been keen to ensure that a wide range of stakeholders had the opportunity to input into our strategy, bringing together clinicians, researchers and those with lived experience of children and young people's cancer, to ensure that our future research work meets the needs of all of those groups. As well as considering what research we will fund in the future, the strategy will explore how we can leverage our unique position as a professional association and charity, as well as our convening power and ability to build collaborations, to impact the entire children and young people's cancer research landscape.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Fundraising

All of our work is dependent on the generosity of our supporters. A programme of fundraising underpins our ability to fund research, support patients and families, and improve treatment and care for children and young people with cancer.

Our Special Named Fund programme continued to grow. After their cancer experiences, families sometimes consider setting up their own charity. For many, our Special Named Funds may be a great alternative. We support families to achieve their fundraising objectives, while taking away the administrative burden of setting up and running a charity. At the end of the year, there were approximately 104 Special Named Funds at CCLG (2023: 98), each raising funds to support research into a specific type of childhood cancer.

During the year, we rolled out a new internal fundraising strategy, which aims to ensure we are able to sustain our income growth and continue to deliver on our charitable objectives: funding research, supporting families and ensuring that all young patients receive the best possible treatment and care. The strategy includes investment in fundraising to develop our activity in key areas, as well as building on previous investments in data infrastructure which will allow us to make more strategic, data-driven decisions around fundraising activity.

We are hugely grateful to all those who chose to support CCLG, by making a donation, taking part in an event, or organising their own fundraiser during the year.

Fundraising policy

We are reliant on donations to fund our vital work. Without the generosity of the public, we would not be able to continue providing support to children and young people diagnosed with cancer, and their families, nor fund research into childhood cancer. We believe that it is essential that we are clear and open about how we raise our funds and about the range of ways people can get involved and support our work.

People raise money for us in many different ways, including through taking part in sporting events, organising events in their local community, or fundraising at their place of work. We also provide opportunities for people to fundraise through providing access to places in key events, such as the London Marathon, and through providing fundraising materials. Our supporters can also sign up to make regular donations. We work with a number of corporate partners, and have received support from charitable trusts and foundations, and through grants from other charities. We do not carry out door-to-door fundraising, nor do we use street fundraising to sign up supporters to regular donations.

Currently, none of our fundraising activities are conducted on our behalf by professional fundraising agencies.

CCLG is registered with the Fundraising Regulator. We are committed to adhering to the Code of Fundraising Practice. During the year, we received no complaints about our fundraising activities.

Regular updates are provided to our board of trustees to ensure that they have a good oversight of our activities.

FINANCIAL REVIEW

Transactions for the year ended 31 December 2024 fall into roughly the same categories as in previous years.

Income generally consists of donations and fundraising income, subscriptions (comprising individual membership subscriptions and hospital subscriptions for health information), registration fees for meetings and events, funding from partner charities such as The Little Princess Trust to support research projects, and legacy income. We are grateful to Young Lives vs Cancer, Teenage Cancer Trust and The Little Princess Trust for their support of specific areas of our work.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

The major items of expenditure for CCLG remain staff salaries, professional meeting and event costs, the costs associated with the production of health information, and the awarding of research grants. Staffing costs represent a significant financial commitment, but our small, expert staff team is also responsible for the achievement of the majority of our charitable objectives. Staffing levels are kept under review, with the small, efficient team carrying out and coordinating the considerable activities of the charity.

Our overall income decreased by £3,554,882, compared with the year ending December 2023. The majority of this was due to a reduction in research funding through our partnership with The Little Princess Trust, which was a planned reduction. The Trust has been investing reserves over the course of several years, as well as making strategic investments in specific research programmes (including the Experimental Cancer Medicines Network (ECMC)), and we now expect the income and expenditure through our partnership to remain broadly stable at this level in future years. We saw an increase in donations and legacies of £124,730 over last year, and a slight increase in investment income due to continued high interest rates.

CCLG has a number of restricted funds. Internal records are kept according to requirements for restriction, i.e. disease-specific donations for research into a specific type of cancer, or donations for a specific piece of work. The restricted funds are ring-fenced to support specific projects or areas of activity and cannot be used to support the general running costs of the organisation.

Expenditure decreased in 2024 by £2,233,875 compared to 2023. Again, this mainly reflects a reduction in research funded through our partnership with The Little Princess Trust compared to the previous year.

We ended the year with an overall deficit of £493,352. There was a surplus of unrestricted income of £36,724, compared with a deficit of £530,076 in restricted income and expenditure. This reflects our previous commitment to increasing our investment in research, and the fact the much of our restricted income is restricted to research into specific types of cancer, building over several years until there are sufficient funds available to invest in high-quality, impactful research projects.

Reserves Policy

The trustees continue to consider the appropriate balance of financial stability and investment in charitable activity. The COVID-19 pandemic followed by a period of global economic uncertainty and inflationary pressure has highlighted the importance of an appropriate reserves policy. It is important we continue to hold a level of reserves which can sustain our activity until we have a fuller picture of what the external environment, particularly in respect of fundraising and charitable giving, looks like in the medium-term.

We have plans in place to ensure CCLG is 'fit for the future' and our reserves policy will ensure we are able to meet those plans. At the end of the year, we have reviewed our reserves policy for CCLG and aim to hold a target level of free reserves (unrestricted funds less tangible fixed assets) of £250,000 - £500,000, which the trustees consider to be approximately three to six months of core expenditure, including staff salaries, accommodation costs and general running costs, based on the 2025 budget. This represents a change in our reserves policy from previous years, based on future income and expenditure projections, broadly stable (and more recently increasing) unrestricted income, and provides the flexibility to ensure that the charity can invest in charitable activities. The Trustees consider it prudent to balance the investment of reserves into charitable activity to meet the needs of our beneficiaries and fulfil the wishes of our donors and supporters. Having a reserves policy based on a range rather than a fixed figure, as previously, gives us the flexibility to be more responsive to appropriate opportunities for charitable investment.

Total reserves at 31 December 2024 were £2,795,200 (2023: £3,288,552) of which £2,368,518 (2023: £2,898,594) are restricted and £426,682 (2023: £389,958) are unrestricted. As at 31 December 2024 the charity's free reserves totalled £399,452 (2023: £358,954) which is comfortably within the range set out in the reserves policy. Given the current economic uncertainty, the trustees consider it prudent to balance the investment of reserves into our charitable activity whilst ensuring sufficient funds are available to ensure the charity is a 'going concern' and able to meet its commitments. The Trustees continue to keep the reserves policy under review to ensure that CCLG is 'fit for the future'.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Our restricted reserves appear high, at £2,368,518 at the end of 2024. Much of our restricted fundraising income is raised by families, ring-fenced for research into specific types of childhood cancer. Research requires significant investment, and thus many of our funds grow over the course of several years before a large sum of money is awarded in the form of a research grant. Our restricted reserves comprise a large number of specific restricted funds which are ring-fenced to a specific purpose, and therefore cannot be used for general activities. Levels of funds are reviewed on a regular basis and spent on charitable activities as soon as sufficient funds are available. Our restricted reserves decreased at the end of 2024 compared with 2023, representing our commitment to increase our investment in research, and we expect to see a further decrease at the end of 2025 as we continue to support a wider range of research projects and explore collaborative opportunities with other funders.

Investment policy

The Trustees previously reviewed our plans for investments to consider the most appropriate way of managing these, balancing cashflow, risk and reward. Given the ongoing uncertainty of the financial impact of the COVID-19 pandemic, and the cost-of-living crisis and high inflation, no further action has been taken on investments.

The high interest rates during the year have resulted in increased investment returns in the form of interest on money held in our bank accounts. Management accounts are produced for the trustees, and a cashflow forecast considerably facilitates management and prediction of charity income.

Risk Management

CCLG is also aware of the requirement to carry out a risk review of its activities. The trustees reviewed the risks the charity faces during the year. A Risk Register is in operation, documenting the systems in place to mitigate those risks, and is kept under review by the trustees.

FUTURE ACTIVITIES

All future activities planned are designed to ensure that CCLG continues to fulfil its objectives for children and young people with cancer, and their families, as the ultimate beneficiaries. As the membership of CCLG continues to grow, so does the activity our members are involved in. Our specialist network groups continue to be increasingly active, supporting our activities and providing specialist advice to commissioners of healthcare services and others. The Executive continues to consider ways that CCLG can advance education and professional development, and share and guide best practice.

During 2024, we have been undertaking a number of strategic activities to lay strong foundations for the future of CCLG. These include:

- A review of our two membership bodies (CCLG and Teenagers and Young Adults with Cancer, TYAC) with a view to merging the two into a single, united association for the benefit of all children and young people with cancer. Following the review, carried out with a wide range of stakeholders, it was agreed there were many benefits to this approach, and in November we confirmed with the membership that we would proceed with merging the two memberships in early 2025.
- At the same time, we carried out a piece of work involving a wide range of stakeholders to understand the perceptions of CCLG, including our perceived strengths, weaknesses and potential opportunities for the organisation. Key themes included the value of our expertise, our strength as a convenor and leader of collaborations, our insights into the health system, and our bridge between professionals and patients and their families. The aim of this work was ultimately to build on our strengths, to improve our positioning and storytelling, and to raise awareness of CCLG and our work, with a long-term view of increasing support for and income to the charity.
- This work, along with the pending merger of the two professional bodies, resulted in a decision to rename the organisation and develop a new brand that would fulfil these aims. As a result, we began operating as CCLG: The Children & Young People's Cancer Association from March 2025.
- We continued with previously paused work on developing, building and launching a new website to accompany the new brand launch, and the make a more accessible online platform for patients and their

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

families, as well as those seeking to support CCLG. The new website launched alongside the new brand in 2025.

Key planned activity for the next 12 months includes:

- Launching our new Research Strategy, which will include a focus on how we can have the most impact on the children and young people's cancer research landscape more broadly, by developing collaborations, supporting the research community, and ensuring that people with lived experience are at the heart of children and young people's cancer research.
- Launching a new 'lived experience' strategy, which sets out our commitments to involving people with lived experience of children and young people's cancer in our work, as well as providing a platform for people with lived experience to get involved in research and policy activity not just for CCLG but the wider sector.
- We will launch the first guidelines, clinical decision tools, and public awareness campaigns as part of our Child Cancer Smart programme of work, raising awareness of the signs and symptoms of cancer in children and young people, and equipping healthcare professionals to make quicker diagnoses.
- We will work to increase the range of health information content we provide, increasing the content available for teenagers and young adults with cancer, as well as providing content in alternative formats, including video and digital content, to better meet the needs of our intended users.
- We will increase our policy, advocacy and public affairs activity, working in collaboration with other organisations as needed, to ensure that our considerable expertise is used to influence decision-makers and other key stakeholders, inform governments, the NHS and other key organisations, and ultimately contributes to improvements for children and young people with cancer.
- We will continue to focus on building productive collaborations with other charities where we can share insights, work collectively, co-fund research projects, and otherwise have a bigger impact than we would be able to do working in isolation.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Children's Cancer and Leukaemia Group (CCLG) was established in 1977 and became a registered charity (number 286669) in 1983. In 2019, a new CIO (registration number 1182637) was formed, with the activities, assets and liabilities of the previous charity transferred to the CIO. The charity's governing instrument is the Constitution and the CIO was first registered in February 2019. In 2020, the CIO became registered with the Scottish Charity Regulator (registration number SC049948).

The board of trustees is independent of the CCLG membership. The board of trustees is responsible for ensuring the charity meets its objectives, delivers on its strategy, has oversight of all activities of the charity, and managing the charity. There are a minimum of two and a maximum of twelve trustees.

If a vacancy arises, the trustees may appoint any eligible person as a trustee. In selecting individuals for appointment as trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction to the charity. This consists of a briefing paper, as well as meetings with the Chair, CEO, and others as deemed appropriate. Regard is given to the training and development needs of any trustees that may arise.

The trustees come from a range of professional backgrounds, and bring new skills and highly relevant experience. Trustees serving during the year were:

David Oxnam (Chair of Board of Trustees)
Gayle Routledge (resigned 13 June 2025)
Rachel Wilcox
David Hobin (resigned 31 March 2024)
Sarah Curtis

The Chief Executive is responsible for the day-to-day operation of the charity on behalf of the trustees. The remuneration of key management is reviewed annually and is set against established pay scales, benchmarked in comparison with similar sized entities including both charities and medical professional

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

associations. The trustees give their time freely and no remuneration was paid in the year. Details of trustee expenses are disclosed in note 12 to the accounts.

Key Management Personnel during the year were:

Ashley Ball-Gamble (Chief Executive)
Claire Shinfield (Director of Engagement)
Vicki Brunt (Head of Fundraising)
Sarah Evans (Head of Research)
Phil Welsh (Head of Communications)
Jeanette Hawkins (Chief Nurse)
Jo Stark (Chief Nurse)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales and Scotland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities (Accounts and Reports) Regulations 2008, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- there is no relevant audit information of which the charity's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

DocuSigned by:

29D0B5FD6D7043G.....
David Oxnam
Chair of the board of trustees
Date: 18-09-2025
Date:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Opinion

We have audited the financial statements of The Children's Cancer and Leukaemia Group (the 'charity') for the year ended 31 December 2024 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2024 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the trustees' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- the charity has not kept adequate and proper accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 12, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under these acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charity.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- obtaining an understanding of the legal and regulatory framework applicable to the charity by considering the nature of the industry in which the charity operates and enquiring of management; and
 - identifying the key laws and regulations considered to have a direct impact on the financial statements including the UK Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, UK Generally Accepted Accounting Practice and UK tax legislation; and
 - assessing how the charity is complying with the applicable legal and regulatory framework by making further enquiries of management and observing the charity's control environment regarding compliance with regulations and fraud prevention; and
 - assessing the susceptibility of the charity's financial statements to material misstatement, including how fraud might occur, by considering the effectiveness of the charity's accounting systems and controls and how these were monitored by management. Where the risk of material misstatement was considered to be higher in certain areas, further audit procedures were designed to address this increased risk; and
-

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
INDEPENDENT AUDITOR'S REPORT (CONTINUED)**

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

- discussing amongst the engagement team how and where fraud might occur in the financial statements and any potential indicators of fraud.

Audit response to risks of irregularities identified

Our procedures to respond to risks identified included the following:

- performing audit work over revenue recognition including analytical procedures and substantive tests of detail of a sample of revenue transactions; and
- reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations; and
- enquiry of charity staff responsible for compliance to identify any instances of non-compliance with laws and regulations; and
- enquiry of management, those charged with governance and other relevant parties around actual and potential litigation claims; and
- reviewing minutes of meetings of those charged with governance; and
- performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias; and
- communicating identified laws and regulations and potential fraud risks to all engagement team members and assessing whether there are any indications of fraud or non-compliance with laws and regulations throughout the audit.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008, and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.


Newby Castleman LLP

Chartered Accountants
Statutory Auditor
West Walk Building
110 Regent Road
Leicester
LE1 7LT

19 September 2025

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Notes	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Total 2023 £
Income from:					
Donations and legacies	3	953,823	627,879	1,581,702	1,456,972
Charitable activities	4	463,611	2,809,187	3,272,798	6,966,164
Investments	5	69,931	-	69,931	56,177
Total		<u>1,487,365</u>	<u>3,437,066</u>	<u>4,924,431</u>	<u>8,479,313</u>
Expenditure on:					
Raising funds	6	342,891	51,712	394,603	348,007
Charitable activities	7	1,103,627	3,919,553	5,023,180	7,303,651
Total		<u>1,446,518</u>	<u>3,971,265</u>	<u>5,417,783</u>	<u>7,651,658</u>
Net incoming/(outgoing) resources before transfers		40,847	(534,199)	(493,352)	827,655
Transfers between funds		(4,123)	4,123	-	-
Net income/(expenditure) for the year/ Net movement in funds		36,724	(530,076)	(493,352)	827,655
Reconciliation of funds					
Total funds brought forward		389,958	2,898,594	3,288,552	2,460,897
Total funds carried forward		<u><u>426,682</u></u>	<u><u>2,368,518</u></u>	<u><u>2,795,200</u></u>	<u><u>3,288,552</u></u>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
BALANCE SHEET**

AS AT 31 DECEMBER 2024

	Notes	2024		2023	
		£	£	£	£
Fixed assets					
Tangible assets	14		27,230		31,004
Current assets					
Stocks	15	46,019		55,061	
Debtors	16	3,387,399		5,373,880	
Cash at bank and in hand		4,480,787		5,105,709	
			7,914,205		10,534,650
Liabilities					
Creditors: amounts falling due within one year	17	(3,704,081)		(4,893,819)	
Net current assets			4,210,124		5,640,831
Total assets less current liabilities			4,237,354		5,671,835
Creditors: amounts falling due after more than one year	18		(1,442,154)		(2,383,283)
Total net assets			2,795,200		3,288,552
The funds of the charity					
Restricted funds	20		2,368,518		2,898,594
Unrestricted funds	21		426,682		389,958
Total charity funds			2,795,200		3,288,552

The financial statements were approved and authorised for issue by the board of trustees on 18-09-2025 and are signed on its behalf by:

DocuSigned by:

David Oxnam

David Oxnam (Chair of Board of Trustees)

Trustee

The notes on pages 19 - 33 form part of these financial statements.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Note	2024		2023	
		£	£	£	£
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	26		(689,399)		1,026,714
Investing activities					
Purchase of tangible fixed assets		(5,454)		(2,592)	
Investment income received		69,931		56,177	
Net cash generated from investing activities			64,477		53,585
Net cash used in financing activities			-		-
Net (decrease)/increase in cash and cash equivalents			(624,922)		1,080,299
Cash and cash equivalents at beginning of year			5,105,709		4,025,410
Cash and cash equivalents at end of year			4,480,787		5,105,709

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

Charity information

The Children's Cancer and Leukaemia Group is governed by its Constitution.

1.1 Basis of preparation

The charity is a public benefit entity as defined by FRS102. These financial statements have been prepared in accordance with: The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

For legacies, income is recognised and included in the financial statements when all of the following criteria are met:

- the charity has entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Where legacies have been notified to the charity but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

1 Accounting policies

(Continued)

Income from charitable activities includes income received from grants, registration fees for meetings, member subscriptions and publication payments. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Investment income is earned through holding assets for investment purposes. It comprises bank interest and is recognised on an accruals basis.

1.5 Expenditure recognition

All expenditure, including the awarding of grants, is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Costs of raising funds includes costs incurred in seeking donations, grants and legacies, website costs and advertising.
- Expenditure on charitable activities includes research, educational activities and professional association activities to further the delivery of the objectives of the charity.

1.6 Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure in line with the objectives of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 10.

1.7 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Computer equipment, furniture and fixtures 5-10 years

1.8 Stocks

Stocks include merchandise stock and educational literature. Stocks that are held for resale are stated at the lower of cost and estimated selling price. Stocks held for distribution as part of the charity's activities are valued at their service potential, which the charity considers to be the cost of the materials.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.10 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

1 Accounting policies (Continued)

1.11 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows:

Allocation of support costs

The allocation of support costs is sensitive to changes in the level of work undertaken on each activity by the charity. The allocation is reassessed annually and amended when necessary to reflect current estimates.

3 Income from donations and legacies

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Donations	626,417	627,879	1,254,296	622,960	703,031	1,325,991
Legacies	327,406	-	327,406	129,981	1,000	130,981
	<u>953,823</u>	<u>627,879</u>	<u>1,581,702</u>	<u>752,941</u>	<u>704,031</u>	<u>1,456,972</u>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION**
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

4 Income from charitable activities

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Registration fees for meetings and other project expenditure	238,380	11,750	250,130	126,757	28,299	155,056
Member subscriptions and publication payments	152,428	-	152,428	153,279	-	153,279
Grant income for research and operations	72,803	2,701,486	2,774,289	72,359	6,506,385	6,578,744
CLIC Sargent chief nurse funding	-	95,951	95,951	-	79,085	79,085
	<u>463,611</u>	<u>2,809,187</u>	<u>3,272,798</u>	<u>352,395</u>	<u>6,613,769</u>	<u>6,966,164</u>

5 Income from investments

	Unrestricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Total 2023 £
Interest	69,931	69,931	56,177	56,177
	<u>69,931</u>	<u>69,931</u>	<u>56,177</u>	<u>56,177</u>

6 Expenditure on raising funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
<u>Costs of raising funds</u>						
Fundraising platform fees	26,222	-	26,222	30,237	-	30,237
Website	2,293	14,934	17,227	3,567	9,474	13,041
Fundraising, marketing and publicity costs	138,031	36,778	174,809	110,813	26,750	137,563
Support costs (note 10)	176,345	-	176,345	167,166	-	167,166
	<u>342,891</u>	<u>51,712</u>	<u>394,603</u>	<u>311,783</u>	<u>36,224</u>	<u>348,007</u>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION**
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

7 Expenditure on charitable activities

	Activities undertaken directly Note 8 £	Grant funding Note 9 £	Support Costs Note 10 £	Total 2024 £	Total 2023 £
Support for research	378,818	3,404,299	184,826	3,967,943	6,381,705
Information for patients and families	66,594	-	275,496	342,090	331,351
Improving treatment and care	418,206	-	294,941	713,147	590,595
	<u>863,618</u>	<u>3,404,299</u>	<u>755,263</u>	<u>5,023,180</u>	<u>7,303,651</u>
Unrestricted funds				1,103,627	950,732
Restricted funds				3,919,553	6,352,919
				<u>5,023,180</u>	<u>7,303,651</u>

8 Expenditure on activities undertaken directly

	Support for research £	Information for patients and families £	Improving treatment and care £	Total 2024 £	Total 2023 £
Staff costs	205,335	-	-	205,335	189,557
Other tumour specific expenditure	156,255	-	-	156,255	42,095
Contact magazine expenses	-	20,306	-	20,306	21,107
Other publication expenses	-	20,446	-	20,446	32,169
Website	17,228	25,842	25,842	68,912	52,163
Cost of meetings	-	-	344,837	344,837	266,303
Travel expenses	-	-	16,893	16,893	13,906
Membership support costs	-	-	24,094	24,094	11,767
Other expenses	-	-	6,540	6,540	6,782
	<u>378,818</u>	<u>66,594</u>	<u>418,206</u>	<u>863,618</u>	<u>635,849</u>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION**
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

9 Expenditure on grant funding

	Support for research	Total 2024	Total 2023
	£	£	£
Grants to institutions:			
University of Birmingham	350,207	350,207	942,299
University of Surrey	112,216	112,216	-
Newcastle University	(474)	(474)	437,890
UCL Institute of Child Health	345,890	345,890	409,691
University of Sheffield	-	-	213,725
University of Nottingham	81,543	81,543	287,497
University of Bristol	61,069	61,069	321,339
Great Ormond Street	702,390	702,390	-
University of Southampton	-	-	222,463
University Hospital of Wales	(33,114)	(33,114)	-
University of Glasgow	216,831	216,831	124,806
University of York	252,682	252,682	559,734
University of Cambridge	493,268	493,268	248,355
Institute of Cancer Research	186,225	186,225	494,146
University of Leeds	61,556	61,556	96,468
University of Oxford	99,701	99,701	199,399
University College Cork	4,950	4,950	52,097
Swansea University	230,943	230,943	-
King's College London	74,458	74,458	-
The Open University	(94)	(94)	-
Brunel University London	-	-	352,568
Leeds Teaching Hospitals NHS Trust	-	-	104,631
University of Edinburgh	-	-	175,990
University of Sussex	-	-	249,969
University of Liverpool	-	-	170,788
Imperial College London	-	-	299,991
Sheffield Children`s Foundation Trust	19,949	19,949	-
University Hospitals Bristol and Weston NHS Trust	19,743	19,743	-
University of East Anglia	124,360	124,360	-
	<u>3,404,299</u>	<u>3,404,299</u>	<u>5,963,846</u>

The charity awards grants for specific research projects to various institutions, as part of their charitable activities.

Negative amounts represent an underspend on grants previously made, returned to CCLG.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

10 Expenditure on support costs

	Basis of allocation	2024	2023
		£	£
Staff costs	*1	716,066	653,872
Depreciation & loss on disposal	*1	9,228	14,074
Occupancy expenses	*1	131,991	143,429
Postage	*1	15,896	14,253
Staff training	*1	8,571	10,205
Professional fees	*1 / *2	49,856	35,289
		<u>931,608</u>	<u>871,122</u>
Analysed between			
Raising funds		176,345	167,166
Charitable activities		755,263	703,956
		<u>931,608</u>	<u>871,122</u>

*1 Support costs, excluding governance costs, have been allocated as follows:

<i>Cost of raising funds</i>	20% (2023 - 20%)
<i>Charitable activities</i>	
Support for research	20% (2023 - 20%)
Information for patients and families	30% (2023 - 30%)
Improving treatment and care	30% (2023 - 30%)

*2 Professional fees include governance costs of £49,856 (2023 - £35,289). Governance costs have been allocated as follows:

<i>Charitable activities</i>	
Support for research	17% (2023 - 17%)
Information for patients and families	22% (2023 - 22%)
Improving treatment and care	61% (2023 - 61%)

The amount charged to the SOFA in respect of auditor's remuneration was:

- statutory audit £10,140 (2023 - £9,780)
- other services £1,382 (2023 - £989)

11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

12 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits during the year.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION**
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

13 Employees

The average monthly number of employees during the year was:

	2024	2023
	Number	Number
Total	24	22

Employment costs

	2024	2023
	£	£
Wages and salaries	769,767	709,013
Social security costs	75,889	68,378
Other pension costs	75,745	66,038
	<u>921,401</u>	<u>843,429</u>

The number of employees whose annual remuneration (excluding pension contributions) was more than £60,000 is as follows:

	2024	2023
	Number	Number
£60,001 - £70,000	1	-
£70,001 - £80,000	-	1
£100,001 - £110,000	1	1
	<u>1</u>	<u>1</u>

Remuneration of key management personnel

The remuneration of key management personnel, is as follows.

	2024	2023
	£	£
Aggregate compensation	<u>377,924</u>	<u>300,774</u>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION**
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

14 Tangible fixed assets

	Computer equipment, furniture and fixtures	Total
	£	£
Cost		
At 1 January 2024	90,030	90,030
Additions	5,454	5,454
	<u> </u>	<u> </u>
At 31 December 2024	95,484	95,484
	<u> </u>	<u> </u>
Depreciation and impairment		
At 1 January 2024	59,026	59,026
Depreciation charged in the year	9,228	9,228
	<u> </u>	<u> </u>
At 31 December 2024	68,254	68,254
	<u> </u>	<u> </u>
Carrying amount		
At 31 December 2024	27,230	27,230
	<u> </u>	<u> </u>
At 31 December 2023	31,004	31,004
	<u> </u>	<u> </u>

15 Stocks

	2024	2023
	£	£
Merchandise stock	23,412	31,790
Educational literature	22,607	23,271
	<u> </u>	<u> </u>
	46,019	55,061
	<u> </u>	<u> </u>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

16 Debtors

	2024	2023
Amounts falling due within one year:	£	£
Trade debtors	25,298	19,656
Grant debtors	2,239,464	3,512,427
Rent deposit	18,600	16,200
Prepayments and accrued income	238,554	150,076
Accrued legacy income	283,500	138,500
	<u>2,805,416</u>	<u>3,836,859</u>

	2024	2023
Amounts falling due after more than one year:	£	£
Grant debtors	581,983	1,537,021
	<u>581,983</u>	<u>1,537,021</u>
Total debtors	<u>3,387,399</u>	<u>5,373,880</u>

17 Creditors: amounts falling due within one year

	2024	2023
	£	£
Deferred income	32,241	19,559
Trade creditors	8,729	16,316
Grant creditors	3,622,339	4,821,058
Accruals	40,772	36,886
	<u>3,704,081</u>	<u>4,893,819</u>

Deferred income includes income received in respect of meetings to be held in the next financial year.

18 Creditors: amounts falling due after more than one year

	2024	2023
	£	£
Grant creditors	1,442,154	2,383,283
	<u>1,442,154</u>	<u>2,383,283</u>

19 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees.

The amount of contribution recognised in unrestricted expenditure was £75,746 (2023 - £66,038).

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

20 Restricted funds

The income funds of the charity include restricted funds which comprise the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at 1 January 2024 £	Movement in funds			Balance at 31 December 2024 £
		Income £	Expenditure £	Transfers £	
Tumour specific funds	1,605,293	1,006,365	(1,072,784)	-	1,538,874
CCLG Prize	364	-	-	-	364
General research fund	5,670	10,250	-	-	15,920
Adam Hay fund	11,262	-	-	-	11,262
CCLG Senior Members Group	7	-	-	-	7
PODC	6,850	915	(5,665)	-	2,100
POTG	2,156	10,170	(16,449)	4,123	-
The Little Princess Trust fund	6,200	2,314,140	(2,314,140)	-	6,200
Treatment Guidelines fund	614	-	-	-	614
TYAC Lisa Thaxter	21,632	-	(19,592)	-	2,040
Child Cancer Smart	37,786	-	(2,596)	-	35,190
PORT	420	-	-	-	420
CCLG Research Network Partner Charity	-	15,000	-	-	15,000
Neuroblastoma Nursing Group	1,500	-	-	-	1,500
PODC - Iraq Fund	9,694	850	(2,653)	-	7,891
Young Lives vs Cancer Chief Nurse Funding	2,332	79,376	(81,119)	-	589
Health Information	16,920	-	-	-	16,920
TYAC General Restricted	1,000	-	-	-	1,000
TYAC Research	66,496	-	-	-	66,496
Projects Restricted Fund	1,102,398	-	(456,267)	-	646,131
	<u>2,898,594</u>	<u>3,437,066</u>	<u>(3,971,265)</u>	<u>4,123</u>	<u>2,368,518</u>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

20 Restricted funds

(Continued)

	Balance at 1 January 2023 £	Movement in funds		Transfers £	Balance at 31 December 2023 £
		Income £	Expenditure £		
Tumour specific funds	1,573,167	805,435	(773,309)	-	1,605,293
CCLG Prize	364	-	-	-	364
General research fund	3,180	2,490	-	-	5,670
Adam Hay fund	11,222	40	-	-	11,262
CCLG Senior Members Group	7	-	-	-	7
PODC	5,896	954	-	-	6,850
POTG	-	10,960	(8,804)	-	2,156
The Little Princess Trust fund	6,200	4,510,486	(4,510,486)	-	6,200
Treatment Guidelines fund	614	-	-	-	614
TYAC Lisa Thaxter	36,632	-	(15,000)	-	21,632
Child Cancer Smart	38,105	-	(319)	-	37,786
PORT	420	-	-	-	420
CCLG Research Network Partner Charity	-	652,188	(652,188)	-	-
Neuroblastoma Nursing Group	10,500	-	(9,000)	-	1,500
PODC - Iraq Fund	8,384	1,310	-	-	9,694
Young Lives vs Cancer Chief Nurse Funding	5,948	83,309	(86,925)	-	2,332
Health Information	16,920	12,300	(12,300)	-	16,920
TYAC General Restricted	1,000	-	-	-	1,000
TYAC Research	66,000	496	-	-	66,496
Projects Restricted Fund	185,378	1,237,832	(320,812)	-	1,102,398
	<u>1,969,937</u>	<u>7,317,800</u>	<u>(6,389,143)</u>	<u>-</u>	<u>2,898,594</u>

Transfers have been made into restricted funds from unrestricted funds to underwrite a cash deficit on a fund.

Tumour specific funds

Represents income received from donors with a specific request that the funds are used in support of grants for a particular tumour type.

CCLG Prize

Represents income received from donors to fund the CCLG Prize.

General research fund

Represents income received from donors with a specific request that the funds are used for research purposes.

Adam Hay fund

This fund has been established to continue work done by the Adam Hat's charity (which merged with CCLG in 2011) in neuroblastoma research and psychological support for children and families.

CCLG Senior Members Group

Represents income received from the Senior Members' Group to be used for their activities.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

20 Restricted funds

(Continued)

PODC

Represents income received from donors to be used for the Paediatric Oncology in Developing Countries (PODC).

POTG

Represents income received from donors to be used for the Paediatric Oncology Trainees' Group (POTG).

The Little Princess Trust fund

Represents income received from The Little Princess Trust to fund future instalments of research grants awarded.

Treatment Guidelines fund

Represents a grant received for the development of rare endocrine tumour guidelines.

TYAC Lisa Thaxter

Represents income received for providing and supporting education and training to professionals working in the field of teenage and young adult cancer. This was previously a restricted fund in TYAC and has transferred to CCLG as part of the closure of TYAC, with the same restrictions maintained.

Child Cancer Smart

Represents income received for a research programme, guideline development and awareness raising focusing on earlier diagnosis of childhood cancer.

PORT

Represents income received for the Paediatric Oncology Reference Team, a group of parents of children with cancer who review clinical trial and other research information to ensure it is appropriate for children with cancer and their families.

CCLG Research Network Partner Charity

Represents income research from other charities to fund research projects.

Neuroblastoma Nursing Group

Represents income received to support the costs of running the national neuroblastoma nursing group, a group of CCLG member nurses with a special interest in neuroblastoma.

PODC - Iraq Fund

Represents donations received to specifically support work to improve the treatment and care of children with cancer in Iraq.

Young Lives vs Cancer Chief Nurse Funding

Funding for the Chief Nurse role and associated projects.

Health Information

Funds received to support the production of health information for patients and families.

TYAC General Restricted

Fundraising and donations to support work specifically for teenagers and young adults with cancer.

TYAC Research

Income restricted to support research projects into teenage and young adult cancer.

Projects Restricted Funds

Income restricted to support specific projects including work related to research.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

21 Unrestricted funds

	Balance at 1 January 2024 £	Movement in funds			Balance at 31 December 2024 £
		Income £	Expenditure £	Transfers £	
General funds	389,958	1,487,365	(1,446,518)	(4,123)	426,682

	Balance at 1 January 2023 £	Movement in funds			Balance at 31 December 2023 £
		Income £	Expenditure £	Transfers £	
General funds	490,960	1,161,513	(1,262,515)	-	389,958

22 Analysis of net assets between funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Fund balances at 31 December 2024 are represented by:			
Tangible assets	27,230	-	27,230
Current assets/(liabilities)	399,452	3,810,672	4,210,124
Long term liabilities	-	(1,442,154)	(1,442,154)
	426,682	2,368,518	2,795,200

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Fund balances at 31 December 2023 are represented by:			
Tangible assets	31,004	-	31,004
Current assets/(liabilities)	358,954	5,281,877	5,640,831
Long term liabilities	-	(2,383,283)	(2,383,283)
	389,958	2,898,594	3,288,552

23 Events after the reporting date

The charity was notified of an additional legacy during the prior year. The timing and amount of the legacy income is uncertain as at the balance sheet date and therefore no income relating to this legacy has been recognised in these accounts.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER
ASSOCIATION
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

24 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2024	2023
	£	£
Within one year	39,096	18,397
Between two and five years	137,310	-
	<u>176,406</u>	<u>18,397</u>

Amounts recognised in the SOFA as an expense during the period in respect of operating lease arrangements are £37,471 (2023 - £36,530).

25 Related party transactions

There have been no other related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 12 to the financial statements.

26 Cash generated from operations

	2024	2023
	£	£
(Deficit)/surplus for the year	(493,352)	827,655
Adjustments for:		
Investment income recognised in statement of financial activities	(69,931)	(56,177)
Depreciation and impairment of tangible fixed assets	9,228	14,074
Movements in working capital:		
Decrease/(increase) in stocks	9,042	(2,032)
Decrease/(increase) in debtors	1,986,481	(451,271)
(Decrease)/increase in creditors	(2,143,549)	675,006
Increase in deferred income	12,682	19,459
Cash (absorbed by)/generated from operations	<u>(689,399)</u>	<u>1,026,714</u>

27 Analysis of changes in net funds

During the year the charity had no borrowings or obligations under finance leases. The changes in net funds of the charity therefore solely comprise of cash and cash equivalents.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

England & Wales - Charity number 1182637

Accounts

Charity Registration No. 1182637 (England and Wales)

Charity Registration No. SC049948 (Scotland)

Company Registration No. CE016951 (England and Wales)

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

**TRUSTEES' REPORT AND
FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED
31 DECEMBER 2023**

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees David Oxnam (Chair of Board of Trustees)
Gayle Routledge
Rachel Wilcox
David Hobin
Sarah Curtis

Chief Executive Ashley Ball-Gamble

Charity number 1182637 (England and Wales)
SC049948 (Scotland)

Company number CE016951

Operating name CCLG

Principal address Century House
24 De Montfort Street
Leicester
LE1 7GB

Auditor Newby Castleman LLP
West Walk Building
110 Regent Road
Leicester
LE1 7LT

Bankers HSBC Bank Plc
2-6 Gallowtree Gate
Leicester
LE1 1DA

Scottish Widows Bank Plc
PO Box 12757
67 Morrison Street
Edinburgh
EH3 8YJ

CAF Bank Ltd
25 Kings Avenue
Kings Hill
Kent
ME19 4JQ

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

CONTENTS

	Page
Trustees' report	1 - 10
Independent auditor's report	11 - 13
Statement of financial activities	14
Balance sheet	15
Statement of cash flows	16
Notes to the financial statements	17 - 31

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees of The Children's Cancer and Leukaemia Group are pleased to present their annual report and financial statements for the year ended 31 December 2023.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

OBJECTIVES AND ACTIVITIES

The objectives of The Children's Cancer and Leukaemia Group (CCLG) as defined in the constitution are:

For the public benefit, the relief of sickness and suffering of children, teenagers and young adults with cancer and advancement of education in the field of children, teenagers and young adults with cancer, in particular but not exclusively by:

1. The relief of sickness and promotion and protection of good health by supporting research into the nature, causes, diagnosis, treatment and social consequences of cancer in children, teenagers and young adults, and to publish the useful results of such research.
2. The relief of suffering of children, teenagers and young adults with cancer and their families and carers, through the provision of information and support services to them.
3. The advancement of the education of the public in all areas relating to cancer in children, teenagers and young adults.
4. The advancement of education and clinical practice by the dissemination of knowledge of the latest research and best practice amongst professionals and practitioners engaged in the treatment, care and support of children, teenagers and young adults with cancer.

The main beneficiaries of the work carried out by the charity are children, teenagers and young adults with cancer and their families in the United Kingdom and elsewhere in the world.

CCLG is the UK and Ireland's professional association for all those involved in the treatment, care and research of children and young people (aged 0-25) with cancer. At the end of 2023, our membership had grown to more than 1,500 members. We also operate 'Teenagers and Young Adults with Cancer' (TYAC), a specific membership group for those working with young people aged 13-25 with a cancer diagnosis, which had over 470 members at the end of the year.

We support our professional members to network, share best practice, advance education, and our activities aim to ensure every child with cancer receives the best possible treatment and care, wherever they live.

We carry out a wide range of activities to support our professional members, including:

- Member interest groups, bringing together professionals working in the same professional group, or with shared clinical or research interests, to develop treatment and care guidelines, to deliver education, to initiate research projects and to develop resources for use by other professionals.
- We deliver a range of meetings and educational events each year to ensure members are kept up to date with the latest developments in care, treatment and research. Our flagship annual meeting provides an opportunity for all of our members to network with colleagues from across the UK and Ireland, share best practice and learn about new innovations and initiatives.
- Professional voice for children, teenagers and young adults: We advise governments and other bodies and ensure that we are represented on important groups or in consultations, for example in the area of NHS commissioning of children's cancer services or the development of NICE quality standards and guidance.
- Our member website is a vital hub for professionals, providing a wealth of resources and educational opportunities, complemented by our new online member community, allowing networking and good practice sharing opportunities beyond group meetings and events.

Our members are dedicated to ensuring that children and young people have a greater chance of survival and a better life after treatment.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

We support children and young people with cancer and their families in a variety of different ways:

- Written by experts, our comprehensive quality-assured range of information booklets, leaflets and online content helps patients and their families understand their diagnosis, treatment and what to expect now and in the future. Our publications are available free of charge to those who need them.
- Our free quarterly magazine, Contact, offers help, support and information for families of children, teenagers and young adults with cancer.
- Our online community provides a 'safe space' for parents of children with cancer to come together and share experiences, ask for advice, and, uniquely, ask expert questions of our professional membership.
- Our website is a comprehensive resource of childhood cancer information, providing a wide range of up-to-date expert information, personal stories and more.

The outstanding progress made in cancer treatment is the result of extensive research studies and clinical trials over the last 50 years which now underpin today's standard treatments. During this time, CCLG has played a key role in the success seen in the world of children's cancer so that now over 80% of children are cured. But there are still some childhood cancers with a poor outlook, and some treatments can have long-lasting and devastating side effects. Further research is vital to improve survival rates and to find kinder treatments. We fund and support a variety of research into childhood cancers including:

- We offer funds and grants to launch new research projects and develop new clinical trials.
- We work in partnership with other charities and organisations to support research. We use our research funding infrastructure, as well as the scientific and medical expertise of our membership, to support smaller charities to meet their research aims. For example, by managing a research funding programme or helping them to identify research to support.
- We can 'ringfence' funds so that our supporters can raise funds towards a cancer-specific research project.
- Our Special Interest Groups provide a forum for discussion and planning of research and bring together potential collaborators. We organise and support scientific meetings where research findings are shared and discussed, and we support our membership to be involved in planning research and attending important meetings through bursaries and sponsorship.
- During the year, following the closure of the National Cancer Research Institute (NCRI) we took over hosting the Children's Research Group and Teenage and Young Adult & Germ Cell Tumour Research Group, along with their subgroups, which set UK research strategy, develop new studies and drive forward the research agenda.
- Since 2017, CCLG has been a member of the Association of Medical Research Charities, demonstrating our commitment to funding high-quality, world class research and confirming the high standard of the processes we use to select and fund research.

We measure our success in achieving our objectives in a number of ways:

- The number of patient information products distributed, and the number of visits to the 'about childhood cancer' section of our website, are some measures used to ascertain our success in supporting patients and their families. We also gather feedback on our information products.
- The number of members and retention of members are some basic measures used to ascertain how we are supporting the community of professionals we serve through our professional association activities.
- The number of research projects funded and their value, and the outcome of research projects including peer-reviewed papers in scientific journals, and the number of projects that led to further funding from ourselves or another research funder.
- We have now begun developing our new strategic plan, set to launch in 2025. As part of this work, we will consider how we better measure and report on our impact.

ACHIEVEMENTS AND PERFORMANCE

Around 1,800 children (aged 0-14) and a further 2,300 teenagers and young adults (aged 15-25) are diagnosed with cancer each year in the UK. Although overall five-year survival for cancer in children and young people is now over 80%, for some cancers there have not been such dramatic improvements in survival, and even where treatment is successful, many survivors have to contend with life-long and life-limiting side effects. We continue to work towards the four main goals set out in our strategic plan, launched in 2018, and the goals of the TYAC strategic plan, launched in 2019, as detailed below. Highlights of our achievements during the year are set out under each of these strategic goals.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

Providing leadership and expertise for the treatment and care of children and young people with cancer

As the UK and Ireland's professional association for those working in the field of paediatric oncology and haematology, CCLG is a leading voice for children's cancer, liaising with community groups, the government and the NHS to influence policies. We use our expertise to improve treatment and care and meet the needs of patients and families. Highlights for 2023 include:

- We hosted the largest ever CCLG Annual Conference in March, bringing together more than 450 professionals to share best practice, hear about the latest research and developments, and network with colleagues. For the first time, the conference included dedicated teenage and young adult cancer sessions, as well as parallel sessions for our multiprofessional membership.
- The Annual Conference also saw the return of the CCLG Member Awards for the second year, recognising dedication and excellence amongst our professional community.
- We held a number of other in-person educational opportunities for members during the year, including a two-day specialist course in renal tumours, as well as expanding our online webinar series.
- We continued to produce and update a number of clinical treatment guidelines, ensuring standardised, high quality and evidence-based treatment for all children, particularly in diseases where there is currently no open clinical trial.
- Launch at the end of 2022, CCLG Connect, an online community for the CCLG membership, continued to grow and see increased engagement from the membership. CCLG Connect provides a space for members to connect with each other, participate in group activities, share best-practice and research outputs, ask questions and disseminate useful resources. So far, feedback on this new resource has been hugely positive.
- Our strategic partnership with Young Lives vs Cancer continued, providing benefits to both organisations. The Chief Nurse role at CCLG is funded by Young Lives vs Cancer, working to provide clinical and health system insight and intelligence to the latter and enhance support for nursing and allied health professionals within CCLG.
- With Young Lives vs Cancer, we called on the government to publish a 10-year cancer plan for children and young people, to ensure that their unique and critical needs are recognised, understood, and addressed. We want to work together as a sector with the Department of Health and Social Care to see a fully resourced, long-term strategy put in place to provide the care and support needed to radically improve experiences and outcomes for children and young people with cancer.
- In partnership with Young Lives vs Cancer, the Ellen MacArthur Cancer Trust, and Teenage Cancer Trust, we commissioned a ground-breaking piece of research that will build a new evidence base looking at the psychosocial needs of young cancer patients and how the current system supports them. The research will also identify gaps and what needs to happen in order to build a better future for children and young people diagnosed with cancer. Dartington Service Design Lab, a charity which improves children's outcomes through research, systems thinking and co-design approaches, was commissioned as the research partner. They undertook experience-led research, co-designed by young people, parents of children with cancer, and key stakeholders. The aim of the research is to improve policies and practice around cancer support and will be published in 2024.
- We launched the first in a series of e-learning units to support the development of multiprofessionals in the early years of a career in children or teenage and young adult cancer services. The full set of nine units will form a foundation course called 'An introduction to cancer in a child, teenager and young adult' and the remaining units will all be available by the end of 2024. The aim is to improve options and access to foundation level learning in a timely way, in a format where learners can choose their own schedule of learning.

Improving diagnosis times by increasing awareness

The significance of a delayed diagnosis presents a challenge for primary health care professionals, who are required to triage symptoms that may point to a cancer diagnosis and make appropriate onward referrals. Many symptoms associated with cancer are non-specific and are seen every day in general practice, whilst a cancer diagnosis is seen infrequently.

Delays in the diagnostic pathway may well lead to more advanced disease at presentation, with subsequent greater risk of death, greater morbidity, and inevitably, distrust of the medical system. There is evidence that tumours presenting in childhood in the UK are larger, at a more advanced stage and require more therapy

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

than those presenting in other parts of Europe. We work to improve diagnosis times for children and young people with cancer. In 2023:

- We continued working on our Child Cancer Smart project, which will result in a number of clinical referral guidelines, and public and professional awareness tools, on the signs and symptoms of childhood cancer. Work to date has comprised a significant amount of research to understand the signs and symptoms of childhood cancer, providing an evidence-based approach, for the first time, to developing tools to support medical professionals in making a diagnosis, as well as a series of public campaigns to raise awareness of the signs and symptoms of childhood cancer. We expect to launch the first tools and campaigns during 2024.
- The Child Cancer Diagnosis Study, a research project funded by the National Institute for Health Research (NIHR) and CCLG, and jointly run by CCLG and The University of Nottingham, closed and the analysis of the data began. This innovative, nationwide research will give us, for the first time, an accurate picture of the routes to diagnosis and where we can develop interventions to drive improvements.
- We published research that shows only 32% of adult survey respondents felt confident in recognising cancer signs and symptoms in children, teenagers and young adults. The survey results demonstrated that most of the respondents underestimated the risk of cancer in children, selected symptoms associated with adult, rather than childhood cancers, and didn't recognise that disturbed growth or pubertal development were indicators of childhood ill health. Using these results, we can put interventions in place to improve awareness and knowledge amongst the general public, including targeted information for certain groups, including healthcare professionals to accelerate diagnosis. This data will be crucial to informing the Child Cancer Smart awareness campaign, providing information about gaps in public awareness and knowledge which we can address through messaging in the campaign.

Strengthening our expert information portfolio to support more families of a child with cancer

Looking after a child with cancer can be a scary and lonely experience for families. Our goal is to deliver the right information at the right time and make a positive difference to their daily lives. We continue to be the leading provider of expert-written, award-winning and quality-assured information about all aspects of childhood cancer, from diagnosis to life when treatment has finished. In 2023:

- We continued to provide free information booklets and leaflets to hospitals and directly to families during the year. A number of new publications were produced, and further existing publications were reviewed and revised.
- We produced four issues of our popular magazine, Contact. Feedback on the new format and design, launched in 2021, continues to be overwhelmingly positive, and Contact continues to support families across the UK and around the world.
- We continued our series of online 'research talks' aimed at parents of children with cancer (and the general public), which aim to explore the world of childhood cancer research in an accessible way, with each episode in the series featuring a talk from an expert speaker, as well as the opportunity for attendees to ask questions. Recordings of the webinars are made available on our YouTube channel for those unable to attend the live events.
- Our closed Facebook group for parents and carers of children with cancer, which allows members to seek advice and support from those with similar experiences, and, uniquely, 'ask the experts' through posting questions answered by our clinical membership community, continued to grow, reaching over 1,500 members.
- We successfully passed our annual reassessment for the Patient Information Forum (PIF) PIFTick accreditation for our health information. This quality standard is awarded following rigorous assessment of our information production processes, and demonstrates our commitment to reliable, expert, high-quality health information.

Supporting and funding world-class research

Our aim is to both support and fund world-class research, deepen understanding and foster collaborations across the childhood cancer community. One of our most important areas of work is to offer opportunities for our members to develop scientific networks and belong to a wider research community dedicated to childhood cancer.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

Our Research Strategy outlines our exciting plans to fund and support innovative world-class research into childhood cancer and recognises the importance of collaboration, both nationally and internationally, to achieve improvements.

- We fund research directly, and work with partner charities to support them to fund the best possible research, using our well-established research funding expertise, experience and infrastructure. In total, between our own research funding and that of the partners we work with, 30 new research projects totalling around £5.8 million were funded in 2023. Grants awarded cover a wide range of childhood cancer types, projects focusing on different parts of the cancer experience, and covering a range of different types of research.
- Our partnership with The Little Princess Trust continues to go from strength to strength. We support The Little Princess Trust to fund the best quality research, with a focus on finding better, kinder treatments. We provide specialist advice and expertise, as well as run and manage their research-funding programme on their behalf. This partnership helps to minimise duplication, and share expertise meaning that ultimately more money is spent directly on research. During the year, the Little Princess Trust awarded CCLG around £4.4 million to fund innovative new research proposals. In September, our partnership with The Little Princess Trust was recognised with a 'highly commended award' in the Charity Partnership of the Year category at the Third Sector Awards.
- During the year, we also made research grants on behalf of, and funded by, Candlelighters and The Harley Staples Cancer Trust.
- During the year, the National Cancer Research Institute (NCRI), a UK-wide partnership between research funders working together to maximise the value and benefits of cancer research for patients and the public, sadly announced its closure. As a NCRI partner, CCLG stepped up to offer support to the children and young people elements of the NCRI's work, allowing this vital work to continue while a longer-term solution is sought. CCLG continues to host the previous NCRI 'Children's' and 'Teenage and Young Adult and Germ Cell Tumour' research groups, which set the research agenda in these areas and contribute to the development of research studies for our patients.
- We continued to publish our research blog, aiming to make research understandable and accessible to all those in the childhood cancer community and beyond, including parents, professionals and the general public. The blog shares research concepts and specific projects in an accessible way, raising awareness of both the research we undertake and of cancer research more generally.
- In September, we hosted our first Research Discovery Day, to offer valuable insight into the research we fund to families and supporters. Among the attendees were parents of children diagnosed with cancer, survivors and CCLG fundraisers, who were able to hear experts from Birmingham Children's Hospital, the University of Nottingham and the University of Oxford talk about how they're working to improve the future for children with cancer. Before that, they heard from Emma Jones, whose daughter Ruby passed away from blood cancer in 2020. Emma spoke about Ruby's wish to donate her life savings to research to help other young cancer patients, and why she carries on her daughter's legacy by raising money for research through Ruby's Live Kindly Live Loudly Fund, a Special Named Fund at CCLG.
- In December 2022, the final workshop of the Children's Cancer Priority Setting Partnership (PSP), initiated by CCLG and co-funded with The Little Princess Trust, took place and the Top 10 Priorities in Children's Cancer Research were announced. In June, we launched the final report of the PSP with a special event. The findings were presented at the launch event, which brought together charities, researchers and research funders, as well as those affected by childhood cancer. Members of the project team spoke about the importance of the PSP, while the audience heard from a childhood cancer survivor and parents of childhood cancer patients about what the report means to them. We continue to work with partners to ensure that the priorities identified by the PSP now influence research funding going forward, to ensure that the needs of young cancer patients are reflected in research.

Teenagers and Young Adults with Cancer (TYAC)

Teenagers and Young Adults with Cancer (TYAC) is the professional association for those working in teenage and young adult (TYA) oncology. TYAC merged with CCLG in 2018, and in 2019 we launched a new strategy for the work of TYAC, setting out how we would continue to drive improvements in TYA cancer care, and support the development of professionals working in the field.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

Fundraising

All of our work is dependent on the generosity of our supporters. A programme of fundraising underpins our ability to fund research, support patients and families, and improve treatment and care for children and young people with cancer.

Our Special Named Fund programme continued to grow. After their cancer experiences, families sometimes consider setting up their own charity. For many, our Special Named Funds may be a great alternative. We support families to achieve their fundraising objectives, while taking away the administrative burden of setting up and running a charity. At the end of the year, there were approximately 98 Special Named Funds at CCLG (2022: 85), each raising funds to support research into a specific type of childhood cancer.

During the year, we began working on a new fundraising strategy, to be launched in 2024, which aims to ensure we are able to sustain our income growth and continue to deliver on our charitable objectives: funding research, supporting families and ensuring that all young patients receive the best possible treatment and care.

We are hugely grateful to all those who chose to support CCLG, by making a donation, taking part in an event, or organising their own fundraiser during the year.

Fundraising policy

We are reliant on donations to fund our vital work. Without the generosity of the public, we would not be able to continue providing support to children and young people diagnosed with cancer, and their families, nor fund research into childhood cancer. We believe that it is essential that we are clear and open about how we raise our funds and about the range of ways people can get involved and support our work.

People raise money for us in many different ways, including through taking part in sporting events, organising events in their local community, or fundraising at their place of work. We also provide opportunities for people to fundraise through providing access to places in key events, such as the London Marathon, and through providing fundraising materials. Our supporters can sign up to make regular donations, or play our lottery which we launched in 2018.

We work with a number of corporate partners, and have received support from charitable trusts and foundations, and through grants from other charities.

We do not carry out door-to-door fundraising, nor do we use street fundraising to sign up supporters to regular donations.

Currently, none of our fundraising activities are conducted on our behalf by professional fundraising agencies.

CCLG is registered with the Fundraising Regulator. We are committed to adhering to the Code of Fundraising Practice. During the year, we received no complaints about our fundraising activities.

Regular updates are provided to our board of trustees to ensure that they have a good oversight of our activities.

FINANCIAL REVIEW

Transactions for the year ended 31 December 2023 fall into roughly the same categories as in previous years. Income generally consists of donations and fundraising income, subscriptions (comprising individual membership subscriptions and hospital subscriptions for health information), registration fees for meetings and events, funding from partner charities such as The Little Princess Trust to support research projects, and legacy income. We are grateful to Young Lives vs Cancer, Teenage Cancer Trust and The Little Princess Trust for their support of specific areas of our work. We also benefitted from a grant from The Medical Research Council UK Government COVID Medical Research Charity Support Fund, a scheme designed to support fundraising medical research charities who fund early-career researchers in response to the COVID-19 pandemic.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

The major items of expenditure for CCLG remain staff salaries, professional meeting and event costs, the costs associated with the production of health information, and the awarding of research grants. Staffing costs represent a significant financial commitment, but our small, expert staff team is also responsible for the achievement of the majority of our charitable objectives. Staffing levels are kept under review, with the small, efficient team carrying out and coordinating the considerable activities of the charity.

Our overall income increased by £167,538, compared with the year ending December 2022. There was a small decrease in donations for the year, and an increase in income from meeting registration fees as more events were held in-person following the reduction in number over the past few years caused by the COVID-19 pandemic.

CCLG has a number of restricted funds. Internal records are kept according to requirements for restriction, i.e. disease-specific donations for research into a specific type of cancer, or donations for a specific piece of work. The restricted funds are ring-fenced to support specific projects or areas of activity and cannot be used to support the general running costs of the organisation.

Expenditure decreased in 2023 by £122,277 compared to 2022. While our expenditure on research decreased, expenditure increased slightly on our health information and professional body activities.

We ended the year with an overall surplus of £827,665. There was a deficit in unrestricted income/expenditure of £101,002, which was planned and represents the Trustees commitment to invest reserves held above the level of our reserves policy into our charitable activities. There was a surplus in restricted income/expenditure of £928,657. Much of our restricted funding is for research, and often funds build over several years before being expended in significant amounts to fund research projects. We plan to invest a significant amount of restricted funds in the next 12 months.

Reserves Policy

The trustees continue to consider the appropriate balance of financial stability and investment in charitable activity. The COVID-19 pandemic has highlighted the importance of an appropriate reserves policy. It is important we continue to hold a level of reserves which can sustain our activity until we have a fuller picture of what post-pandemic fundraising might look like in the medium-term.

We have plans in place to ensure CCLG is 'fit for the future' and our reserves policy will ensure we are able to meet those plans. At the end of the year, we have reviewed our reserves policy for CCLG and aim to hold a target level of free reserves (unrestricted funds less tangible fixed assets) of £400,000, which the trustees consider to be approximately six months of core expenditure, including staff salaries, accommodation costs and general running costs. Total reserves at 31 December 2023 were £3,288,552 of which £2,898,594 are restricted and £389,958 are unrestricted. As at 31 December 2023 the charity's free reserves totalled £358,954 which is just below the reserves policy. Given the current economic uncertainty, the trustees consider it prudent to balance the investment of reserves into our charitable activity whilst ensuring sufficient funds are available to ensure the charity is a 'going concern' and able to meet its commitments. The Trustees continue to keep the reserves policy under review to ensure that CCLG is 'fit for the future'.

Our restricted reserves appear high, at £2,898,594 at the end of 2023. Much of our restricted fundraising income is raised by families, ring-fenced for research into specific types of childhood cancer. Research requires significant investment, and thus many of our funds grow over the course of several years before a large sum of money is awarded in the form of a research grant. Our restricted reserves comprise a large number of specific restricted funds which are ring-fenced to a specific purpose, and therefore cannot be used for general activities. Levels of funds are reviewed on a regular basis and spent on charitable activities as soon as sufficient funds are available. We are planning to invest a significant amount of restricted reserves into research during 2024.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

Investment policy

The Trustees previously reviewed our plans for investments to consider the most appropriate way of managing these, balancing cashflow, risk and reward. Given the ongoing uncertainty of the financial impact of the COVID-19 pandemic, and the cost-of-living crisis and high inflation, no further action has been taken on investments. The high interest rates during the year have resulted in increased investment returns in the form of interest on

money held in our bank accounts. Management accounts are produced for the trustees, and a cashflow forecast considerably facilitates management and prediction of charity income.

Risk Management

CCLG is also aware of the requirement to carry out a risk review of its activities. The trustees reviewed the risks the charity faces during the year. A Risk Register is in operation, documenting the systems in place to mitigate those risks, and is kept under review by the trustees.

FUTURE ACTIVITIES

All future activities planned are designed to ensure that CCLG continues to fulfil its objectives for children and young people with cancer, and their families, as the ultimate beneficiaries. As the membership of CCLG continues to grow, so does the activity our members are involved in. Our specialist network groups continue to be increasingly active, supporting our activities and providing specialist advice to commissioners of healthcare services and others. The Executive continues to consider ways that CCLG can advance education and professional development, and share and guide best practice.

Key planned activity for the next 12 months includes:

- Researching, designing, building and launching a new website.
- Merging the CCLG and TYAC memberships into a single membership body, for professionals working in the field of childhood and/or teenage and young adult cancers. This will increase the range of support available for members and enabling the resources currently used to maintain two membership functions to be reinvested into other activities.
- Towards the end of the year, we will launch a refreshed brand for the organisation, that better articulates the wide range of activities we are involved in, reflects that the organisation works across the 0-25 age range, and engages a larger number of supporters. This will include the launch of a new website that uses more modern technology and better meets the needs of our various audiences.
- We will develop and launch a new research strategy, which reflects our position as a leader in setting the research agenda, and aligns our funding work with the Top 10 Research Priorities for Children's Cancer identified through the Children's Cancer Priority Setting Partnership. A key aim of the strategy will be increasing collaborative and partnership working across the sector to ensure more world-class research is funded, more quickly.
- Reviewing our health information content and increasing the range of content available in alternative formats, in particular videos, to better meet the needs of our intended users
- We will launch the first guidelines, clinical decision tools and public awareness campaigns from our Child Cancer Smart work, raising awareness of the signs and symptoms of cancer in children and young people, and equipping healthcare professionals to make quicker diagnoses.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Children's Cancer and Leukaemia Group (CCLG) was established in 1977 and became a registered charity (number 286669) in 1983. In 2019, a new CIO (registration number 1182637) was formed, with the activities, assets and liabilities of the previous charity transferred to the CIO.

The charity's governing instrument is the Constitution and the CIO was first registered in February 2019. In 2020, the CIO became registered with the Scottish Charity Regulator (registration number SC049948).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

The board of trustees is independent of the CCLG membership. The board of trustees is responsible for managing the charity finances in support of the objectives defined by the CCLG Executive. There are a minimum of two and a maximum of eight trustees. One of the trustees will be an elected member of the CCLG Executive, providing a link between these two groups.

If a vacancy arises, the trustees may appoint any eligible person as a trustee. In selecting individuals for appointment as trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction to the charity. This consists of a briefing paper, as well as meetings with the Chair, CEO, and others as deemed appropriate.

Regard is given to the training and development needs of any trustees that may arise. The board of trustees meets quarterly and is supported by staff. Four meetings were held in 2023.

The trustees come from a range of professional backgrounds, and bring new skills and highly relevant experience. Trustees serving during the year were:

David Oxnam (Chair of Board of Trustees)

Gayle Routledge

Rachel Wilcox

David Hobin

Sarah Curtis

The Chief Executive is responsible for the day-to-day operation of the charity on behalf of the trustees. The remuneration of key management is reviewed annually and is set against established pay scales, benchmarked in comparison with similar sized entities including both charities and medical professional associations. The trustees give their time freely and no remuneration was paid in the year. Details of trustee expenses are disclosed in note 12 to the accounts.

Key Management Personnel during the year were:

Ashley Ball-Gamble (Chief Executive)

Vicki Brunt (Head of Fundraising)

Claire Shinfield (Head of Engagement)

Jeanette Hawkins (Chief Nurse)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales and Scotland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities (Accounts and Reports) Regulations 2008, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

DocuSigned by:



.....29D0B5FD6D7043C.....

David Oxnam

Chair of the board of trustees

16-08-2024

Date:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Opinion

We have audited the financial statements of The Children's Cancer and Leukaemia Group (the 'charity') for the year ended 31 December 2023 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2023 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the trustees' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- the charity has not kept adequate and proper accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 9, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under these acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charity.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- obtaining an understanding of the legal and regulatory framework applicable to the charity by considering the nature of the industry in which the charity operates and enquiring of management; and
- identifying the key laws and regulations considered to have a direct impact on the financial statements including the UK Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, UK Generally Accepted Accounting Practice and UK tax legislation; and
- assessing how the charity is complying with the applicable legal and regulatory framework by making further enquiries of management and observing the charity's control environment regarding compliance with regulations and fraud prevention; and
- assessing the susceptibility of the charity's financial statements to material misstatement, including how fraud might occur, by considering the effectiveness of the charity's accounting systems and controls and how these were monitored by management. Where the risk of material misstatement was considered to be higher in certain areas, further audit procedures were designed to address this increased risk; and

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

- discussing amongst the engagement team how and where fraud might occur in the financial statements and any potential indicators of fraud.

Audit response to risks of irregularities identified

Our procedures to respond to risks identified included the following:

- performing audit work over revenue recognition including analytical procedures and substantive tests of detail of a sample of revenue transactions; and
- reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations; and
- enquiry of charity staff responsible for compliance to identify any instances of non-compliance with laws and regulations; and
- enquiry of management, those charged with governance and other relevant parties around actual and potential litigation claims; and
- reviewing minutes of meetings of those charged with governance; and
- performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias; and
- communicating identified laws and regulations and potential fraud risks to all engagement team members and assessing whether there are any indications of fraud or non-compliance with laws and regulations throughout the audit.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008, and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.


Newby Castleman LLP

Chartered Accountants
Statutory Auditor
West Walk Building
110 Regent Road
Leicester
LE1 7LT

27 August 2024

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Total 2022 £
Income from:					
Donations and legacies	3	752,941	2,047,741	2,800,682	1,897,074
Charitable activities	4	352,395	5,270,059	5,622,454	6,408,766
Investments	5	56,177	-	56,177	5,935
Total		<u>1,161,513</u>	<u>7,317,800</u>	<u>8,479,313</u>	<u>8,311,775</u>
Expenditure on:					
Raising funds	6	311,783	36,224	348,007	377,048
Charitable activities	7	950,732	6,352,919	7,303,651	7,396,887
Total		<u>1,262,515</u>	<u>6,389,143</u>	<u>7,651,658</u>	<u>7,773,935</u>
Net (expenditure)/income for the year/ Net movement in funds		(101,002)	928,657	827,655	537,840
Reconciliation of funds					
Total funds brought forward		<u>490,960</u>	<u>1,969,937</u>	<u>2,460,897</u>	<u>1,923,057</u>
Total funds carried forward		<u><u>389,958</u></u>	<u><u>2,898,594</u></u>	<u><u>3,288,552</u></u>	<u><u>2,460,897</u></u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

BALANCE SHEET

AS AT 31 DECEMBER 2023

	Notes	2023		2022	
		£	£	£	£
Fixed assets					
Tangible assets	14		31,004		42,486
Current assets					
Stocks	15	55,061		53,029	
Debtors	16	5,373,880		4,922,609	
Cash at bank and in hand		5,105,709		4,025,410	
		10,534,650		9,001,048	
Liabilities					
Creditors: amounts falling due within one year	17	(4,893,819)		(3,967,898)	
Net current assets			5,640,831		5,033,150
Total assets less current liabilities			5,671,835		5,075,636
Creditors: amounts falling due after more than one year	18		(2,383,283)		(2,614,739)
Total net assets			3,288,552		2,460,897
The funds of the charity					
Restricted funds	20		2,898,594		1,969,937
Unrestricted funds	21		389,958		490,960
Total charity funds			3,288,552		2,460,897

16-08-2024

The financial statements were approved and authorised for issue by the board of trustees on and are signed on its behalf by:

DocuSigned by:

David Oxnam

.....29D0B3FD6D7043C.....

David Oxnam (Chair of Board of Trustees)

Trustee

The notes on pages 17 - 31 form part of these financial statements.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2023

	Note	2023 £	£	2022 £	£
Cash flows from operating activities					
Cash generated from/(absorbed by) operations	26		1,026,714		(13,527)
Investing activities					
Purchase of tangible fixed assets		(2,592)		(14,113)	
Investment income received		56,177		5,935	
Net cash generated from/(used in) investing activities			53,585		(8,178)
Net cash used in financing activities			-		-
Net increase/(decrease) in cash and cash equivalents			1,080,299		(21,705)
Cash and cash equivalents at beginning of year			4,025,410		4,047,115
Cash and cash equivalents at end of year			5,105,709		4,025,410

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

Charity information

The Children's Cancer and Leukaemia Group is governed by its Constitution.

1.1 Basis of preparation

The charity is a public benefit entity as defined by FRS102. These financial statements have been prepared in accordance with: The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

For legacies, income is recognised and included in the financial statements when all of the following criteria are met:

- the charity has entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Where legacies have been notified to the charity but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Government grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

Income from charitable activities includes income received from grants, registration fees for meetings, member subscriptions and publication payments. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Investment income is earned through holding assets for investment purposes. It comprises bank interest and is recognised on an accruals basis.

1.5 Expenditure recognition

All expenditure, including the awarding of grants, is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Costs of raising funds includes costs incurred in seeking donations, grants and legacies, website costs and advertising.
- Expenditure on charitable activities includes research, educational activities and professional association activities to further the delivery of the objectives of the charity.

1.6 Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure in line with the objectives of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 10.

1.7 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Computer equipment, furniture and fixtures 5-10 years

1.8 Stocks

Stocks include merchandise stock and educational literature. Stocks that are held for resale are stated at the lower of cost and estimated selling price. Stocks held for distribution as part of the charity's activities are valued at their service potential, which the charity considers to be the cost of the materials.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.10 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies (Continued)

1.11 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows:

Allocation of support costs

The allocation of support costs is sensitive to changes in the level of work undertaken on each activity by the charity. The allocation is reassessed annually and amended when necessary to reflect current estimates.

3 Income from donations and legacies

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Donations	622,960	703,031	1,325,991	574,290	825,676	1,399,966
Legacies	129,981	1,000	130,981	222,369	33,417	255,786
	<u>752,941</u>	<u>704,031</u>	<u>1,456,972</u>	<u>796,659</u>	<u>859,093</u>	<u>1,655,752</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

4 Income from charitable activities

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Registration fees for meetings and other project expenditure	126,757	28,299	155,056	90,942	18,244	109,186
Member subscriptions and publication payments	153,279	-	153,279	162,715	-	162,715
Grant income for research and operations	72,359	6,506,385	6,578,744	93,509	6,205,417	6,298,926
CLIC Sargent chief nurse funding	-	79,085	79,085	-	79,261	79,261
	<u>352,395</u>	<u>6,613,769</u>	<u>6,966,164</u>	<u>347,166</u>	<u>6,302,922</u>	<u>6,650,088</u>

5 Income from investments

	Unrestricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Total 2022 £
Interest	56,177	56,177	5,935	5,935
	<u>56,177</u>	<u>56,177</u>	<u>5,935</u>	<u>5,935</u>

6 Expenditure on raising funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
<u>Costs of raising funds</u>						
Fundraising platform fees	30,237	-	30,237	24,576	-	24,576
Website	3,567	9,474	13,041	2,077	-	2,077
Fundraising, marketing and publicity costs	110,813	26,750	137,563	188,604	-	188,604
Support costs (note 10)	167,166	-	167,166	161,791	-	161,791
	<u>311,783</u>	<u>36,224</u>	<u>348,007</u>	<u>377,048</u>	<u>-</u>	<u>377,048</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

7 Expenditure on charitable activities

	Activities undertaken directly Note 8 £	Grant funding Note 9 £	Support Costs Note 10 £	Total 2023 £	Total 2022 £
Support for research	244,693	5,963,846	173,166	6,381,705	6,613,379
Information for patients and families	72,837	-	258,514	331,351	299,845
Improving treatment and care	318,319	-	272,276	590,595	483,663
	<u>635,849</u>	<u>5,963,846</u>	<u>703,956</u>	<u>7,303,651</u>	<u>7,396,887</u>
Unrestricted funds				950,732	872,045
Restricted funds				6,352,919	6,524,842
				<u>7,303,651</u>	<u>7,396,887</u>

8 Expenditure on activities undertaken directly

	Support for research £	Information for patients and families £	Improving treatment and care £	Total 2023 £	Total 2022 £
Staff costs	189,557	-	-	189,557	97,944
Other tumour specific expenditure	42,095	-	-	42,095	10,530
Contact magazine expenses	-	21,107	-	21,107	20,360
Other publication expenses	-	32,169	-	32,169	28,312
Website	13,041	19,561	19,561	52,163	8,311
Cost of meetings	-	-	266,303	266,303	192,068
Travel expenses	-	-	13,906	13,906	11,729
Membership support costs	-	-	11,767	11,767	12,453
Other expenses	-	-	6,782	6,782	6,728
	<u>244,693</u>	<u>72,837</u>	<u>318,319</u>	<u>635,849</u>	<u>388,435</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

9 Expenditure on grant funding

	Support for research £	Total 2023 £	Total 2022 £
Grants to institutions:			
University of Birmingham	942,299	942,299	939,992
Newcastle University	437,890	437,890	1,146,110
UCL Institute of Child Health	409,691	409,691	991,135
University of Sheffield	213,725	213,725	-
University of Nottingham	287,497	287,497	432,059
University of Bristol	321,339	321,339	401,433
Queen's University Belfast	-	-	(3,925)
University of Southampton	222,463	222,463	-
University of Glasgow	124,806	124,806	140,420
University of York	559,734	559,734	317,285
University of Cambridge	248,355	248,355	325,179
Institute of Cancer Research	494,146	494,146	210,885
University of Leeds	96,468	96,468	357,187
University of Manchester	-	-	(1,077)
University of Oxford	199,399	199,399	33,854
University College Cork	52,097	52,097	-
University of Leicester	-	-	112,515
Birmingham Children's Hospital	-	-	53,277
King's College London	-	-	850,659
The Open University	-	-	29,909
Brunel University London	352,568	352,568	-
Leeds Teaching Hospitals NHS Trust	104,631	104,631	-
University of Edinburgh	175,990	175,990	-
University of Sussex	249,969	249,969	-
University of Liverpool	170,788	170,788	-
Imperial College London	299,991	299,991	-
	<u>5,963,846</u>	<u>5,963,846</u>	<u>6,336,897</u>

The charity awards grants for specific research projects to various institutions, as part of their charitable activities.

Negative amounts represent an underspend on grants previously made, returned to CCLG.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

10 Expenditure on support costs

	Basis of allocation	2023 £	2022 £
Staff costs	*1	653,872	656,900
Depreciation & loss on disposal	*1	14,074	13,069
Occupancy expenses	*1	143,429	120,538
Postage	*1	14,253	14,789
Staff training	*1	10,205	3,658
Professional fees	*1 / *2	35,289	24,392
		<u>871,122</u>	<u>833,346</u>
Analysed between			
Raising funds		167,166	161,791
Charitable activities		703,956	671,555
		<u>871,122</u>	<u>833,346</u>

*1 Support costs, excluding governance costs, have been allocated as follows:

<i>Cost of raising funds</i>	20% (2022 - 20%)
<i>Charitable activities</i>	
Support for research	20% (2022 - 20%)
Information for patients and families	30% (2022 - 30%)
Improving treatment and care	30% (2022 - 30%)

*2 Professional fees include governance costs of £35,289 (2022 - £24,392). Governance costs have been allocated as follows:

<i>Charitable activities</i>	
Support for research	17% (2022 - 17%)
Information for patients and families	22% (2022 - 22%)
Improving treatment and care	61% (2022 - 61%)

The amount charged to the SOFA in respect of auditor's remuneration was:

- statutory audit £9,780 (2022 - £9,300)
- other services £989 (2022 - £1,253)

11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

12 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits during the year.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

13 Employees

The average monthly number of employees during the year was:

	2023	2022
	Number	Number
Total	22	22

Employment costs

	2023	2022
	£	£
Wages and salaries	709,013	633,405
Social security costs	68,378	63,204
Other pension costs	66,038	58,235
	<u>843,429</u>	<u>754,844</u>

The number of employees whose annual remuneration (including pension contributions) was more than £60,000 is as follows:

	2023	2022
	Number	Number
£60,001 - £70,000	1	-
£70,001 - £80,000	-	1
£80,001 - £90,000	1	-
£90,001 - £100,000	-	1
£100,001 - £110,000	1	-
	<u>1</u>	<u>1</u>

Remuneration of key management personnel

The remuneration of key management personnel, is as follows.

	2023	2022
	£	£
Aggregate compensation	272,052	253,428
	<u>272,052</u>	<u>253,428</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

14 Tangible fixed assets

	Computer equipment, furniture and fixtures £	Total £
Cost		
At 1 January 2023	87,438	87,438
Additions	2,592	2,592
	<u>90,030</u>	<u>90,030</u>
At 31 December 2023	90,030	90,030
Depreciation and impairment		
At 1 January 2023	44,952	44,952
Depreciation charged in the year	14,074	14,074
	<u>59,026</u>	<u>59,026</u>
At 31 December 2023	59,026	59,026
Carrying amount		
At 31 December 2023	31,004	31,004
	<u>42,486</u>	<u>42,486</u>
At 31 December 2022	42,486	42,486

15 Stocks

	2023 £	2022 £
Merchandise stock	31,790	30,263
Educational literature	23,271	22,766
	<u>55,061</u>	<u>53,029</u>
	<u>55,061</u>	<u>53,029</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

16 Debtors

	2023	2022
	£	£
Amounts falling due within one year:		
Trade debtors	19,656	7,833
Grant debtors	3,512,427	2,830,745
Rent deposit	16,200	16,200
Prepayments and accrued income	150,076	155,731
Accrued legacy income	138,500	172,500
	<u>3,836,859</u>	<u>3,183,009</u>
	2023	2022
	£	£
Amounts falling due after more than one year:		
Grant debtors	<u>1,537,021</u>	<u>1,739,600</u>
Total debtors	<u>5,373,880</u>	<u>4,922,609</u>

17 Creditors: amounts falling due within one year

	2023	2022
	£	£
Deferred income	19,559	100
Trade creditors	16,316	17,056
Grant creditors	4,821,058	3,911,669
Accruals	36,886	39,073
	<u>4,893,819</u>	<u>3,967,898</u>

Deferred income includes income received in respect of meetings postponed until the next financial year.

18 Creditors: amounts falling due after more than one year

	2023	2022
	£	£
Grant creditors	<u>2,383,283</u>	<u>2,614,739</u>

19 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees.

The amount recognised in unrestricted expenditure was £66,038 (2022 - £58,235).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

20 Restricted funds

The income funds of the charity include restricted funds which comprise the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds				Balance at 31 December 2023 £
	Balance at 1 January 2023 £	Income £	Expenditure £	Transfers £	
Tumour specific funds	1,573,167	805,435	(773,309)	-	1,605,293
CCLG Prize	364	-	-	-	364
General research fund	3,180	2,490	-	-	5,670
Adam Hay fund	11,222	40	-	-	11,262
CCLG Senior Members Group	7	-	-	-	7
PODC	5,896	954	-	-	6,850
POTG	-	10,960	(8,804)	-	2,156
The Little Princess Trust fund	6,200	4,510,486	(4,510,486)	-	6,200
Treatment Guidelines fund	614	-	-	-	614
TYAC Lisa Thaxter	36,632	-	(15,000)	-	21,632
Child Cancer Smart	38,105	-	(319)	-	37,786
PORT	420	-	-	-	420
CCLG Research Network					
Partner Charity	-	652,188	(652,188)	-	-
Neuroblastoma Nursing Group	10,500	-	(9,000)	-	1,500
PODC - Iraq Fund	8,384	1,310	-	-	9,694
Young Lives vs Cancer Chief					
Nurse Funding	5,948	83,309	(86,925)	-	2,332
Health Information	16,920	12,300	(12,300)	-	16,920
TYAC General Restricted	1,000	-	-	-	1,000
TYAC Research	66,000	496	-	-	66,496
Projects Restricted Fund	185,378	1,237,832	(320,812)	-	1,102,398
	<u>1,969,937</u>	<u>7,317,800</u>	<u>(6,389,143)</u>	<u>-</u>	<u>2,898,594</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

20 Restricted funds

(Continued)

	Balance at 1 January 2022 £	Movement in funds			Balance at 31 December 2022 £
		Income £	Expenditure £	Transfers £	
Tumour specific funds	1,112,573	761,793	(301,199)	-	1,573,167
CCLG Prize	54	310	-	-	364
General research fund	3,940	2,000	(2,760)	-	3,180
Adam Hay fund	11,102	120	-	-	11,222
CCLG Senior Members Group	7	-	-	-	7
PODC	4,782	1,114	-	-	5,896
POTG	210	8,350	(9,737)	1,177	-
The Little Princess Trust fund	6,200	5,639,669	(5,639,669)	-	6,200
Treatment Guidelines fund	18,225	-	(17,611)	-	614
TYAC Lisa Thaxter	44,132	-	(7,500)	-	36,632
Child Cancer Smart	72,867	5,000	(39,762)	-	38,105
PORT	420	-	-	-	420
CCLG Research Network					
Partner Charity	42,467	324,425	(366,892)	-	-
Neuroblastoma Nursing Group	10,500	-	-	-	10,500
PODC - Iraq Fund	4,108	4,276	-	-	8,384
Young Lives vs Cancer Chief					
Nurse Funding	-	79,261	(73,313)	-	5,948
Health Information	-	27,375	(10,455)	-	16,920
TYAC General Restricted	-	1,000	-	-	1,000
TYAC Research	-	66,000	-	-	66,000
Projects Restricted Fund	-	241,322	(55,944)	-	185,378
	<u>1,331,587</u>	<u>7,162,015</u>	<u>(6,524,842)</u>	<u>1,177</u>	<u>1,969,937</u>

Transfers have been made into restricted funds from unrestricted funds to underwrite a cash deficit on a fund.

Tumour specific funds

Represents income received from donors with a specific request that the funds are used in support of grants for a particular tumour type.

CCLG Prize

Represents income received from donors to fund the CCLG Prize.

General research fund

Represents income received from donors with a specific request that the funds are used for research purposes.

Adam Hay fund

This fund has been established to continue work done by the Adam Hat's charity (which merged with CCLG in 2011) in neuroblastoma research and psychological support for children and families.

CCLG Senior Members Group

Represents income received from the Senior Members' Group to be used for their activities.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

20 Restricted funds

(Continued)

PODC

Represents income received from donors to be used for the Paediatric Oncology in Developing Countries (PODC).

POTG

Represents income received from donors to be used for the Paediatric Oncology Trainees' Group (POTG).

The Little Princess Trust fund

Represents income received from The Little Princess Trust to fund future instalments of research grants awarded.

Treatment Guidelines fund

Represents a grant received for the development of rare endocrine tumour guidelines.

TYAC Lisa Thaxter

Represents income received for providing and supporting education and training to professionals working in the field of teenage and young adult cancer. This was previously a restricted fund in TYAC and has transferred to CCLG as part of the closure of TYAC, with the same restrictions maintained.

Child Cancer Smart

Represents income received for a research programme, guideline development and awareness raising focusing on earlier diagnosis of childhood cancer.

PORT

Represents income received for the Paediatric Oncology Reference Team, a group of parents of children with cancer who review clinical trial and other research information to ensure it is appropriate for children with cancer and their families.

CCLG Research Network Partner Charity

Represents income research from other charities to fund research projects.

Neuroblastoma Nursing Group

Represents income received to support the costs of running the national neuroblastoma nursing group, a group of CCLG member nurses with a special interest in neuroblastoma.

PODC - Iraq Fund

Represents donations received to specifically support work to improve the treatment and care of children with cancer in Iraq.

Young Lives vs Cancer Chief Nurse Funding

Funding for the Chief Nurse role and associated projects.

Health Information

Funds received to support the production of health information for patients and families.

TYAC General Restricted

Fundraising and donations to support work specifically for teenagers and young adults with cancer.

TYAC Research

Income restricted to support research projects into teenage and young adult cancer.

Projects Restricted Funds

Income restricted to support specific projects including work related to research.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

21 Unrestricted funds

	Balance at 1 January 2023 £	Movement in funds			Balance at 31 December 2023 £
		Income £	Expenditure £	Transfers £	
General funds	490,960	1,161,513	(1,262,515)	-	389,958

	Balance at 1 January 2022 £	Movement in funds			Balance at 31 December 2022 £
		Income £	Expenditure £	Transfers £	
General funds	591,470	1,149,760	(1,249,093)	(1,177)	490,960

22 Analysis of net assets between funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Fund balances at 31 December 2023 are represented by:			
Tangible assets	31,004	-	31,004
Current assets/(liabilities)	358,954	5,281,877	5,640,831
Long term liabilities	-	(2,383,283)	(2,383,283)
	<u>389,958</u>	<u>2,898,594</u>	<u>3,288,552</u>
	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Fund balances at 31 December 2022 are represented by:			
Tangible assets	42,486	-	42,486
Current assets/(liabilities)	448,474	4,584,676	5,033,150
Long term liabilities	-	(2,614,739)	(2,614,739)
	<u>490,960</u>	<u>1,969,937</u>	<u>2,460,897</u>

23 Events after the reporting date

The charity was notified of an additional legacy during the year. The timing and amount of the legacy income is uncertain as at the balance sheet date and therefore no income relating to this legacy has been recognised in these accounts.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

24 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2023 £	2022 £
Within one year	18,397	36,530
Between two and five years	-	18,397
	<u>18,397</u>	<u>54,927</u>

Amounts recognised in the SOFA as an expense during the period in respect of operating lease arrangements are £36,530 (2022 - £34,730).

25 Related party transactions

There have been no other related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 12 to the financial statements.

26 Cash generated from operations

	2023 £	2022 £
Surplus for the year	827,655	537,840
Adjustments for:		
Investment income recognised in statement of financial activities	(56,177)	(5,935)
Depreciation and impairment of tangible fixed assets	14,074	13,069
Movements in working capital:		
(Increase) in stocks	(2,032)	(17,603)
(Increase) in debtors	(451,271)	(1,153,289)
Increase in creditors	675,006	612,291
Increase in deferred income	19,459	100
Cash generated from/(absorbed by) operations	<u><u>1,026,714</u></u>	<u><u>(13,527)</u></u>

27 Analysis of changes in net funds

During the year the charity had no borrowings or obligations under finance leases. The changes in net funds of the charity therefore solely comprise of cash and cash equivalents.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

England & Wales - Charity number 1182637

Accounts

Charity Registration No. 1182637 (England and Wales)

Charity Registration No. SC049948 (Scotland)

Company Registration No. CE016951 (England and Wales)

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

**TRUSTEES' REPORT AND
FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED
31 DECEMBER 2022**

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	David Oxnam (Chair of Board of Trustees) Gayle Routledge Rachel Wilcox David Hobin Sarah Curtis
Chief Executive	Ashley Ball-Gamble
Charity number	1182637 (England and Wales) SC049948 (Scotland)
Company number	CE016951
Operating name	CCLG
Principal address	Century House 24 De Montfort Street Leicester LE1 7GB
Auditor	Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT
Bankers	HSBC Bank Plc 2-6 Gallowtree Gate Leicester LE1 1DA Scottish Widows Bank Plc PO Box 12757 67 Morrison Street Edinburgh EH3 8YJ CAF Bank Ltd 25 Kings Avenue Kings Hill Kent ME19 4JQ

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

CONTENTS

	Page
Trustees' report	1 - 10
Independent auditor's report	11 - 13
Statement of financial activities	14
Balance sheet	15
Statement of cash flows	16
Notes to the financial statements	17 - 31

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees of The Children's Cancer and Leukaemia Group are pleased to present their annual report and financial statements for the year ended 31 December 2022.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

OBJECTIVES AND ACTIVITIES

The objectives of The Children's Cancer and Leukaemia Group (CCLG) as defined in the constitution are:

For the public benefit, the relief of sickness and suffering of children, teenagers and young adults with cancer and advancement of education in the field of children, teenagers and young adults with cancer, in particular but not exclusively by:

1. The relief of sickness and promotion and protection of good health by supporting research into the nature, causes, diagnosis, treatment and social consequences of cancer in children, teenagers and young adults, and to publish the useful results of such research.
2. The relief of suffering of children, teenagers and young adults with cancer and their families and carers, through the provision of information and support services to them.
3. The advancement of the education of the public in all areas relating to cancer in children, teenagers and young adults.
4. The advancement of education and clinical practice by the dissemination of knowledge of the latest research and best practice amongst professionals and practitioners engaged in the treatment, care and support of children, teenagers and young adults with cancer.

The main beneficiaries of the work carried out by the charity are children, teenagers and young adults with cancer and their families in the United Kingdom and elsewhere in the world.

CCLG is the UK and Ireland's professional association for all those involved in the treatment and care of children with cancer (including leukaemia). Our multidisciplinary and multi-professional membership continues to grow. At the end of 2022, there were in excess of 1,300 members. In addition, we host Teenagers and Young Adults with Cancer (TYAC), a multidisciplinary and multi-professional membership association for those involved in the treatment and care of teenagers and young adults with cancer. At the end of 2022, there were more than 400 TYAC members.

Through our membership activities, we provide an active forum for professionals to work together to share best practice and advance education and professional development. Members are able to network with both national and international colleagues for advice and support and receive information and vital updates on specific diseases and treatments. This ensures every child with cancer receives the best possible treatment and care available wherever they live.

The activities of our professional association and membership body include:

- Specialist networks groups: These are a core part of our professional activities enabling professionals to work with others who share the same clinical interests.
- Key conferences and events: We organise a range of meetings each year to ensure members are kept up to date with the latest developments in cancer research, care, and treatment. Our annual meeting offers an opportunity for all of our members to network with colleagues from across Britain and Ireland.
- Professional voice for children, teenagers and young adults: We advise governments and other bodies and ensure that we are represented on important groups or in consultations, for example in the area of NHS commissioning of children's cancer services or the development of NICE quality standards and guidance.
- Online members' area: A vital hub for professionals involved in the care of children and young people with cancer, providing a wealth of resources and educational opportunities for our membership.

Our members are dedicated to ensuring that children and young people have a greater chance of survival and a better life after treatment.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

We support children and young people with cancer and their families in a variety of different ways:

- Written by experts, our comprehensive quality-assured range of information booklets, leaflets and online content helps patients and their families understand their diagnosis, treatment and what to expect now and in the future. Our publications are available free of charge to those who need them.
- Our free quarterly magazine, Contact, offers help, support and information for families of children, teenagers and young adults with cancer.
- We also organise informative events for parents and families each year. Since 2014, we have organised the UK Childhood Cancer Conference. This hugely successful event brings together parents, researchers, healthcare professionals and charities to discuss the latest research into childhood cancer and talk about the issues which affect parents.
- Our website is a comprehensive resource of childhood cancer information. Our online 'Childhood Cancer Information Hub', brings together information resources (booklets and leaflets, web pages, film and video content and more) into a single 'one-stop-shop', which is easily searchable and can be filtered by cancer type, audience, etc.

The outstanding progress made in cancer treatment is the result of extensive research studies and clinical trials over the last 40 years which now underpin today's standard treatments. During this time, CCLG has played a key role in the success seen in the world of children's cancer so that now over 80% of children are cured. But there are still some childhood cancers with a poor outlook, and some treatments can have long-lasting and devastating side effects. Further research is vital to improve survival rates and to find kinder treatments. We fund and support a variety of research into childhood cancers including:

- The CCLG Tissue Bank is the UK's largest collection of tumour, DNA and other tissue samples from childhood cancer patients. Samples enable scientists and researchers to get as close to the disease as possible so they can find new ways of diagnosing children, new treatments and cures for patients.
- We offer funds and grants to launch new research projects and develop new clinical trials.
- We work in partnership with other charities and organisations to support research. We use our research-funding infrastructure, as well as the scientific and medical expertise of our membership, to support smaller charities to meet their research aims. For example, by managing a research funding programme or helping them to identify research to support.
- We can 'ringfence' funds so that our supporters can raise funds towards a cancer-specific research project.
- Our Special Interest Groups provide a forum for discussion and planning of research and bring together potential collaborators. We organise and support scientific meetings where research findings are shared and discussed, and we support our membership to be involved in planning research and attending important meetings through bursaries and sponsorship.
- We support the next generation of childhood cancer researchers through our trainee scheme in partnership with the National Cancer Research Institute. This allows trainee paediatric oncologists to be involved in the development and management of clinical trials, by attending meetings, being mentored by experienced researchers, and gaining insight into research activity.
- Since 2017, CCLG has been a member of the Association of Medical Research Charities, demonstrating our commitment to funding high-quality, world class research and confirming the high standard of the processes we use to select and fund research.

We measure our success in achieving our objectives in a number of ways:

- The number of patient information products distributed, and the number of visits to the 'about childhood cancer' section of our website, are some measures used to ascertain our success in supporting patients and their families. We also gather feedback on our information products.
- The number of publications in journals, the number of studies accessing the CCLG Tissue Bank, and the amount of tissue samples banked, are some measures used to ascertain the success of our research programme including the CCLG Tissue Bank.
- The number of members and retention of members are some basic measures used to ascertain how we are supporting the community of professionals we serve through our professional association activities.
- The number of research projects funded and their value, and the outcome of research projects including peer-reviewed papers in scientific journals.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

ACHIEVEMENTS AND PERFORMANCE

Around 1,800 children (aged 0-14) and a further 2,300 teenagers and young adults (aged 15-25) are diagnosed with cancer each year in the UK. Although overall five-year survival for cancer in children and young people is now over 80%, for some cancers there have not been such dramatic improvements in survival, and even where treatment is successful, many survivors have to contend with life-long and life-limiting side effects. We continue to work towards the four main goals set out in our strategic plan, launched in 2018, and the goals of the TYAC strategic plan, launched in 2019, as detailed below. Highlights of our achievements during the year are set out under each of these strategic goals.

Providing leadership and expertise for the treatment and care of children and young people with cancer

As the UK and Ireland's professional association for those working in the field of paediatric oncology and haematology, CCLG is a leading voice for children's cancer, liaising with community groups, the government and the NHS to influence policies. We use our expertise to improve treatment and care and meet the needs of patients and families. In 2022:

- Our Annual Meeting returned to being an in-person event, following a virtual meeting in 2021 as a result of the COVID-19 pandemic. This event brought together more than 250 professionals to share the most up-to-date news, research and developments in all areas of treatment and care. A new format programme resulted in increased opportunities to participate in the event for our multi-professional membership.
- At the Annual Meeting, we celebrated our first ever Member Awards and Research Awards, with a ceremony taking place as part of the meeting dinner. The Awards celebrated the outstanding contribution of members and researchers to the work of CCLG and children with cancer. A total of eight Member Awards and five Research Awards were presented, introduced to acknowledge and reward teams and individuals for best practice excellence and cutting-edge research. Our Member Awards categories included the 'Johann Visser Award for Outstanding Contribution', for those who have gone above and beyond to support the work and services of CCLG and its members, named in honour of long-standing CCLG member Dr Johann Visser who sadly passed away in 2020.
- We held a number of other in-person educational opportunities for members during the year, including a two-day specialist course in soft tissue sarcomas, a supportive care education day, and continued our series of late effects and nursing online lectures.
- We continued to produce and update a number of clinical treatment guidelines, ensuring standardised, high quality and evidence-based treatment for all children, particularly in diseases where there is currently no open clinical trial.
- We launched CCLG Connect, an online community for the CCLG membership, towards the end of the year. This provides a space for members to connect with each other, participate in group activities, share best-practice and research outputs, ask questions and disseminate useful resources. So far, feedback on these new resources has been hugely positive.
- Our strategic partnership with Young Lives vs Cancer continued, providing benefits to both organisations. The Chief Nurse role at CCLG is funded by Young Lives vs Cancer, working to provide clinical and health system insight and intelligence to the latter and enhance support for nursing and allied health professionals within CCLG.
- Following changes to the Young Lives vs Cancer (formerly CLIC Sargent) nursing programme, we worked with Young Lives vs Cancer to develop a new Chief Nurse role at CCLG. The role is funded by Young Lives vs Cancer and employed by CCLG, working to enhance support for nursing and allied health professionals (AHPs), manage a range of nursing and AHP programmes at CCLG, supporting our nursing and AHP working groups, and provide clinical and health system insight and intelligence to Young Lives vs Cancer.
- We published the Career and Education Framework for Children and Young People (CYP) Cancer Nursing. This new version was extensively updated in 2022 by a working party from across the joint Royal College of Nursing (RCN) and CCLG nursing groups. The framework sets out competencies for knowledge and skills across a range of topic areas in CYP cancer care relevant to career stages. This highlights the professional development required for nurses at all levels of practice aspiring to build or maintain a career in cancer nursing. The framework is intended for use by all nurses who provide care to children and young people (CYP) with cancer, or cancer-like disease, in paediatric services, or services that are unbound by age which may encounter CYP with cancer.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

- We published the Systemic Anti-Cancer Therapy (SACT) Passport for CYP Cancer Services. The passport provides a national standardisation of education and assessment for the fundamental skills and knowledge required to safely handle and administer SACT. It is designed for practitioners handling and administering SACT and treating children and young people within Principal Treatment Centres (PTCs), Paediatric Oncology Shared Care Units (POSCUs), and community services. The passport will work most effectively if all UK CYP cancer PTCs and POSCUs adopt it for their SACT training programmes to facilitate standardisation and ease of transfer of skills without repetition and duplication of resources.
- In February 2022, the Secretary of State for Health and Social Care announced the development of a new '10-year cancer plan' to set out a vision to deliver world class cancer care for England. As part of the process of developing this plan, stakeholders including patients, professionals, charities and others were invited to submit evidence to help determine the priorities for the plan. CCLG drew on our expert membership and consulted with parents of children with cancer to develop a detailed response to this call for evidence. We wanted to be clear that children and young people's cancers are different from adult cancers, and that all too often childhood cancers are included in strategies, plans and documents that focus on 'all cancers' – which really means adult cancers. The 10-year cancer plan was not progressed by Government, and instead a new major conditions strategy was proposed. In early 2023, with our partners at Young Lives vs Cancer, we renewed our call for a specific children and young people's cancer plan.

Improving diagnosis times by increasing awareness

The significance of a delayed diagnosis presents a challenge for primary health care professionals, who are required to triage symptoms that may point to a cancer diagnosis and make appropriate onward referrals. Many symptoms associated with cancer are non-specific and are seen every day in general practice, whilst a cancer diagnosis is seen infrequently.

Delays in the diagnostic pathway may well lead to more advanced disease at presentation, with subsequent greater risk of death, greater morbidity, and inevitably, distrust of the medical system. There is evidence that tumours presenting in childhood in the UK are larger, at a more advanced stage and require more therapy than those presenting in other parts of Europe. We work to improve diagnosis times for children and young people with cancer. In 2022:

- We continued working on our Child Cancer Smart project, which will result in a number of clinical referral guidelines, and public and professional awareness tools, on the signs and symptoms of childhood cancer. Some of this activity, which relies on the input and support of a range of health professionals, was delayed due to the pressures on the NHS during the COVID-19 pandemic. Progress has been made during the year and we plan to publish the first guidelines and tools resulting from the Child Cancer Smart project in 2023.
- The Child Cancer Diagnosis Study, a research project funded by the National Institute for Health Research (NIHR) and CCLG, and jointly run by CCLG and The University of Nottingham, continued in all Principal Treatment Centres in the UK. This innovative, nationwide research will give us, for the first time, an accurate picture of the routes to diagnosis and where we can develop interventions to drive improvements. In March 2022, we published the protocol for the Study in the prestigious British Medical Journal, so that clinicians and researchers around the world could launch similar studies to help close the gap between diagnosis and treatment of childhood cancer.
- In September 2022, as part of Childhood Cancer Awareness Month, we relaunched our #SpotChildCancer campaign, urging parents to be aware of the signs and symptoms of childhood cancer and to 'trust their instincts' if they feel something is 'not right' with their child.

Strengthening our expert information portfolio to support more families of a child with cancer

Looking after a child with cancer can be a scary and lonely experience for families. Our goal is to deliver the right information at the right time and make a positive difference to their daily lives. We continue to be the leading provider of expert-written, award-winning and quality-assured information about all aspects of childhood cancer, from diagnosis to life when treatment has finished. In 2022:

- We continued to provide information booklets and leaflets to hospitals and directly to families during the year. A number of new publications were produced, and further existing publications were reviewed and revised.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

- We produced four issues of our popular magazine, Contact. Feedback on the new format and design, launched in 2021, continues to be overwhelmingly positive, and Contact continues to support families across the UK and around the world.
- We launched a comprehensive information resource aimed at survivors of childhood cancer. This new late effects information portfolio aims to help prepare childhood cancer patients for how their life may be affected as a result of their treatment. It includes an updated guide for survivors of childhood cancer, as well as 24 new factsheets about different late effects, and online information.
- We launched a series of online 'research talks' aimed at parents of children with cancer (and the general public), which aim to explore the world of childhood cancer research in an accessible way, with each episode in the series featuring a talk from an expert speaker, as well as the opportunity for attendees to ask questions. Recordings of the webinars are made available on our YouTube channel for those unable to attend the live events.
- Our closed Facebook group for parents and carers of children with cancer, which allows members to seek advice and support from those with similar experiences, and, uniquely, 'ask the experts' through posting questions answered by our clinical membership community, continued to grow, reaching over 1,400 members.
- We successfully passed our second reassessment for the Patient Information Forum (PIF) PIFTick accreditation for our health information. This quality standard is awarded following rigorous assessment of our information production processes, and demonstrates our commitment to reliable, expert, high-quality health information.

Supporting and funding world-class research

Our aim is to both support and fund world-class research, deepen understanding and foster collaborations across the childhood cancer community. One of our most important areas of work is to offer opportunities for our members to develop scientific networks and belong to a wider research community dedicated to childhood cancer.

Our Research Strategy outlines our exciting plans to fund and support innovative world-class research into childhood cancer and recognises the importance of collaboration, both nationally and internationally, to achieve improvements.

- We fund research directly, and work with partner charities to support them to fund the best possible research, using our well-established research funding expertise, experience and infrastructure. In total, between our own research funding and that of the partners we work with, 31 new research projects totalling over £6.2 million were funded in 2022. Grants awarded cover a wide range of childhood cancer types, projects focusing on different parts of the cancer experience, and covering a range of different types of research, including discovery science, clinical trials, late effects and systematic reviews. We awarded the first research grants under the TYAC brand during the year, focusing on late effects in teenagers and young adults.
- Our partnership with The Little Princess Trust continues to go from strength to strength. We support The Little Princess Trust to fund the best quality research, with a focus on finding better, kinder treatments. We provide specialist advice and expertise, as well as run and manage their research-funding programme on their behalf. This partnership helps to minimise duplication, and share expertise meaning that ultimately more money is spent directly on research. During the year, the Little Princess Trust awarded CCLG just over £5.5 million to fund 24 projects, including three large 'innovation grants' designed to support innovative new research proposals. During the year, we launched a similar partnership initiative with Candlelighters, a Leeds-based charity, to support them with their research funding programme.
- We became a partner of the National Cancer Research Institute (NCRI), a UK-wide partnership between research funders working together to maximise the value and benefits of cancer research for patients and the public. NCRI partners are organisations that fund cancer research in the UK, working together to coordinate their research with the aim of avoiding unnecessary duplication and maximising the impact of research for cancer patients and the public.
- We published our first Research Impact Report, showcasing the impact our research has had on driving forward pioneering breakthrough into finding a cure for childhood cancer. The report highlights that over £15.5 million worth of research has been funded through CCLG making a vital difference to treatments and care for children with cancer.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

- We launched a new research blog, aiming to make research understandable and accessible to all those in the childhood cancer community and beyond, including parents, professionals and the general public. The blog shares research concepts and specific projects in an accessible way, raising awareness of both the research we undertake and of cancer research more generally.
- In December, the final workshop of the Children's Cancer Priority Setting Partnership (PSP), initiated by CCLG and co-funded with The Little Princess Trust, took place and the Top 10 Priorities in Children's Cancer Research were announced. The PSP ran under the auspices of the James Lind Alliance (JLA). The JLA is a non-profit making initiative established in 2004. It brings patients, carers and clinicians together in Priority Setting Partnerships (PSPs) to identify and prioritise the top 10 unanswered questions or evidence uncertainties that they agree are the most important. The aim of this is to make sure that health research funders are aware of the issues that matter most to the people who need to use the research in their everyday lives. The publication of the Top 10 Priorities in Children's Cancer Research aims to highlight to researchers and research funders key areas of focus that matter to childhood cancer patients and survivors, their families, and the professionals that care for them.

Teenagers and Young Adults with Cancer (TYAC)

Teenagers and Young Adults with Cancer (TYAC) is the professional association for those working in teenage and young adult (TYA) oncology. TYAC merged with CCLG in 2018, and in 2019 we launched a new strategy for the work of TYAC, setting out how we would continue to drive improvements in TYA cancer care, and support the development of professionals working in the field.

During the year, we continued to develop good practice guidance for professionals working with teenagers and young adults with cancer, launched a number of new networking and educational groups for professionals, including one focused on palliative and end of life care, and another jointly with CCLG focusing on developing ambulatory care services.

Fundraising

All of our work is dependent on the generosity of our supporters. A programme of fundraising underpins our ability to fund research, support patients and families, and improve treatment and care for children and young people with cancer. In 2022:

- Our Special Named Fund programme continued to grow. After their cancer experiences, families sometimes consider setting up their own charity. For many, our Special Named Funds may be a great alternative. We support families to achieve their fundraising objectives, while taking away the administrative burden of setting up and running a charity. At the end of the year, there were approximately 85 Special Named Funds at CCLG (2021: 70), each raising funds to support research into a specific type of childhood cancer.
- We capitalised on the 'lessons learned' around virtual fundraising during the pandemic, continuing to offer a range of 'virtual events', as well as beginning to implement other elements of our new fundraising strategy as COVID-19 restrictions allowed.
- We continued to invest sustainably in our fundraising infrastructure, including recruiting our first posts focused on fundraising from grant-making trusts and foundations, and further developing our fundraising offer.

Fundraising policy

We are reliant on donations to fund our vital work. Without the generosity of the public, we would not be able to continue providing support to children and young people diagnosed with cancer, and their families, nor fund research into childhood cancer. We believe that it is essential that we are clear and open about how we raise our funds and about the range of ways people can get involved and support our work.

People raise money for us in many different ways, including through taking part in sporting events, organising events in their local community, or fundraising at their place of work. We also provide opportunities for people to fundraise through providing access to places in key events, such as the London Marathon, and through providing fundraising materials. Our supporters can sign up to make regular donations, or play our lottery which we launched in 2018.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

We work with a number of corporate partners, and have received support from charitable trusts and foundations, and through grants from other charities.

We do not carry out door-to-door fundraising, nor do we use street fundraising to sign up supporters to regular donations.

Currently, none of our fundraising activities are conducted on our behalf by professional fundraising agencies.

CCLG is registered with the Fundraising Regulator. We are committed to adhering to the Code of Fundraising Practice. During the year, we received no complaints about our fundraising activities.

Regular updates are provided to our board of trustees to ensure that they have a good oversight of our activities.

FINANCIAL REVIEW

Transactions for the year ended 31 December 2022 fall into roughly the same categories as in previous years. Income generally consists of donations and fundraising income, subscriptions (comprising individual membership subscriptions and hospital subscriptions for health information), registration fees for meetings and events, funding from partner charities such as The Little Princess Trust to support research projects and legacy income. We are grateful to Young Lives vs Cancer, Teenage Cancer Trust and The Little Princess Trust for their support of specific areas of our work. We also benefitted from a grant from The Medical Research Council UK Government COVID Medical Research Charity Support Fund, a scheme designed to support fundraising medical research charities who fund early-career researchers in response to the COVID-19 pandemic.

The major items of expenditure for CCLG remain staff salaries, professional meeting and event costs, the costs associated with the production of health information, and the awarding of research grants. Staffing costs represent a significant financial commitment, but our small, expert staff team is also responsible for the achievement of the majority of our charitable objectives. Staffing levels are kept under review, with the small, efficient team carrying out and coordinating the considerable activities of the charity.

Our overall income increased by £2,642,141, compared with the year ending December 2021. We saw an increase in donations and fundraising income during the year, as well as an increase in income from charitable activities, including an increase investment in research by our partners The Little Princess Trust.

CCLG has a number of restricted funds. Internal records are kept according to requirements for restriction, i.e. disease-specific donations for research into a specific type of cancer, or donations for a specific piece of work. The restricted funds are ring-fenced to support specific projects or areas of activity and cannot be used to support the general running costs of the organisation.

Expenditure increased in 2022 by £2,373,420 compared to 2021. The primary reason for the increase was an increase in research funding, although we saw increased costs across much of our activity as a result of both the COVID-19 pandemic (e.g. increased costs of holding events as the events industry recovers) and the cost-of-living crises (e.g. increased energy costs).

We ended the year with an overall surplus of £537,840. There was a deficit in unrestricted income/expenditure of £100,510, which was planned and represents the Trustees commitment to invest reserves held above the level of our reserves policy into our charitable activities. There was a surplus in restricted income/expenditure of £638,350. Much of our restricted funding is for research, and often funds build over several years before being expended in significant amounts to fund research projects. We plan to spend a significant amount of restricted funds in the next 12 months.

Reserves Policy

The trustees continue to consider the appropriate balance of financial stability and investment in charitable activity. The COVID-19 pandemic has highlighted the importance of an appropriate reserves policy. It is important we continue to hold a level of reserves which can sustain our activity until we have a fuller picture of what post-pandemic fundraising might look like in the medium-term.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

We have plans in place to ensure CCLG is 'fit for the future' and our reserves policy will ensure we are able to meet those plans. At the end of the year, we have reviewed our reserves policy for CCLG and aim to hold a target level of free reserves (unrestricted funds less tangible fixed assets) of £400,000, which the trustees consider to be approximately six months of core expenditure, including staff salaries, accommodation costs and general running costs. Total reserves at 31 December 2022 were £2,460,897 of which £1,969,937 are restricted and £490,960 are unrestricted. As at 31 December 2022 the charity's free reserves totalled £448,474, which is in line with the reserves policy. Given the current economic uncertainty, the trustees consider it prudent to continue to spend excess reserves on its charitable activities, while keeping the reserves policy under review. The trustees consider that this ensures that CCLG is 'fit for the future'.

Our restricted reserves appear high, at £1,969,937 at the end of 2022. Much of our restricted income is raised by families, ring-fenced for research into specific types of childhood cancer. Research requires significant investment, and thus many of our funds grow over the course of several years before a large sum of money is awarded in the form of a research grant. Our restricted reserves comprise a large number of specific restricted funds which are ring-fenced to a specific purpose, and therefore cannot be used for general activities. Levels of funds are reviewed on a regular basis and spent on charitable activities as soon as sufficient funds are available. We are planning to invest a significant amount of restricted reserves into research during 2023.

Investment policy

The Trustees previously reviewed our plans for investments to consider the most appropriate way of managing these, balancing cashflow, risk and reward. Given the ongoing uncertainty of the financial impact of the COVID-19 pandemic, the cost-of-living crisis, high inflation, and future grant commitments, no further action has been taken on investments. Management accounts are produced for the trustees, and a cashflow forecast considerably facilitates management and prediction of charity income.

Risk Management

CCLG is also aware of the requirement to carry out a risk review of its activities. The trustees reviewed the risks the charity faces during the year. A Risk Register is in operation, documenting the systems in place to mitigate those risks, and is kept under review by the trustees.

FUTURE ACTIVITIES

All future activities planned are designed to ensure that CCLG continues to fulfil its objectives for children and young people with cancer, and their families, as the ultimate beneficiaries. As the membership of CCLG continues to grow, so does the activity our members are involved in. Our specialist network groups continue to be increasingly active, supporting our activities and providing specialist advice to commissioners of healthcare services and others. The CCLG executive continues to consider ways that CCLG can advance education and professional development, and share and guide best practice. The CCLG executive is a committee comprised of elected members of the CCLG professional body, along with the CEO, who have delegated authority from the Trustees for deciding and implementing the strategy of the organisation as it relates to the clinical, research and professional elements of our work.

Key planned activity for the next 12 months includes:

- Researching, designing, building and launching a new website, that uses more modern technology and better meets the needs of our various audiences.
- Developing and launching a new research strategy, which reflects the Top 10 Research Priorities for Children's Cancer identified through the Children's Cancer Priority Setting Partnership.
- Reviewing our health information content and increasing the range of content available in alternative formats, in particular videos, to better meet the needs of our intended users.
- Launch the first guidelines and awareness tools as part of our ongoing Child Cancer Smart early diagnosis work.
- In partnership with other charities, to launch the first Teenage and Young Adult Cancer Awareness Month, to raise awareness of the unique needs of this age group, to raise awareness of the signs and symptoms of cancer in this age group, and to raise further funds to support targeted, specialist research in cancers affecting this age group.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

- Develop our range of patient/parent information products in response to demand and specific needs identified by both end-users and professionals. We also aim to continue raising awareness of CCLG and its activities, with a view to continuing to increase the income and resources available to us to meet our objectives.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Children's Cancer and Leukaemia Group (CCLG) was established in 1977 and became a registered charity (number 286669) in 1983. In 2019, a new CIO (registration number 1182637) was formed, with the activities, assets and liabilities of the previous charity transferred to the CIO.

The charity's governing instrument is the Constitution and the CIO was first registered in February 2019. In 2020, the CIO became registered with the Scottish Charity Regulator (registration number SC049948).

The board of trustees is independent of the CCLG membership. The board of trustees is responsible for managing the charity finances in support of the objectives defined by the CCLG Executive. There are a minimum of two and a maximum of eight trustees. One of the trustees will be an elected member of the CCLG Executive, providing a link between these two groups.

If a vacancy arises, the trustees may appoint any eligible person as a trustee. In selecting individuals for appointment as trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction to the charity. This consists of a briefing paper, as well as meetings with the Chair, CEO, and others as deemed appropriate. Regard is given to the training and development needs of any trustees that may arise. The board of trustees meets quarterly and is supported by staff. Four meetings were held in 2022.

The trustees come from a range of professional backgrounds, and bring new skills and highly relevant experience. Trustees serving during the year were:

David Oxnam (Chair of Board of Trustees)

Gayle Routledge

Rachel Wilcox

David Hobin

Sarah Curtis

The Chief Executive is responsible for the day-to-day operation of the charity on behalf of the trustees. The remuneration of key management is reviewed annually and is set against established pay scales, benchmarked in comparison with similar sized entities including both charities and medical professional associations. The trustees give their time freely and no remuneration was paid in the year. Details of trustee expenses are disclosed in note 12 to the accounts.

Key Management Personnel during the year were:

Ashley Ball-Gamble (Chief Executive)

Gill Smitherman (Head of Fundraising)

Claire Shinfield (Head of Engagement)

Jeanette Hawkins (Chief Nurse)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales and Scotland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities (Accounts and Reports) Regulations 2008, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

David Oxnam
Chair of the board of trustees

Dated: 28 June 2023

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Opinion

We have audited the financial statements of The Children's Cancer and Leukaemia Group (the 'charity') for the year ended 31 December 2022 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2022 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the trustees' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- the charity has not kept adequate and proper accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on pages 9-10, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under these acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charity.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- obtaining an understanding of the legal and regulatory framework applicable to the charity by considering the nature of the industry in which the charity operates and enquiring of management; and
- identifying the key laws and regulations considered to have a direct impact on the financial statements including the UK Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, UK Generally Accepted Accounting Practice and UK tax legislation; and
- assessing how the charity is complying with the applicable legal and regulatory framework by making further enquiries of management and observing the charity's control environment regarding compliance with regulations and fraud prevention; and
- assessing the susceptibility of the charity's financial statements to material misstatement, including how fraud might occur, by considering the effectiveness of the charity's accounting systems and controls and how these were monitored by management. Where the risk of material misstatement was considered to be higher in certain areas, further audit procedures were designed to address this increased risk; and

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

- discussing amongst the engagement team how and where fraud might occur in the financial statements and any potential indicators of fraud.

Audit response to risks of irregularities identified

Our procedures to respond to risks identified included the following:

- performing audit work over revenue recognition including analytical procedures and substantive tests of detail of a sample of revenue transactions; and
- reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations; and
- enquiry of charity staff responsible for compliance to identify any instances of non-compliance with laws and regulations; and
- enquiry of management, those charged with governance and other relevant parties around actual and potential litigation claims; and
- reviewing supporting documentation regarding actual and potential litigation claims; and
- reviewing minutes of meetings of those charged with governance; and
- performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias; and
- communicating identified laws and regulations and potential fraud risks to all engagement team members and assessing whether there are any indications of fraud or non-compliance with laws and regulations throughout the audit.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008, and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Newby Castleman LLP

Chartered Accountants
Statutory Auditor
West Walk Building
110 Regent Road
Leicester
LE1 7LT

29 June 2023

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £	Total 2021 £
Income from:					
Donations and legacies	3	796,659	1,100,415	1,897,074	1,454,655
Charitable activities	4	347,166	6,061,600	6,408,766	4,213,122
Investments	5	5,935	-	5,935	1,858
Total		1,149,760	7,162,015	8,311,775	5,669,635
Expenditure on:					
Raising funds	6	377,048	-	377,048	327,061
Charitable activities	7	872,045	6,524,842	7,396,887	5,036,553
Other	11	-	-	-	36,901
Total		1,249,093	6,524,842	7,773,935	5,400,515
Net (outgoing)/incoming resources before transfers		(99,333)	637,173	537,840	269,120
Transfers between funds		(1,177)	1,177	-	-
Net (expenditure)/income for the year/ Net movement in funds		(100,510)	638,350	537,840	269,120
Reconciliation of funds					
Total funds brought forward		591,470	1,331,587	1,923,057	1,653,937
Total funds carried forward		490,960	1,969,937	2,460,897	1,923,057

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

BALANCE SHEET

AS AT 31 DECEMBER 2022

	Notes	2022		2021	
		£	£	£	£
Fixed assets					
Tangible assets	14		42,486		41,442
Current assets					
Stocks	15	53,029		35,426	
Debtors	16	4,922,609		3,769,320	
Cash at bank and in hand		4,025,410		4,047,115	
			9,001,048		7,851,861
Liabilities					
Creditors: amounts falling due within one year	17	(3,967,898)		(3,395,160)	
Net current assets			5,033,150		4,456,701
Total assets less current liabilities			5,075,636		4,498,143
Creditors: amounts falling due after more than one year	18		(2,614,739)		(2,575,086)
Total net assets			2,460,897		1,923,057
The funds of the charity					
Restricted funds	20		1,969,937		1,331,587
Unrestricted funds	21		490,960		591,470
Total charity funds			2,460,897		1,923,057

The financial statements were approved and authorised for issue by the board of trustees on 28 August 2023 and are signed on its behalf by:

David Oxnam (Chair of Board of Trustees)
Trustee

The notes on pages 17 - 31 form part of these financial statements.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2022

	Note	2022	£	2021	£
		£		£	
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	25		(13,527)		128,855
Investing activities					
Purchase of tangible fixed assets		(14,113)		(10,123)	
Investment income received		5,935		1,858	
Net cash used in investing activities			(8,178)		(8,265)
Net cash used in financing activities			-		-
Net (decrease)/increase in cash and cash equivalents			(21,705)		120,590
Cash and cash equivalents at beginning of year			4,047,115		3,926,525
Cash and cash equivalents at end of year			4,025,410		4,047,115

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

Charity information

The Children's Cancer and Leukaemia Group is governed by its Constitution.

1.1 Basis of preparation

The charity is a public benefit entity as defined by FRS102. These financial statements have been prepared in accordance with: The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

For legacies, income is recognised and included in the financial statements when all of the following criteria are met:

- the charity has entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Where legacies have been notified to the charity but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Government grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

Income from charitable activities includes income received from grants, registration fees for meetings, member subscriptions and publication payments. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Investment income is earned through holding assets for investment purposes. It comprises bank interest and is recognised on an accruals basis.

1.5 Expenditure recognition

All expenditure, including the awarding of grants, is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Costs of raising funds includes costs incurred in seeking donations, grants and legacies, website costs and advertising.
- Expenditure on charitable activities includes research, educational activities and professional association activities to further the delivery of the objectives of the charity.
- Other expenditure includes wages and salaries covered by income from the Coronavirus Job Retention Scheme.

1.6 Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure in line with the objectives of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 10.

1.7 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Computer equipment, furniture and fixtures 5-10 years

1.8 Stocks

Stocks include merchandise stock and educational literature. Stocks that are held for resale are stated at the lower of cost and estimated selling price. Stocks held for distribution as part of the charity's activities are valued at their service potential, which the charity considers to be the cost of the materials.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

1.10 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities.

1.11 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows:

Allocation of support costs

The allocation of support costs is sensitive to changes in the level of work undertaken on each activity by the charity. The allocation is reassessed annually and amended when necessary to reflect current estimates.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

3 Income from donations and legacies

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £
Donations	574,290	825,676	1,399,966	586,019	578,545	1,164,564
Legacies	222,369	33,417	255,786	103,190	150,000	253,190
Government grants	-	241,322	241,322	-	36,901	36,901
	<u>796,659</u>	<u>1,100,415</u>	<u>1,897,074</u>	<u>689,209</u>	<u>765,446</u>	<u>1,454,655</u>

4 Income from charitable activities

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £
Registration fees for meetings and other project expenditure	90,942	18,244	109,186	26,772	6,500	33,272
Member subscriptions and publication payments	162,715	-	162,715	159,731	-	159,731
Grant income for research and operations	93,509	5,964,095	6,057,604	59,850	3,907,695	3,967,545
CLIC Sargent chief nurse funding	-	79,261	79,261	-	52,574	52,574
	<u>347,166</u>	<u>6,061,600</u>	<u>6,408,766</u>	<u>246,353</u>	<u>3,966,769</u>	<u>4,213,122</u>

5 Income from investments

	Unrestricted funds 2022 £	Total 2022 £	Unrestricted funds 2021 £	Total 2021 £
Interest	5,935	5,935	1,858	1,858
	<u>5,935</u>	<u>5,935</u>	<u>1,858</u>	<u>1,858</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

6 Expenditure on raising funds

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £
<u>Costs of raising funds</u>						
Fundraising platform fees	24,576	-	24,576	18,843	-	18,843
Website	2,077	-	2,077	5,917	-	5,917
Fundraising, marketing and publicity costs	188,604	-	188,604	165,383	480	165,863
Support costs (note 10)	161,791	-	161,791	136,438	-	136,438
	<u>377,048</u>	<u>-</u>	<u>377,048</u>	<u>326,581</u>	<u>480</u>	<u>327,061</u>

7 Expenditure on charitable activities

	Activities undertaken directly Note 8 £	Grant funding Note 9 £	Support Costs Note 10 £	Total 2022 £	Total 2021 £
Support for research	110,551	6,336,897	165,931	6,613,379	4,480,854
Information for patients and families	51,789	-	248,056	299,845	259,557
Improving treatment and care	226,095	-	257,568	483,663	296,142
	<u>388,435</u>	<u>6,336,897</u>	<u>671,555</u>	<u>7,396,887</u>	<u>5,036,553</u>
Unrestricted funds				872,045	697,984
Restricted funds				<u>6,524,842</u>	<u>4,338,569</u>
				<u>7,396,887</u>	<u>5,036,553</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

8 Expenditure on activities undertaken directly

	Support for research	Information for patients and families	Improving treatment and care	Total 2022	Total 2021
	£	£	£	£	£
Staff costs	97,944	-	-	97,944	51,393
Other tumour specific expenditure	10,530	-	-	10,530	13,190
Contact magazine expenses	-	20,360	-	20,360	36,825
Other publication expenses	-	28,312	-	28,312	1,403
Website	2,077	3,117	3,117	8,311	23,669
Cost of meetings	-	-	192,068	192,068	31,782
Travel expenses	-	-	11,729	11,729	1,072
Membership support costs	-	-	12,453	12,453	20,558
Other expenses	-	-	6,728	6,728	7,577
	<u>110,551</u>	<u>51,789</u>	<u>226,095</u>	<u>388,435</u>	<u>187,469</u>

9 Expenditure on grant funding

	Support for research	Information for patients and families	Improving treatment and care	Total 2022	Total 2021
	£	£	£	£	£
Grants to institutions:					
University of Birmingham	939,992	-	-	939,992	496,909
Newcastle University	1,146,110	-	-	1,146,110	1,326,430
UCL Institute of Child Health	991,135	-	-	991,135	414,795
University of Nottingham	432,059	-	-	432,059	137,689
University of Bristol	401,433	-	-	401,433	206,658
Queen's University Belfast	(3,925)	-	-	(3,925)	-
Great Ormond Street	-	-	-	-	99,576
University of Glasgow	140,420	-	-	140,420	31,793
University of York	317,285	-	-	317,285	-
University of Cambridge	325,179	-	-	325,179	251,723
Institute of Cancer Research	210,885	-	-	210,885	599,310
University of Leeds	357,187	-	-	357,187	198,979
University of Manchester	(1,077)	-	-	(1,077)	86,108
University of Oxford	33,854	-	-	33,854	-
University College Dublin	-	-	-	-	78,303
Swansea University	-	-	-	-	208,533
University of Bath	-	-	-	-	104,155
The Royal Marsden Hospital	-	-	-	-	15,000
Blood Cancer UK	-	-	-	-	11,928
University of Leicester	112,515	-	-	112,515	-
Birmingham Children's Hospital	53,277	-	-	53,277	-
King's College London	850,659	-	-	850,659	-
The Open University	29,909	-	-	29,909	-
	<u>6,336,897</u>	<u>-</u>	<u>-</u>	<u>6,336,897</u>	<u>4,267,889</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

9 Expenditure on grant funding

(Continued)

The charity awards grants for specific research projects to various institutions, as part of their charitable activities.

Negative amounts represent an underspend on grants previously made returned to CCLG.

10 Expenditure on support costs

	Basis of allocation	2022 £	2021 £
Staff costs	*1	656,900	545,405
Depreciation & loss on disposal	*1	13,069	10,204
Occupancy expenses	*1	120,538	95,731
Postage	*1	14,789	13,621
Staff training	*1	3,658	2,660
Professional fees	*1 / *2	24,392	35,446
Redundancy costs	*1	-	14,566
		<u>833,346</u>	<u>717,633</u>
Analysed between			
Raising funds		161,791	136,438
Charitable activities		671,555	581,195
		<u>833,346</u>	<u>717,633</u>

*1 Support costs, excluding governance costs, have been allocated as follows:

<i>Cost of raising funds</i>	20% (2021 - 20%)
<i>Charitable activities</i>	
Support for research	20% (2021 - 20%)
Information for patients and families	30% (2021 - 30%)
Improving treatment and care	30% (2021 - 30%)

*2 Professional fees include governance costs of £24,392 (2021 - £35,446). Governance costs have been allocated as follows:

<i>Charitable activities</i>	
Support for research	17% (2021 - 17%)
Information for patients and families	22% (2021 - 22%)
Improving treatment and care	61% (2021 - 61%)

The amount charged to the SOFA in respect of auditor's remuneration was:

- statutory audit £9,300 (2021 - £9,000)
- other services £1,253 (2021 - £3,414)

11 Other expenditure

	Restricted funds 2022 £	Total 2022 £	Restricted funds 2021 £	Total 2021 £
Wages	-	-	36,901	36,901
	<u>-</u>	<u>-</u>	<u>36,901</u>	<u>36,901</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

12 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits during the year.

13 Employees

The average monthly number of employees during the year was:

	2022	2021
	Number	Number
Total	22	18

Employment costs

	2022	2021
	£	£
Wages and salaries	633,405	530,285
Social security costs	63,204	51,546
Other pension costs	58,235	51,868
Redundancy costs	-	14,566
	<u>754,844</u>	<u>648,265</u>

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2022	2021
	Number	Number
£70,001 - £80,000	1	1
£90,001 - £100,000	1	-
	<u>2</u>	<u>1</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

14 Tangible fixed assets

	Computer equipment, furniture and fixtures £	Total £
Cost		
At 1 January 2022	73,325	73,325
Additions	14,113	14,113
	<u>87,438</u>	<u>87,438</u>
At 31 December 2022	87,438	87,438
Depreciation and impairment		
At 1 January 2022	31,883	31,883
Depreciation charged in the year	13,069	13,069
	<u>44,952</u>	<u>44,952</u>
At 31 December 2022	44,952	44,952
Carrying amount		
At 31 December 2022	42,486	42,486
	<u>41,442</u>	<u>41,442</u>
At 31 December 2021	41,442	41,442

15 Stocks

	2022 £	2021 £
Merchandise stock	30,263	14,483
Educational literature	22,766	20,943
	<u>53,029</u>	<u>35,426</u>
	<u>53,029</u>	<u>35,426</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

16 Debtors

	2022	2021
	£	£
Amounts falling due within one year:		
Trade debtors	7,833	81
Grant debtors	2,830,745	2,349,235
Rent deposit	16,200	16,200
Prepayments and accrued income	155,731	130,113
Accrued legacy income	172,500	205,000
	<u>3,183,009</u>	<u>2,700,629</u>

	2022	2021
	£	£
Amounts falling due after more than one year:		
Grant debtors	<u>1,739,600</u>	<u>1,068,691</u>
Total debtors	<u>4,922,609</u>	<u>3,769,320</u>

17 Creditors: amounts falling due within one year

	2022	2021
	£	£
Deferred income	100	-
Trade creditors	17,056	55,830
Grant creditors	3,911,669	3,293,878
Accruals	39,073	45,452
	<u>3,967,898</u>	<u>3,395,160</u>

18 Creditors: amounts falling due after more than one year

	2022	2021
	£	£
Grant creditors	<u>2,614,739</u>	<u>2,575,086</u>

19 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees.

The amount recognised in unrestricted expenditure was £58,235 (2021 - £51,868).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

20 Restricted funds

The income funds of the charity include restricted funds which comprise the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds				Balance at 31 December 2022 £
	Balance at 1 January 2022 £	Income £	Expenditure £	Transfers £	
Tumour specific funds	1,112,573	761,793	(301,199)	-	1,573,167
CCLG Prize	54	310	-	-	364
General research fund	3,940	2,000	(2,760)	-	3,180
Adam Hay fund	11,102	120	-	-	11,222
CCLG Senior Members Group	7	-	-	-	7
PODC	4,782	1,114	-	-	5,896
POTG	210	8,350	(9,737)	1,177	-
The Little Princess Trust fund	6,200	5,639,669	(5,639,669)	-	6,200
Treatment Guidelines fund	18,225	-	(17,611)	-	614
TYAC Lisa Thaxter	44,132	-	(7,500)	-	36,632
Child Cancer Smart	72,867	5,000	(39,762)	-	38,105
PORT	420	-	-	-	420
CCLG Research Network Partner Charity	42,467	324,425	(366,892)	-	-
Neuroblastoma Nursing Group	10,500	-	-	-	10,500
PODC - Iraq Fund	4,108	4,276	-	-	8,384
Young Lives vs Cancer Chief Nurse Funding	-	79,261	(73,313)	-	5,948
Health Information	-	27,375	(10,455)	-	16,920
TYAC General Restricted	-	1,000	-	-	1,000
TYAC Research	-	66,000	-	-	66,000
Projects Restricted Fund	-	241,322	(55,944)	-	185,378
	<u>1,331,587</u>	<u>7,162,015</u>	<u>(6,524,842)</u>	<u>1,177</u>	<u>1,969,937</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

20 Restricted funds

(Continued)

	Movement in funds				Balance at 31 December 2021 £
	Balance at 1 January 2021 £	Income £	Expenditure £	Transfers £	
Tumour specific funds	744,648	780,510	(412,585)	-	1,112,573
CCLG Prize	54	-	-	-	54
General research fund	3,940	-	-	-	3,940
Adam Hay fund	10,982	120	-	-	11,102
CCLG Senior Members Group	7	-	-	-	7
PODC	3,338	1,444	-	-	4,782
POTG	2,139	2,947	(4,876)	-	210
The Little Princess Trust fund	6,200	3,907,695	(3,907,695)	-	6,200
Treatment Guidelines fund	18,435	-	(210)	-	18,225
TYAC Lisa Thaxter	45,412	-	(1,280)	-	44,132
Child Cancer Smart	73,500	-	(633)	-	72,867
PORT	400	20	-	-	420
CCLG Research Network Partner Charity	36,328	-	6,139	-	42,467
Neuroblastoma Nursing Group	10,500	-	-	-	10,500
Childhood Cancer Priority Setting Partnership	17,909	-	(17,909)	-	-
PODC - Iraq Fund	1,530	2,578	-	-	4,108
Coronavirus Job Retention Scheme	-	36,901	(36,901)	-	-
	<u>975,322</u>	<u>4,732,215</u>	<u>(4,375,950)</u>	<u>-</u>	<u>1,331,587</u>

Transfers have been made into restricted funds from unrestricted funds to underwrite a cash deficit on a fund.

Tumour specific funds

Represents income received from donors with a specific request that the funds are used in support of grants for a particular tumour type.

CCLG Prize

Represents income received from donors to fund the CCLG Prize.

General research fund

Represents income received from donors with a specific request that the funds are used for research purposes.

Adam Hay fund

This fund has been established to continue work done by the Adam Hat's charity (which merged with CCLG in 2011) in neuroblastoma research and psychological support for children and families.

CCLG Senior Members Group

Represents income received from the Senior Members' Group to be used for their activities.

PODC

Represents income received from donors to be used for the Paediatric Oncology in Developing Countries (PODC).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

20 Restricted funds

(Continued)

POTG

Represents income received from donors to be used for the Paediatric Oncology Trainees' Group (POTG).

The Little Princess Trust fund

Represents income received from The Little Princess Trust to fund future instalments of research grants awarded.

Treatment Guidelines fund

Represents a grant received for the development of rare endocrine tumour guidelines.

TYAC Lisa Thaxter

Represents income received for providing and supporting education and training to professionals working in the field of teenage and young adult cancer. This was previously a restricted fund in TYAC and has transferred to CCLG as part of the closure of TYAC, with the same restrictions maintained.

Child Cancer Smart

Represents income received for a research programme, guideline development and awareness raising focusing on earlier diagnosis of childhood cancer.

PORT

Represents income received for the Paediatric Oncology Reference Team, a group of parents of children with cancer who review clinical trial and other research information to ensure it is appropriate for children with cancer and their families.

CCLG Research Network Partner Charity

Represents income research from other charities to fund research projects.

Young Lives vs Cancer Chief Nurse Funding

Funding for the Chief Nurse role and associated projects.

Neuroblastoma Nursing Group

Represents income received to support the costs of running the national neuroblastoma nursing group, a group of CCLG member nurses with a special interest in neuroblastoma.

Childhood Cancer Priority Setting Partnership

Represents grant income received to support the James Lind Alliance supported Childhood Cancer Priority Setting Partnership being led by CCLG.

PODC - Iraq Fund

Represents donations received to specifically support work to improve the treatment and care of children with cancer in Iraq.

Coronavirus Job Retention Scheme

Represents amounts received from the Government to cover staff costs during the Covid-19 pandemic.

Health Information

Funds received to support the production of health information for patients and families.

TYAC General Restricted

Fundraising and donations to support work specifically for teenagers and young adults with cancer.

TYAC Research

Income restricted to support research projects into teenage and young adult cancer.

Projects Restricted Funds

Income restricted to support specific projects including work related to research.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

21 Unrestricted funds

	Balance at 1 January 2022 £	Movement in funds			Balance at 31 December 2022 £
		Income £	Expenditure £	Transfers £	
General funds	591,470	1,149,760	(1,249,093)	(1,177)	490,960

	Balance at 1 January 2021 £	Movement in funds			Balance at 31 December 2021 £
		Income £	Expenditure £	Transfers £	
General funds	678,615	937,420	(1,024,565)	-	591,470

22 Analysis of net assets between funds

	Unrestricted Funds 2022 £	Restricted Funds 2022 £	Total 2022 £
Fund balances at 31 December 2022 are represented by:			
Tangible assets	42,486	-	42,486
Current assets/(liabilities)	448,474	4,584,676	5,033,150
Long term liabilities	-	(2,614,739)	(2,614,739)
	490,960	1,969,937	2,460,897

	Unrestricted Funds 2021 £	Restricted Funds 2021 £	Total 2021 £
Fund balances at 31 December 2021 are represented by:			
Tangible assets	41,442	-	41,442
Current assets/(liabilities)	550,028	3,906,673	4,456,701
Long term liabilities	-	(2,575,086)	(2,575,086)
	591,470	1,331,587	1,923,057

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

23 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2022 £	2021 £
Within one year	36,530	27,530
Between two and five years	18,397	48,177
	<u>54,927</u>	<u>75,707</u>

Amounts recognised in the SOFA as an expense during the period in respect of operating lease arrangements are £34,730 (2021 - £27,530).

24 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel, is as follows.

	2022 £	2021 £
Aggregate compensation	<u>253,428</u>	<u>217,459</u>

There have been no other related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 12 to the financial statements.

25 Cash generated from operations

	2022 £	2021 £
Surplus for the year	537,840	269,120
Adjustments for:		
Investment income recognised in statement of financial activities	(5,935)	(1,858)
Depreciation and impairment of tangible fixed assets	13,069	10,204
Movements in working capital:		
(Increase)/decrease in stocks	(17,603)	3,271
(Increase) in debtors	(1,153,289)	(663,738)
Increase in creditors	612,291	511,856
Increase in deferred income	100	-
Cash (absorbed by)/generated from operations	<u>(13,527)</u>	<u>128,855</u>

26 Analysis of changes in net funds

During the year the charity had no borrowings or obligations under finance leases. The changes in net funds of the charity therefore solely comprise of cash and cash equivalents.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

England & Wales - Charity number 1182637

Accounts

Charity Registration No. 1182637 (England and Wales)

Charity Registration No. SC049948 (Scotland)

Company Registration No. CE016951 (England and Wales)

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

**TRUSTEES' REPORT AND
FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED
31 DECEMBER 2021**

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	David Oxnam (Chair of Board of Trustees) Gayle Routledge Rachel Wilcox David Hobin Sarah Curtis	(Appointed 14 April 2021) (Appointed 14 April 2021)
Chief Executive	Ashley Ball-Gamble	
Charity number	1182637 (England and Wales) SC049948 (Scotland)	
Company number	CE016951	
Operating name	CCLG	
Principal address	Century House 24 De Montfort Street Leicester LE1 7GB	
Auditor	Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT	
Bankers	HSBC Bank Plc 2-6 Gallowtree Gate Leicester LE1 1DA	
	Scottish Widows Bank Plc PO Box 12757 67 Morrison Street Edinburgh EH3 8YJ	
	CAF Bank Ltd 25 Kings Avenue Kings Hill Kent ME19 4JQ	

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

CONTENTS

	Page
Trustees' report	1 - 10
Independent auditor's report	11 - 13
Statement of financial activities	14
Balance sheet	15
Statement of cash flows	16
Notes to the financial statements	17 - 30

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2021

The trustees of The Children's Cancer and Leukaemia Group are pleased to present their annual report and financial statements for the year ended 31 December 2021.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

OBJECTIVES AND ACTIVITIES

The objectives of The Children's Cancer and Leukaemia Group (CCLG) as defined in the constitution are:

For the public benefit, the relief of sickness and suffering of children, teenagers and young adults with cancer and advancement of education in the field of children, teenagers and young adults with cancer, in particular but not exclusively by:

1. The relief of sickness and promotion and protection of good health by supporting research into the nature, causes, diagnosis, treatment and social consequences of cancer in children, teenagers and young adults, and to publish the useful results of such research.
2. The relief of suffering of children, teenagers and young adults with cancer and their families and carers, through the provision of information and support services to them.
3. The advancement of the education of the public in all areas relating to cancer in children, teenagers and young adults.
4. The advancement of education and clinical practice by the dissemination of knowledge of the latest research and best practice amongst professionals and practitioners engaged in the treatment, care and support of children, teenagers and young adults with cancer.

The main beneficiaries of the work carried out by the charity are children, teenagers and young adults with cancer and their families in the United Kingdom and elsewhere in the world.

CCLG is the UK and Ireland's professional association for all those involved in the treatment and care of children with cancer (including leukaemia). Our multidisciplinary and multi-professional membership continues to grow. At the end of 2021, there were in excess of 1000 members. In addition, we host Teenagers and Young Adults with Cancer (TYAC), a multidisciplinary and multi-professional membership association for those involved in the treatment and care of teenagers and young adults with cancer. At the end of 2021, there were more than 400 TYAC members.

Through our membership activities, we provide an active forum for professionals to work together to share best practice and advance education and professional development. Members are able to network with both national and international colleagues for advice and support and receive information and vital updates on specific diseases and treatments. This ensures every child with cancer receives the best possible treatment and care available wherever they live.

The activities of our professional association and membership body include:

- Specialist networks groups: These are a core part of our professional activities enabling professionals to work with others who share the same clinical interests.
- Key conferences and events: We organise a range of meetings each year to ensure members are kept up to date with the latest developments in cancer research, care, and treatment. Our annual meeting in January offers an opportunity for all of our members to network with colleagues from across Britain and Ireland.
- Professional voice for children, teenagers and young adults: We advise governments and other bodies and ensure that we are represented on important groups or in consultations, for example in the area of NHS commissioning of children's cancer services or the development of NICE quality standards and guidance.
- Online members' area: A vital hub for professionals involved in the care of children and young people with cancer, providing a wealth of resources and educational opportunities for our membership.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

Our members are dedicated to ensuring that children and young people have a greater chance of survival and a better life after treatment.

We support children and young people with cancer and their families in a variety of different ways:

- Written by experts, our comprehensive quality-assured range of information booklets and leaflets helps patients and their families understand their diagnosis, treatment and what to expect now and in the future. Our publications are available free of charge to those who need them.
- Our free quarterly magazine, Contact, offers help, support and information for families of children, teenagers and young adults with cancer.
- We also organise informative events for parents and families each year. Since 2014, we have organised the UK Childhood Cancer Conference. This hugely successful event brings together parents, researchers, healthcare professionals and charities to discuss the latest research into childhood cancer and talk about the issues which affect parents.
- Our website is a comprehensive resource of childhood cancer information. Our online 'Childhood Cancer Information Hub', brings together information resources (booklets and leaflets, web pages, film and video content and more) into a single 'one-stop-shop', which is easily searchable and can be filtered by cancer type, audience, etc.

The outstanding progress made in cancer treatment is the result of extensive research studies and clinical trials over the last 40 years which now underpin today's standard treatments. During this time, CCLG has played a key role in the success seen in the world of children's cancer so that now over 80% of children are cured.

But there are still some childhood cancers with a poor outlook, and some treatments can have long-lasting and devastating side effects. Further research is vital to improve survival rates and to find kinder treatments.

We fund and support a variety of research into childhood cancers including:

- The CCLG Tissue Bank is the UK's largest collection of tumour, DNA and other tissue samples from childhood cancer patients. Samples enable scientists and researchers to get as close to the disease as possible so they can find new ways of diagnosing children, new treatments and cures for patients.
- We offer funds and grants to launch new research projects and develop new clinical trials.
- We work in partnership with other charities and organisations to support research. We use our research-funding infrastructure, as well as the scientific and medical expertise of our membership, to support smaller charities to meet their research aims. For example, by managing a research funding programme or helping them to identify research to support.
- We can 'ringfence' funds so that our supporters can raise funds towards a cancer-specific research project.
- Our Special Interest Groups provide a forum for discussion and planning of research and bring together potential collaborators. We organise and support scientific meetings where research findings are shared and discussed, and we support our membership to be involved in planning research and attending important meetings through bursaries and sponsorship.
- We support the next generation of childhood cancer researchers through our trainee scheme in partnership with the National Cancer Research Institute. This allows trainee paediatric oncologists to be involved in the development and management of clinical trials, by attending meetings, being mentored by experienced researchers, and gaining insight into research activity.
- In 2017, CCLG was accepted into membership of the Association of Medical Research Charities, demonstrating our commitment to funding high-quality, world class research and confirming the high standard of the processes we use to select and fund research.

We measure our success in achieving our objectives in a number of ways:

- The number of patient information products distributed, and the number of visits to the 'about childhood cancer' section of our website, are some measures used to ascertain our success in supporting patients and their families. We also gather feedback on our information products.
- The number of publications in journals, the number of studies accessing the CCLG Tissue Bank, and the amount of tissue samples banked, are some measures used to ascertain the success of our research programme including the CCLG Tissue Bank.
- The number of members and retention of members are some basic measures used to ascertain how we are supporting the community of professionals we serve through our professional association activities.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

- The number of research projects funded and their value, and the outcome of research projects including peer-reviewed papers in scientific journals.

ACHIEVEMENTS AND PERFORMANCE

More than 1,800 children and a further 2,300 teenagers and young adults are diagnosed with cancer each year in the UK. Although overall five-year survival for cancer in children and young people is now over 80%, for some cancers there have not been such dramatic improvements in survival, and even where treatment is successful, many survivors have to contend with life-long and life-limiting side effects. We continue to work towards the four main goals set out in our strategic plan, launched in 2018, and the goals of the TYAC strategic plan, launched in 2019, as detailed below. Highlights of our achievements are detailed below.

The global COVID-19 pandemic continued to have an impact on our work during 2021. Many of our usual activities were not able to continue in their usual way, including our face-to-face professional education meeting and events. At the start of the year, the continued impact of restrictions on our fundraising activity was unknown, and so we set a cautious – but optimistic – budget, planning to invest reserves in our activities. In the first half of the year, we continued to use the Government's Coronavirus Job Retention Scheme to flexibly furlough a number of staff, to help mitigate for a loss in income. We also restructured the staff team during the year, to ensure that as we emerged from the pandemic and associated restrictions, we had the right team in place to return to growing our financial resources and delivering our services. This resulted in some redundancies, as well as the recruitment of some new posts. The Trustees would like to thank the staff team for their continued commitment to CCLG during a difficult time.

Providing leadership and expertise for the treatment and care of children and young people with cancer

As the UK and Ireland's professional association for those working in the field of paediatric oncology and haematology, CCLG is a leading voice for children's cancer, liaising with community groups, the government and the NHS to influence policies. We use our expertise to improve treatment and care and meet the needs of patients and families. In 2021:

- We held our key member event, the annual CCLG Winter Meeting, as a virtual event, bringing together more than 200 professionals to share the most up-to-date news, research and information in all areas of treatment and care. Feedback for the virtual format was largely positive, which has resulted in a new-format for the planned return to an in-person meeting in 2022, ensuring we continue to meet the needs of our membership.
- Following the success of the virtual Winter Meeting, we held a number of other online educational events throughout the year, including launching a successful series of 'late effects' webinars, and a supportive care education day. As we emerge from the pandemic, we anticipate continuing to hold a mixture of in-person and virtual education events for professionals, and for 2022 have planned a continuation of our late effects series, and a nursing lecture series.
- We continued to produce and update a number of clinical treatment guidelines, ensuring standardised, high quality and evidence-based treatment for all children, particularly in diseases where there is currently no open clinical trial.
- Following the commissioning of a significant piece of research into the experience and needs of our membership, we developed a strategy for ensuring that our members get the most from their membership, and that we support them in their roles. In the latter part of the year, we commenced development work on a new online community for our membership, which will support networking, education, and the activities of our working groups. CCLG Connect will launch later in 2022.
- Following changes to the Young Lives vs Cancer (formerly CLIC Sargent) nursing programme, we worked with Young Lives vs Cancer to develop a new Chief Nurse role at CCLG. The role is funded by Young Lives vs Cancer and employed by CCLG, working to enhance support for nursing and allied health professionals (AHPs), manage a range of nursing and AHP programmes at CCLG, supporting our nursing and AHP working groups, and provide clinical and health system insight and intelligence to Young Lives vs Cancer.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

Improving diagnosis times by increasing awareness

The significance of a delayed diagnosis presents a challenge for primary health care professionals, who are required to triage symptoms that may point to a cancer diagnosis and make appropriate onward referrals. Many symptoms associated with cancer are non-specific and are seen every day in general practice, whilst a cancer diagnosis is seen infrequently. Delays in the diagnostic pathway may well lead to more advanced disease at presentation, with subsequent greater risk of death, greater morbidity, and inevitably, distrust of the medical system. There is evidence that tumours presenting in childhood in the UK are larger, at a more advanced stage and require more therapy than those presenting in other parts of Europe. We work to improve diagnosis times for children and young people with cancer. In 2021:

- We published the CCLG Referral Guidelines for Suspected Cancer in Children and Young People, a comprehensive guide for GPs and other healthcare professionals to support them to identify the signs and symptoms of childhood cancers, and the action to take in terms of referral. The Guidelines were endorsed by the National Institute of Health and Care Excellence (NICE).
- We continued working on our Child Cancer Smart project, which will result in a number of clinical referral guidelines, and public and professional awareness tools, on the signs and symptoms of childhood cancer. Some of this activity, which relies on the input and support of a range of health professionals, was delayed due to the pressures on the NHS during the COVID-19 pandemic. We hope to catch up on much of this work during 2022.
- The Child Cancer Diagnosis Study, a research project funded by the National Institute for Health Research (NIHR) and CCLG, and jointly run by CCLG and The University of Nottingham, opened in all Principal Treatment Centres in the UK. This innovative, nationwide research will give us, for the first time, an accurate picture of the routes to diagnosis and where we can develop interventions to drive improvements.

Strengthening our expert information portfolio to support more families of a child with cancer

Looking after a child with cancer can be a scary and lonely experience for families. Our goal is to deliver the right information at the right time and make a positive difference to their daily lives.

We continue to be the leading provider of expert-written, award-winning and quality-assured information about all aspects of childhood cancer, from diagnosis to life when treatment has finished. In 2021:

- We continued to provide free information booklets and leaflets to hospitals and directly to families during the year. A number of new publications were produced, and further existing publications were reviewed and revised.
- We relaunched our popular magazine, Contact, with a new design and format, and increased the page count of each issue from 12 to 20, introducing a number of new features. Four issues were produced during the year, with each issue having a circulation in excess of 6,000 copies. Feedback on the new format and design was overwhelmingly positive, and Contact continues to support families across the UK and around the world.
- Our annual Childhood Cancer Conference took place virtually, following a hiatus in 2020 due to the pandemic. This unique event, bringing together parents, professionals and researchers, was attended by more than 200 people and the content has since continued to be popular on our YouTube channel.
- Our closed Facebook group for parents and carers of children with cancer, which allows members to seek advice and support from those with similar experiences, and, uniquely, 'ask the experts' through posting questions answered by our clinical membership community, continued to grow, reaching over 1,300 members. Much of the activity in the group during the year was driven by the COVID-19 pandemic.
- We successfully passed our first reassessment for the Patient Information Forum (PIF) PIFTick accreditation for our health information. This new quality standard, replacing the former Information Standard which was discontinued, is awarded following rigorous assessment of our information production processes, and demonstrates our commitment to reliable, expert, high-quality health information.

Supporting and funding world-class research

Our aim is to both support and fund world-class research, deepen understanding and foster collaborations across the childhood cancer community. One of our most important areas of work is to offer opportunities for our members to develop scientific networks and belong to a wider research community dedicated to childhood cancer. Our Research Strategy outlines our exciting plans to fund and support innovative world-class research

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

into childhood cancer and recognises the importance of collaboration, both nationally and internationally, to achieve improvements:

- We fund research directly, and work with partner charities to support them to fund the best possible research, using our well-established research funding expertise, experience and infrastructure. In total, between our own research funding and that of the partners we work with, 21 new research projects totalling over £4.2 million were funded in 2021.
- Our partnership with The Little Princess Trust continues to go from strength to strength. We support The Little Princess Trust to fund the best quality research, with a focus on finding better, kinder treatments. We provide specialist advice and expertise, as well as run and manage their research-funding programme on their behalf. This partnership helps to minimise duplication, and share expertise meaning that ultimately more money is spent directly on research. During the year, the Little Princess Trust awarded CCLG just over £3.9 million to fund 17 projects, including two large 'innovation grants' designed to support innovative new research proposals.
- Work continued on a Priority Setting Partnership for children's cancer during the year, initiated by CCLG and co-funded with The Little Princess Trust, and under the auspices of the James Lind Alliance (JLA). The JLA is a non-profit making initiative established in 2004. It brings patients, carers and clinicians together in Priority Setting Partnerships (PSPs) to identify and prioritise the top 10 unanswered questions or evidence uncertainties that they agree are the most important. The aim of this is to make sure that health research funders are aware of the issues that matter most to the people who need to use the research in their everyday lives. Through virtual meetings, we were able to continue with this work, and the children's cancer PSP will complete its work programme over the next years to define the top 10 research priorities in childhood cancer, which will feed into CCLG's future research strategy.

Teenagers and Young Adults with Cancer (TYAC)

Teenagers and Young Adults with Cancer (TYAC) is the professional association for those working in teenage and young adult (TYA) oncology. TYAC merged with CCLG in 2018, and in 2019 we launched a new strategy for the work of TYAC, setting out how we would continue to drive improvements in TYA cancer care, and support the development of professionals working in the field.

During the year, we launched a new TYAC website, hosting a wide-range of expert cancer information written specifically for young people with cancer. We launched a new research strategy for TYAC, setting out our plans for increasing funding for specialist research into cancer in this age group, and launched our first research grant call, focusing on the late effects of teenage and young adult cancer. We established a Research Advisory Group for TYAC, and committed to developing the research community in this field through the TYAC Research Academy. We successfully held a virtual TYAC education conference, and launched a new small grants programme to support the development of TYAC good practice guidance for professionals working with teenagers and young adults.

Fundraising

All of our work is dependent on the generosity of our supporters. A programme of fundraising underpins our ability to fund research, support patients and families, and improve treatment and care for children and young people with cancer. In 2021:

- Our Special Named Fund programme continued to grow. After their cancer experiences, families sometimes consider setting up their own charity. For many, our Special Named Funds may be a great alternative. We support families to achieve their fundraising objectives, while taking away the administrative burden of setting up and running a charity. At the end of the year, there were approximately 70 Special Named Funds at CCLG (2020: 60), each raising funds to support research into a specific type of childhood cancer.
- We capitalised on the 'lessons learned' around virtual fundraising during the pandemic, continuing to offer a range of 'virtual events', as well as beginning to implement other elements of our new fundraising strategy as COVID-19 restrictions allowed.
- We continued to invest sustainably in our fundraising infrastructure, including recruiting our first posts focused on fundraising from grant-making trusts and foundations, and further developing our fundraising offer.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

COVID-19

In response to the COVID-19 pandemic, we continued to undertake a number of activities during the year to support the families of children and young people with cancer during the unprecedented circumstances:

- We produced ongoing guidance, first published in March 2020, interpreting the national generic guidance, for families of a child with cancer during the pandemic. This was revised multiple times during the year by a core working group of CCLG experts. The guidance covered: whether children with specific diseases or at specific times during their treatment were clinically extremely vulnerable or clinically vulnerable to severe COVID-19 disease, and what this meant in terms of restrictions including shielding and school attendance; responses to various questions and issues as they arose including increased susceptibility for BAME communities, emerging complications of the disease, changes to hospital procedures etc; various research projects and their results; responding to news and media stories; and vaccination questions once vaccines were approved. In total since it was launched, the guidance has had 17 updates and been viewed almost 100,000 times.
- Our Facebook Group for parents and carers of children with cancer grew in membership to over 1,300 members during the year. We offered the opportunity for parents and carers to 'ask the expert' their questions around childhood cancer and especially questions relating to COVID-19, as well as share experiences with others in the group and to ask them for advice. During the year we answered a large number of questions and feedback indicates this was a hugely valued opportunity, particularly as the government general advice around COVID was not tailored enough for children with illnesses.

Fundraising policy

We are reliant on donations to fund our vital work. Without the generosity of the public, we would not be able to continue providing support to children and young people diagnosed with cancer, and their families, nor fund research into childhood cancer.

We believe that it is essential that we are clear and open about how we raise our funds and about the range of ways people can get involved and support our work.

People raise money for us in many different ways, including through taking part in sporting events, organising events in their local community, or fundraising at their place of work. We also provide opportunities for people to fundraise through providing access to places in key events, such as the London Marathon, and through providing fundraising materials.

Our supporters can sign up to make regular donations, or play our lottery which we launched in 2018.

We work with a number of corporate partners, and have received support from charitable trusts and foundations, and through grants from other charities. We do not carry out door-to-door fundraising, nor do we use street fundraising to sign up supporters to regular donations. Currently, none of our fundraising activities are conducted on our behalf by professional fundraising agencies.

CCLG is registered with the Fundraising Regulator. We are committed to adhering to the Code of Fundraising Practice. During the year, we received no complaints about our fundraising activities. Regular updates are provided to our board of trustees to ensure that they have a good oversight of our activities.

FINANCIAL REVIEW

Transactions for the year ended 31 December 2021 fall into roughly the same categories as in previous years. Income generally consists of donations and fundraising income, subscriptions (comprising individual membership subscriptions and hospital subscriptions for health information), registration fees for meetings and events, funding from partner charities such as The Little Princess Trust to support research projects, legacy income, and again income from the Coronavirus Job Retention Scheme. We are grateful to Young Lives vs Cancer and Teenage Cancer Trust for their continued support of TYAC activity.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

The major items of expenditure for CCLG remain staff salaries, professional meeting and event costs, the costs associated with the production of health information, and the awarding of research grants.

Staffing costs represent a significant financial commitment, but our small, expert staff team is also responsible for the achievement of the majority of our charitable objectives. Staffing levels are kept under review, with the small, efficient team carrying out and coordinating the considerable activities of the charity. As previously mentioned, during the year we carried out a review of our staffing needs, to ensure we had the right team in place to recover from the impact of the COVID-19 pandemic and to achieve our strategic and business goals. This resulted in four redundancies during the year (three voluntary, one compulsory) as well as the creation of a number of new posts. Overall headcount at the end of the year was the same as the end of the previous year.

Despite COVID-19 restrictions remaining in force, in one form or another, for much of the year, we started to see encouraging signs of recovery. Our overall income increased by £1,778,879, compared with the year ending December 2020. We saw an increase in donations and fundraising income during the year, as well as an increase in income from charitable activities, primarily as our research partnership with The Little Princess Trust returned to a pre-pandemic pattern of activity.

CCLG has a number of restricted funds. Internal records are kept according to requirements for restriction, i.e. tumour specific donations or donations for a specific piece of work. The restricted funds are ring-fenced to support specific projects or areas of activity and cannot be used to support the general running costs of the organisation.

Expenditure increased in 2021 by £1,352,392 compared to 2020. The primary reason for the increase was again a return to pre-pandemic pattern of activity for our research partnership activity.

Budgeting for the year was always going to be challenging with the unpredictable nature of the pandemic, changing restrictions, and their impact. The Trustees continued to monitor this on an ongoing basis. We had planned to call on our unrestricted reserves during the year, to enable us to meet our commitments and to cautiously reinvest some of these into our charitable activity, as the unrestricted reserves held at the end of 2021 were over the level required by our reserves policy. We ended the year with an overall surplus of £269,120 but a deficit in unrestricted income/expenditure of £87,145. This deficit is lower than originally budgeted for, reflecting better performance against our budget than anticipated.

Reserves Policy

The trustees continue to consider the appropriate balance of financial stability and investment in charitable activity. The COVID-19 pandemic has highlighted the importance of an appropriate reserves policy. Given the ongoing uncertainty around the pandemic and the length of time likely until we recover fully, it is important we continue to hold a level of reserves which can sustain our activity until we have a better picture of what post-pandemic fundraising might look like, both in the short- and medium-term. We have plans in place to ensure CCLG is 'fit for the future' and our reserves policy will ensure we are able to meet those plans.

At the end of the year, we have reviewed our reserves policy for CCLG and aim to hold a target level of free reserves (unrestricted funds less tangible fixed assets) of £400,000, which the trustees consider to be approximately six months of core expenditure, including staff salaries, accommodation costs and general running costs.

Total reserves at 31 December 2021 were £1,923,057 of which £1,331,587 are restricted and £591,470 are unrestricted. As at 31 December 2021 the charity's free reserves totalled £550,028, which is in excess of the reserves policy. Given the current economic uncertainty, the trustees consider it prudent to continue to reinvest excess reserves into charitable activity, while keeping the reserves policy under review. The trustees consider that this ensures that CCLG is 'fit for the future'.

Our restricted reserves appear high, at £1,331,587 at the end of 2021. Much of our restricted income is raised by families, ring-fenced for research into specific types of childhood cancer. Research requires significant investment, and thus many of our funds grow over the course of several years before a large sum of money is awarded in the form of a research grant. Our restricted reserves comprise a large number of specific restricted

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

funds which are ring-fenced to a specific purpose, and therefore cannot be used for general activities. Levels of funds are reviewed on a regular basis and spent on charitable activities as soon as sufficient funds are available. We are planning to invest a significant amount of restricted reserves into research during 2022.

The financial impact of the COVID-19 pandemic

As highlighted throughout this report, the COVID-19 pandemic in 2021 continues to have an impact on CCLG, both in our operations and our income generation. Fundraising events that were cancelled in 2020 began to take place again during the year, and overall fundraising activity began to recover, particularly in the latter part of the year. The inability to hold 'in-person' meetings and events meant that the majority of our education and scientific meetings and conferences – another key source of income – took place virtually, reducing the income received, although this was mitigated to some extent by a corresponding decrease in the expenditure of holding such events.

We continued to monitor income and expenditure closely during the year. Despite ending the year with a deficit in terms of unrestricted income/expenditure, given the circumstances our income and expenditure performed slightly better than expected.

We have developed a fundraising plan for 2022 which has a combination of in-person and virtual activities, based on our learning and evaluation of our activity over the last two years, and hope to continue to recover during 2022.

As well as focusing on mitigating the impact on the charity as much as possible, to secure the future of our work, The Trustees and the Chief Executive have liaised closely during this year to ensure the wellbeing of staff. We continued to use the government's Coronavirus Job Retention Scheme ("furlough scheme"), taking the difficult decision to 'flexibly furlough' a number of our staff team, to support the costs of employing staff during the crisis. This necessitated focusing our work on the most important projects. Supporting our staff throughout this period has been a key priority for the Trustees and Senior Leadership Team. Our staff team is at the heart of what we do and are passionate about the impact CCLG has on children with cancer and their families. We recognise that our committed staff team also have lives outside of their work for CCLG which will have also been affected. The Trustees and Senior Leadership Team are extremely grateful for the dedication of the team, and how they have adapted to the current situation to ensure our vital work continues.

Investment policy

The Trustees previously reviewed our plans for investments to consider the most appropriate way of managing these, balancing cashflow, risk and reward. Given the uncertainty of the financial impact of the COVID-19 pandemic, no further action has been taken on investments. Management accounts are produced for the trustees, and a cashflow forecast considerably facilitates management and prediction of charity income.

Risk Management

CCLG is also aware of the requirement to carry out a risk review of its activities. The trustees reviewed the risks the charity faces during the year. A Risk Register is in operation, documenting the systems in place to mitigate those risks, and is kept under review by the trustees.

FUTURE ACTIVITIES

All future activities planned are designed to ensure that CCLG continues to fulfil its objectives for children and young people with cancer, and their families, as the ultimate beneficiaries.

As the membership of CCLG continues to grow, so does the activity our members are involved in. Our specialist network groups continue to be increasingly active, supporting our activities and providing specialist advice to commissioners of healthcare services and others. The Executive continues to consider ways that CCLG can advance education and professional development, and share and guide best practice.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

The CCLG executive is a committee comprised of elected members of the CCLG professional body, along with the CEO, who have delegated authority from the Trustees for deciding and implementing the strategy of the organisation as it relates to the clinical, research and professional elements of our work.

At the end of 2020, as an AMRC member we participated in their 5-yearly peer review audit, which gave us the opportunity to review our research strategy and associated processes. We concluded that our current research strategy remains appropriate and plan to launch a new research strategy once the ongoing Children's Cancer Priority Setting Partnership has concluded and published the top ten research priorities in this field.

We plan to continue to develop our range of patient/parent information products in response to demand and specific needs identified by both end-users and professionals. In 2022, we will launch an updated and revised version of our Parents' Guide, our key publication which is given to all families upon diagnosis, and expand our range of information in different formats, including video content.

We also aim to continue raising awareness of CCLG and its activities, with a view to continuing to increase the income and resources available to us to meet our objectives.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Children's Cancer and Leukaemia Group (CCLG) was established in 1977 and became a registered charity (number 286669) in 1983. In 2019, a new CIO (registration number 1182637) was formed, with the activities, assets and liabilities of the previous charity transferred to the CIO. The charity's governing instrument is the Constitution and the CIO was first registered in February 2019. In 2020, the CIO became registered with the Scottish Charity Regulator (registration number SC049948).

The board of trustees is independent of the CCLG membership. The board of trustees is responsible for managing the charity finances in support of the objectives defined by the CCLG Executive. There are a minimum of two and a maximum of eight trustees. One of the trustees will be the CCLG Treasurer, an elected member of the CCLG Executive, providing a link between these two groups.

If a vacancy arises, the trustees may appoint any eligible person as a trustee. In selecting individuals for appointment as trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity.

Upon appointment, trustees are provided with an induction to the charity. This consists of a briefing paper, as well as meetings with the Chair, CEO, and others as deemed appropriate. Regard is given to the training and development needs of any trustees that may arise.

The board of trustees meets quarterly and is supported by staff. Four meetings were held in 2021.

The trustees come from a range of professional backgrounds, and bring new skills and highly relevant experience.

Trustees serving during the year were:

David Oxnam

Dr Daniel Saunders (resigned 1 December 2021)

Gayle Routledge

Rachel Wilcox

Dr David Hobin (appointed 14 April 2021)

Dr Sarah Curtis (appointed 14 April 2021)

The Chief Executive is responsible for the day-to-day operation of the charity on behalf of the trustees. The remuneration of key management is reviewed annually and is set against established pay scales, benchmarked in comparison with similar sized entities including both charities and medical professional associations. The trustees give their time freely and no remuneration was paid in the year. Details of trustee expenses are disclosed in note 12 to the accounts.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

Key Management Personnel during the year were:

Ashley Ball-Gamble (Chief Executive)
Gill Smitherman (Head of Fundraising)
Claire Shinfield (Head of Engagement)
Jeanette Hawkins (Chief Nurse)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales and Scotland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities (Accounts and Reports) Regulations 2008, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

David Oxnam
Chair of the board of trustees

Dated: 17 August 2022

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Opinion

We have audited the financial statements of The Children's Cancer and Leukaemia Group (the 'charity') for the year ended 31 December 2021 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the trustees' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- the charity has not kept adequate and proper accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 10, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under these acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charity.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- obtaining an understanding of the legal and regulatory framework applicable to the charity by considering the nature of the industry in which the charity operates and enquiring of management; and
- identifying the key laws and regulations considered to have a direct impact on the financial statements including the UK Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, UK Generally Accepted Accounting Practice and UK tax legislation; and
- assessing how the charity is complying with the applicable legal and regulatory framework by making further enquiries of management and observing the charity's control environment regarding compliance with regulations and fraud prevention; and
- assessing the susceptibility of the charity's financial statements to material misstatement, including how fraud might occur, by considering the effectiveness of the charity's accounting systems and controls and how these were monitored by management. Where the risk of material misstatement was considered to be higher in certain areas, further audit procedures were designed to address this increased risk; and

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

- discussing amongst the engagement team how and where fraud might occur in the financial statements and any potential indicators of fraud.

Audit response to risks of irregularities identified

Our procedures to respond to risks identified included the following:

- reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations; and
- enquiry of charity staff responsible for compliance to identify any instances of non-compliance with laws and regulations; and
- enquiry of management, those charged with governance and other relevant parties around actual and potential litigation claims; and
- reviewing supporting documentation regarding actual and potential litigation claims; and
- reviewing minutes of meetings of those charged with governance; and
- performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias; and
- communicating identified laws and regulations and potential fraud risks to all engagement team members and assessing whether there are any indications of fraud or non-compliance with laws and regulations throughout the audit.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditors/audit-assurance/auditor-s-responsibilities-for-the-audit-of-the-fi/description-of-the-auditor%e2%80%99s-responsibilities-for>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008, and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Newby Castleman LLP

Chartered Accountants
Statutory Auditor
West Walk Building
110 Regent Road
Leicester
LE1 7LT

30 August 2022

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Total 2020 £
Income from:					
Donations and legacies	3	689,209	765,446	1,454,655	1,301,787
Charitable activities	4	246,353	3,966,769	4,213,122	2,586,948
Investments	5	1,858	-	1,858	2,021
Total		<u>937,420</u>	<u>4,732,215</u>	<u>5,669,635</u>	<u>3,890,756</u>
Expenditure on:					
Raising funds	6	326,581	480	327,061	207,508
Charitable activities	7	697,984	4,338,569	5,036,553	3,768,858
Other	11	-	36,901	36,901	71,757
Total		<u>1,024,565</u>	<u>4,375,950</u>	<u>5,400,515</u>	<u>4,048,123</u>
Net (expenditure)/income for the year/ Net movement in funds		(87,145)	356,265	269,120	(157,367)
Reconciliation of funds					
Total funds brought forward		<u>678,615</u>	<u>975,322</u>	<u>1,653,937</u>	<u>1,811,304</u>
Total funds carried forward		<u><u>591,470</u></u>	<u><u>1,331,587</u></u>	<u><u>1,923,057</u></u>	<u><u>1,653,937</u></u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

BALANCE SHEET

AS AT 31 DECEMBER 2021

	Notes	2021 £	£	2020 £	£
Fixed assets					
Tangible assets	14		41,442		41,523
Current assets					
Stocks	15	35,426		38,697	
Debtors	16	3,769,320		3,105,582	
Cash at bank and in hand		4,047,115		3,926,525	
		7,851,861		7,070,804	
Liabilities					
Creditors: amounts falling due within one year	17	(3,395,160)		(3,053,855)	
Net current assets					
			4,456,701		4,016,949
Total assets less current liabilities					
			4,498,143		4,058,472
Creditors: amounts falling due after more than one year					
	18		(2,575,086)		(2,404,535)
Total net assets					
			1,923,057		1,653,937
The funds of the charity					
Restricted funds	20		1,331,587		975,322
Unrestricted funds	21		591,470		678,615
Total charity funds					
			1,923,057		1,653,937

The financial statements were approved and authorised for issue by the board of trustees on 17 August 2022 and are signed on its behalf by:

David Oxnam (Chair of Board of Trustees)
Trustee

The notes on pages 17 - 30 form part of these financial statements.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2021

	Note	2021 £	£	2020 £	£
Cash flows from operating activities					
Cash generated from operations	26		128,855		1,148,161
Investing activities					
Purchase of tangible fixed assets		(10,123)		-	
Investment income received		1,858		2,021	
Net cash (used in)/generated from investing activities			(8,265)		2,021
Net cash used in financing activities			-		-
Net increase in cash and cash equivalents			120,590		1,150,182
Cash and cash equivalents at beginning of year			3,926,525		2,776,343
Cash and cash equivalents at end of year			4,047,115		3,926,525

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies

Charity information

The Children's Cancer and Leukaemia Group is governed by its Constitution.

1.1 Basis of preparation

The charity is a public benefit entity as defined by FRS102. These financial statements have been prepared in accordance with: The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

For legacies, income is recognised and included in the financial statements when all of the following criteria are met:

- the charity has entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Where legacies have been notified to the charity but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Government grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies

(Continued)

Income from charitable activities includes income received from grants, registration fees for meetings, member subscriptions and publication payments. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Investment income is earned through holding assets for investment purposes. It comprises bank interest and is recognised on an accruals basis.

1.5 Expenditure recognition

All expenditure, including the awarding of grants, is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Costs of raising funds includes costs incurred in seeking donations, grants and legacies, website costs and advertising.
- Expenditure on charitable activities includes research, educational activities and professional association activities to further the delivery of the objectives of the charity.
- Other expenditure includes wages and salaries covered by income from the Coronavirus Job Retention Scheme.

1.6 Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure in line with the objectives of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 10.

1.7 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Computer equipment, furniture and fixtures 5-10 years

1.8 Stocks

Stocks include merchandise stock and educational literature. Stocks that are held for resale are stated at the lower of cost and estimated selling price. Stocks held for distribution as part of the charity's activities are valued at their service potential, which the charity considers to be the cost of the materials.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies

(Continued)

1.10 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities.

1.11 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows:

Allocation of support costs

The allocation of support costs is sensitive to changes in the level of work undertaken on each activity by the charity. The allocation is reassessed annually and amended when necessary to reflect current estimates.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

3 Income from donations and legacies

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £
Donations	586,019	578,545	1,164,564	372,572	432,458	805,030
Legacies	103,190	150,000	253,190	425,000	-	425,000
Government grants	-	36,901	36,901	-	71,757	71,757
	<u>689,209</u>	<u>765,446</u>	<u>1,454,655</u>	<u>797,572</u>	<u>504,215</u>	<u>1,301,787</u>

4 Income from charitable activities

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £
Registration fees for meetings	26,772	59,074	85,846	64,709	7,119	71,828
Member subscriptions and publication payments	159,731	-	159,731	159,481	-	159,481
Grant income for research and operations	59,850	3,907,695	3,967,545	60,000	2,295,639	2,355,639
	<u>246,353</u>	<u>3,966,769</u>	<u>4,213,122</u>	<u>284,190</u>	<u>2,302,758</u>	<u>2,586,948</u>

5 Income from investments

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £
Interest	1,858	-	1,858	2,021	-	2,021

6 Expenditure on raising funds

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £
<u>Costs of raising funds</u>						
Fundraising platform fees	18,843	-	18,843	11,703	-	11,703
Website	5,917	-	5,917	3,792	-	3,792
Fundraising, marketing and publicity costs	165,383	480	165,863	59,035	-	59,035
Support costs (note 10)	136,438	-	136,438	132,978	-	132,978

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

6 Expenditure on raising funds (Continued)

326,581	480	327,061	207,508	-	207,508
---------	-----	---------	---------	---	---------

7 Expenditure on charitable activities

	Activities undertaken directly Note 8 £	Grant funding Note 9 £	Support Costs Note 10 £	Total 2021 £	Total 2020 £
Support for research	70,500	4,267,889	142,465	4,480,854	3,200,215
Information for patients and families	47,104	-	212,453	259,557	242,727
Improving treatment and care	69,865	-	226,277	296,142	325,916
	<u>187,469</u>	<u>4,267,889</u>	<u>581,195</u>	<u>5,036,553</u>	<u>3,768,858</u>
Unrestricted funds				697,984	703,225
Restricted funds				4,338,569	3,065,633
				<u>5,036,553</u>	<u>3,768,858</u>

8 Expenditure on activities undertaken directly

	Support for research £	Information for patients and families £	Improving treatment and care £	Total 2021 £	Total 2020 £
Staff costs	51,393	-	-	51,393	17,020
Other tumour specific expenditure	13,190	-	-	13,190	15,729
Contact magazine expenses	-	36,825	-	36,825	18,680
Other publication expenses	-	1,403	-	1,403	12,484
Website	5,917	8,876	8,876	23,669	15,169
Cost of meetings	-	-	31,782	31,782	81,017
Travel expenses	-	-	1,072	1,072	4,870
Membership support costs	-	-	20,558	20,558	8,919
Other expenses	-	-	7,577	7,577	8,189
	<u>70,500</u>	<u>47,104</u>	<u>69,865</u>	<u>187,469</u>	<u>182,077</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

9 Expenditure on grant funding

	Support for research	Information for patients and families	Improving treatment and care	Total 2021	Total 2020
	£	£	£	£	£
Grants to institutions:					
University of Birmingham	496,909	-	-	496,909	166,952
University of Surrey	-	-	-	-	9,844
Newcastle University	1,326,430	-	-	1,326,430	74,582
UCL Institute of Child Health	414,795	-	-	414,795	424,623
University of Sheffield	-	-	-	-	206,625
University of Nottingham	137,689	-	-	137,689	255,841
University of Ulster	-	-	-	-	216,108
University of Bristol	206,658	-	-	206,658	-
Great Ormond Street	99,576	-	-	99,576	14,954
University of Southampton	-	-	-	-	245,079
University of Glasgow	31,793	-	-	31,793	439,610
University of York	-	-	-	-	105,027
University of Cambridge	251,723	-	-	251,723	136,392
Institute of Cancer Research	599,310	-	-	599,310	299,236
University of Leeds	198,979	-	-	198,979	110,775
University of Manchester	86,108	-	-	86,108	-
University of Portsmouth	-	-	-	-	100,901
University of Oxford	-	-	-	-	219,195
University College Dublin	78,303	-	-	78,303	-
Swansea University	208,533	-	-	208,533	-
University of Bath	104,155	-	-	104,155	-
The Royal Marsden Hospital	15,000	-	-	15,000	-
Blood Cancer UK	11,928	-	-	11,928	-
	<u>4,267,889</u>	<u>-</u>	<u>-</u>	<u>4,267,889</u>	<u>3,025,744</u>

The charity awards grants for specific research projects to various institutions, as part of their charitable activities.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

10 Expenditure on support costs

	Basis of allocation	2021 £	2020 £
Staff costs	*1	545,405	505,149
Depreciation & loss on disposal	*1	10,204	9,627
Occupancy expenses	*1	95,731	131,841
Postage	*1	13,621	12,275
Staff training	*1	2,660	6,000
Professional fees	*1 / *2	35,446	29,123
Redundancy costs	*1	14,566	-
		<u>717,633</u>	<u>694,015</u>
Analysed between			
Raising funds		136,438	132,978
Charitable activities		581,195	561,037
		<u>717,633</u>	<u>694,015</u>

*1 Support costs, excluding governance costs, have been allocated as follows:

<i>Cost of raising funds</i>	20% (2020 - 20%)
<i>Charitable activities</i>	
Support for research	20% (2020 - 20%)
Information for patients and families	30% (2020 - 30%)
Improving treatment and care	30% (2020 - 30%)

*2 Professional fees include governance costs of £35,446 (2020 - £29,123). Governance costs have been allocated as follows:

<i>Charitable activities</i>	
Support for research	17% (2020 - 17%)
Information for patients and families	22% (2020 - 22%)
Improving treatment and care	61% (2020 - 61%)

The amount charged to the SOFA in respect of auditor's remuneration was:

- Statutory audit £9,000 (2020 - £8,580),
- Preparation of cessation accounts for old unincorporated charity, prior to re-registering as a CIO £Nil (2020 - £5,820).

11 Other expenditure

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £
Wages	-	36,901	36,901	-	71,757	71,757
	<u>-</u>	<u>36,901</u>	<u>36,901</u>	<u>-</u>	<u>71,757</u>	<u>71,757</u>

12 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits during the year. No trustees were reimbursed for travel expenses during the year (2020 - 1 trustee was reimbursed for travel expenses of £63).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

13 Employees

The average monthly number of employees during the year was:

	2021	2020
	Number	Number
Total	18	18

Employment costs

	2021	2020
	£	£
Wages and salaries	530,285	499,229
Social security costs	51,546	45,200
Other pension costs	51,868	49,497
Redundancy costs	14,566	-
	<u>648,265</u>	<u>593,926</u>

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2021	2020
	Number	Number
£80,001 - £90,000	1	1

14 Tangible fixed assets

	Computer equipment, furniture and fixtures	Total
	£	£
Cost		
At 1 January 2021	63,202	63,202
Additions	10,123	10,123
At 31 December 2021	<u>73,325</u>	<u>73,325</u>
Depreciation and impairment		
At 1 January 2021	21,679	21,679
Depreciation charged in the year	10,204	10,204
At 31 December 2021	<u>31,883</u>	<u>31,883</u>
Carrying amount		
At 31 December 2021	<u>41,442</u>	<u>41,442</u>
At 31 December 2020	<u>41,523</u>	<u>41,523</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

15 Stocks

	2021 £	2020 £
Merchandise stock	14,483	23,564
Educational literature	20,943	15,133
	<u>35,426</u>	<u>38,697</u>

16 Debtors

	2021 £	2020 £
Amounts falling due within one year:		
Trade debtors	81	10,152
Grant debtors	2,349,235	1,661,876
Rent deposit	16,200	16,200
Prepayments and accrued income	130,113	140,633
Accrued legacy income	205,000	445,000
	<u>2,700,629</u>	<u>2,273,861</u>

	2021 £	2020 £
Amounts falling due after more than one year:		
Grant debtors	1,068,691	831,721
	<u>1,068,691</u>	<u>831,721</u>
Total debtors	<u>3,769,320</u>	<u>3,105,582</u>

17 Creditors: amounts falling due within one year

	2021 £	2020 £
Trade creditors	55,830	20,902
Grant creditors	3,293,878	2,987,921
Accruals	45,452	45,032
	<u>3,395,160</u>	<u>3,053,855</u>

18 Creditors: amounts falling due after more than one year

	2021 £	2020 £
Grant creditors	2,575,086	2,404,535
	<u>2,575,086</u>	<u>2,404,535</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

19 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees.

The amount recognised in unrestricted expenditure was £51,868 (2020 - £49,497).

20 Restricted funds

The income funds of the charity include restricted funds which comprise the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at 1 January 2021 £	Movement in funds		Balance at 31 December 2021 £
		Income £	Expenditure £	
Tumour specific funds	744,648	780,510	(412,585)	1,112,573
CCLG Prize	54	-	-	54
General research fund	3,940	-	-	3,940
Adam Hay fund	10,982	120	-	11,102
CCLG Senior Members Group	7	-	-	7
PODC	3,338	1,444	-	4,782
POTG	2,139	2,947	(4,876)	210
The Little Princess Trust fund	6,200	3,907,695	(3,907,695)	6,200
Treatment Guidelines fund	18,435	-	(210)	18,225
TYAC Lisa Thaxter	45,412	-	(1,280)	44,132
Child Cancer Smart	73,500	-	(633)	72,867
PORT	400	20	-	420
CCLG Research Network Partner Charity	36,328	-	6,139	42,467
Neuroblastoma Nursing Group	10,500	-	-	10,500
Childhood Cancer Priority Setting Partnership	17,909	-	(17,909)	-
PODC - Iraq Fund	1,530	2,578	-	4,108
Coronavirus Job Retention Scheme	-	36,901	(36,901)	-
	<u>975,322</u>	<u>4,732,215</u>	<u>(4,375,950)</u>	<u>1,331,587</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

20 Restricted funds

(Continued)

	Balance at 1 January 2020 £	Movement in funds		Balance at 31 December 2020 £
		Income £	Expenditure £	
Tumour specific funds	930,227	425,593	(611,172)	744,648
CCLG Prize	304	-	(250)	54
General research fund	2,982	6,387	(5,429)	3,940
Adam Hay fund	11,861	120	(999)	10,982
CCLG Senior Members Group	7	-	-	7
PODC	3,317	1,462	(1,441)	3,338
POTG	2,139	-	-	2,139
The Little Princess Trust fund	6,200	2,248,667	(2,248,667)	6,200
Treatment Guidelines fund	18,661	-	(226)	18,435
TYAC Lisa Thaxter	45,412	-	-	45,412
Child Cancer Smart	174,944	-	(101,444)	73,500
PORT	200	200	-	400
CCLG Research Network Partner Charity	72,656	46,972	(83,300)	36,328
CYP Coalition Activity	9,034	-	(9,034)	-
Neuroblastoma Nursing Group	6,000	4,500	-	10,500
Childhood Cancer Priority Setting Partnership	21,580	-	(3,671)	17,909
PODC - Iraq Fund	215	1,315	-	1,530
Coronavirus Job Retention Scheme	-	71,757	(71,757)	-
	<u>1,305,739</u>	<u>2,806,973</u>	<u>(3,137,390)</u>	<u>975,322</u>

Tumour specific funds

Represents income received from donors with a specific request that the funds are used in support of grants for a particular tumour type.

CCLG Prize

Represents income received from donors to fund the CCLG Prize.

General research fund

Represents income received from donors with a specific request that the funds are used for research purposes.

Adam Hay fund

This fund has been established to continue work done by the Adam Hat's charity (which merged with CCLG in 2011) in neuroblastoma research and psychological support for children and families.

CCLG Senior Members Group

Represents income received from the Senior Members' Group to be used for their activities.

PODC

Represents income received from donors to be used for the Paediatric Oncology in Developing Countries (PODC).

POTG

Represents income received from donors to be used for the Paediatric Oncology Trainees' Group (POTG).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

20 Restricted funds

(Continued)

The Little Princess Trust fund

Represents income received from The Little Princess Trust to fund future instalments of research grants awarded.

Treatment Guidelines fund

Represents a grant received for the development of rare endocrine tumour guidelines.

TYAC Lisa Thaxter

Represents income received for providing and supporting education and training to professionals working in the field of teenage and young adult cancer. This was previously a restricted fund in TYAC and has transferred to CCLG as part of the closure of TYAC, with the same restrictions maintained.

Child Cancer Smart

Represents income received for a research programme, guideline development and awareness raising focusing on earlier diagnosis of childhood cancer.

PORT

Represents income received for the Paediatric Oncology Reference Team, a group of parents of children with cancer who review clinical trial and other research information to ensure it is appropriate for children with cancer and their families.

CCLG Research Network Partner Charity

Represents income research from other charities to fund research projects.

CYP Coalition Activity

Represents income received from charity members of the Children and Young People's Cancer Coalition for the costs of providing the Coalition secretariat.

Neuroblastoma Nursing Group

Represents income received to support the costs of running the national neuroblastoma nursing group, a group of CCLG member nurses with a special interest in neuroblastoma.

Childhood Cancer Priority Setting Partnership

Represents grant income received to support the James Lind Alliance supported Childhood Cancer Priority Setting Partnership being led by CCLG.

PODC - Iraq Fund

Represents donations received to specifically support work to improve the treatment and care of children with cancer in Iraq.

Coronavirus Job Retention Scheme

Represents amounts received from the Government to cover staff costs during the Covid-19 pandemic.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

21 Unrestricted funds

The unrestricted funds of the charity include general funds and designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	Balance at 1 January 2021 £	Movement in funds		Balance at 31 December 2021 £
		Income £	Expenditure £	
General funds	678,615	937,420	(1,024,565)	591,470

	Balance at 1 January 2020 £	Movement in funds		Balance at 31 December 2020 £
		Income £	Expenditure £	
General funds	505,565	1,083,783	(910,733)	678,615

22 Analysis of net assets between funds

	Unrestricted Funds 2021 £	Restricted Funds 2021 £	Total 2021 £
Fund balances at 31 December 2021 are represented by:			
Tangible assets	41,442	-	41,442
Current assets/(liabilities)	550,028	3,906,673	4,456,701
Long term liabilities	-	(2,575,086)	(2,575,086)
	<u>591,470</u>	<u>1,331,587</u>	<u>1,923,057</u>

	Unrestricted Funds 2020 £	Restricted Funds 2020 £	Total 2020 £
Fund balances at 31 December 2020 are represented by:			
Tangible assets	41,523	-	41,523
Current assets/(liabilities)	637,092	3,379,857	4,016,949
Long term liabilities	-	(2,404,535)	(2,404,535)
	<u>678,615</u>	<u>975,322</u>	<u>1,653,937</u>

23 Events after the reporting date

Legacy income amounting to £171,554 was notified after 31 December 2021 and has not been recognised in these accounts. £81,554 has subsequently been received.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

24 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2021 £	2020 £
Within one year	27,530	27,530
Between two and five years	48,177	75,707
	<u>75,707</u>	<u>103,237</u>

Amounts recognised in the SOFA as an expense during the period in respect of operating lease arrangements are £27,530 (2020 - £27,530).

25 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel, is as follows.

	2021 £	2020 £
Aggregate compensation	<u>217,459</u>	<u>161,873</u>

There have been no other related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 12 to the financial statements.

26 Cash generated from operations

	2021 £	2020 £
Surplus/(deficit) for the year	269,120	(157,367)
Adjustments for:		
Investment income recognised in statement of financial activities	(1,858)	(2,021)
Depreciation and impairment of tangible fixed assets	10,204	9,627
Movements in working capital:		
Decrease/(increase) in stocks	3,271	(8,183)
(Increase) in debtors	(663,738)	(323,644)
Increase in creditors	511,856	1,648,844
(Decrease) in deferred income	-	(19,095)
Cash generated from operations	<u>128,855</u>	<u>1,148,161</u>

27 Analysis of changes in net funds

During the year the charity had no borrowings or obligations under finance leases. The changes in net funds of the charity therefore solely comprise of cash and cash equivalents.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

England & Wales - Charity number 1182637

Accounts

Charity Registration No. 1182637 (England and Wales)

Charity Registration No. SC049948 (Scotland)

Company Registration No. CE016951 (England and Wales)

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

**TRUSTEES' REPORT AND
FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED
31 DECEMBER 2020**

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	David Oxnam (Chair of Board of Trustees) Dr Daniel Saunders (Treasurer) Gayle Routledge Rachel Wilcox David Hobin Sarah Curtis	(Appointed 14 April 2021) (Appointed 14 April 2021)
Chief Executive	Ashley Gamble	
Charity number	1182637 (England and Wales) SC049948 (Scotland)	
Company number	CE016951	
Operating name	CCLG	
Principal address	Century House 24 De Montfort Street Leicester LE1 7GB	
Auditor	Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT	
Bankers	HSBC Bank Plc 2-6 Gallowtree Gate Leicester LE1 1DA	
	National Westminster Bank Plc 1 Granby Street Leicester LE1 6EJ	
	Scottish Widows Bank Plc PO Box 12757 67 Morrison Street Edinburgh EH3 8YJ	
	CAF Bank Ltd 25 Kings Avenue Kings Hill Kent ME19 4JQ	

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

CONTENTS

	Page
Trustees' report	1 - 10
Independent auditor's report	11 - 13
Statement of financial activities	14
Balance sheet	15
Statement of cash flows	16
Notes to the financial statements	17 - 33

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2020

The trustees of The Children's Cancer and Leukaemia Group are pleased to present their annual report and financial statements for the year ended 31 December 2020.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

OBJECTIVES AND ACTIVITIES

The objectives of The Children's Cancer and Leukaemia Group (CCLG) as defined in the constitution are:

For the public benefit, the relief of sickness and suffering of children, teenagers and young adults with cancer and advancement of education in the field of children, teenagers and young adults with cancer, in particular but not exclusively by:

1. The relief of sickness and promotion and protection of good health by supporting research into the nature, causes, diagnosis, treatment and social consequences of cancer in children, teenagers and young adults, and to publish the useful results of such research.
2. The relief of suffering of children, teenagers and young adults with cancer and their families and carers, through the provision of information and support services to them.
3. The advancement of the education of the public in all areas relating to cancer in children, teenagers and young adults.
4. The advancement of education and clinical practice by the dissemination of knowledge of the latest research and best practice amongst professionals and practitioners engaged in the treatment, care and support of children, teenagers and young adults with cancer.

The main beneficiaries of the work carried out by the charity are children, teenagers and young adults with cancer and their families in the United Kingdom and elsewhere in the world.

CCLG is the UK and Ireland's professional association for all those involved in the treatment and care of children with cancer (including leukaemia). Our multidisciplinary and multi-professional membership continues to grow. At the end of 2020, there were in excess of 1000 members. In addition, we host Teenagers and Young Adults with Cancer (TYAC), a multidisciplinary and multi-professional membership association for those involved in the treatment and care of teenagers and young adults with cancer. At the end of 2020, there were more than 400 TYAC members.

Through our membership activities, we provide an active forum for professionals to work together to share best practice and advance education and professional development. Members are able to network with both national and international colleagues for advice and support and receive information and vital updates on specific diseases and treatments. This ensures every child with cancer receives the best possible treatment and care available wherever they live.

The activities of our professional association and membership body include:

- Specialist networks groups: These are a core part of our professional activities enabling professionals to work with others who share the same clinical interests.
- Key conferences and events: We organise a range of meetings each year to ensure members are kept up to date with the latest developments in cancer research, care, and treatment. Our annual meeting in January offers an opportunity for all of our members to network with colleagues from across Britain and Ireland.
- Professional voice for children, teenagers and young adults: We advise governments and other bodies and ensure that we are represented on important groups or in consultations, for example in the area of NHS commissioning of children's cancer services or the development of NICE quality standards and guidance.
- Online members' area: A vital hub for professionals involved in the care of children and young people with cancer, providing a wealth of resources and educational opportunities for our membership.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

Our members are dedicated to ensuring that children and young people have a greater chance of survival and a better life after treatment.

We support children and young people with cancer and their families in a variety of different ways:

- Written by experts, our comprehensive quality-assured range of information booklets and leaflets helps patients and their families understand their diagnosis, treatment and what to expect now and in the future. Our publications are available free of charge to those who need them.
- Our free quarterly magazine, Contact, offers help, support and information for families of children, teenagers and young adults with cancer.
- We also organise informative events for parents and families each year. Since 2014, we have organised the UK Childhood Cancer Conference. This hugely successful event brings together parents, researchers, healthcare professionals and charities to discuss the latest research into childhood cancer and talk about the issues which affect parents.
- Our website is a comprehensive resource of childhood cancer information. Our online 'Childhood Cancer Information Hub', brings together information resources (booklets and leaflets, web pages, film and video content and more) into a single 'one-stop-shop', which is easily searchable and can be filtered by cancer type, audience, etc.

The outstanding progress made in cancer treatment is the result of extensive research studies and clinical trials over the last 40 years which now underpin today's standard treatments. During this time, CCLG has played a key role in the success seen in the world of children's cancer so that now over 80% of children are cured.

But there are still some childhood cancers with a poor outlook, and some treatments can have long-lasting and devastating side effects. Further research is vital to improve survival rates and to find kinder treatments.

We fund and support a variety of research into childhood cancers including:

- The CCLG Tissue Bank is the UK's largest collection of tumour, DNA and other tissue samples from childhood cancer patients. Samples enable scientists and researchers to get as close to the disease as possible so they can find new ways of diagnosing children, new treatments and cures for patients.
- We offer funds and grants to launch new research projects and develop new clinical trials.
- We work in partnership with other charities and organisations to support research. We use our research-funding infrastructure, as well as the scientific and medical expertise of our membership, to support smaller charities to meet their research aims. For example, by managing a research funding programme or helping them to identify research to support.
- We can 'ringfence' funds so that our supporters can raise funds towards a cancer-specific research project.
- Our Special Interest Groups provide a forum for discussion and planning of research and bring together potential collaborators. We organise and support scientific meetings where research findings are shared and discussed, and we support our membership to be involved in planning research and attending important meetings through bursaries and sponsorship.
- We support the next generation of childhood cancer researchers through our trainee scheme in partnership with the National Cancer Research Institute. This allows trainee paediatric oncologists to be involved in the development and management of clinical trials, by attending meetings, being mentored by experienced researchers, and gaining insight into research activity.
- In 2017, CCLG was accepted into membership of the Association of Medical Research Charities, demonstrating our commitment to funding high-quality, world class research and confirming the high standard of the processes we use to select and fund research.

We measure our success in achieving our objectives in a number of ways:

- The number of patient information products distributed, and the number of visits to the 'about childhood cancer' section of our website, are some measures used to ascertain our success in supporting patients and their families. We also gather feedback on our information products.
- The number of publications in journals, the number of studies accessing the CCLG Tissue Bank, and the amount of tissue samples banked, are some measures used to ascertain the success of our research programme including the CCLG Tissue Bank.
- The number of members and retention of members are some basic measures used to ascertain how we are supporting the community of professionals we serve through our professional association activities.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

- The number of research projects funded and their value, and the outcome of research projects including peer-reviewed papers in scientific journals.

ACHIEVEMENTS AND PERFORMANCE

2020 was our first full year as a charitable incorporated organisation (CIO) following conversion in 2019 after the previous unincorporated charity ended its longstanding hosting agreement with the University of Leicester. Following the transfer, the CIO continues the same activities the unincorporated charity undertook.

Like many charities, the global COVID-19 pandemic had a huge impact on our work during 2020. Some of our usual activities were unable to continue, such as professional education meetings and events. The need to minimise the impact on our finances resulted in using the Government's Coronavirus Job Retention Scheme to flexibly furlough a number of staff, resulting in a reduced ability to carry out other activities. The impact of restrictions to control the virus had a huge impact on our ability to raise funds, with in-person community events being unable to be held for most of the year and the cancellation of major mass participation events such as the London Marathon.

Despite the challenges of 2020, CCLG continues to go from strength to strength. We continued to work towards the four main goals set out in our strategic plan launched in January 2018, and the goals of the TYAC strategic plan launched in 2019.

Providing leadership and expertise for the treatment and care of children and young people with cancer

As the UK and Ireland's professional association for those working in the field of paediatric oncology and haematology, CCLG is a leading voice for children's cancer, liaising with community groups, the government and the NHS to influence policies. We use our expertise to improve treatment and care and meet the needs of patients and families. In 2020:

- Our key event, the annual CCLG Winter Meeting, was the largest to date, bringing together more than 300 professionals (prior to Covid-19 restrictions) to share the most up-to-date news, research and information in all areas of treatment and care. For the first time, the meeting was extended to three days, and included a joint session with the National Cancer Research Institute (NCRI) Children's Group, providing updates and guest lectures on clinical research activity.
- Usually, we would have a further programme of meetings and educational events throughout the year. Unfortunately, the COVID pandemic meant the majority of these were unable to go ahead. When it became clear that no events of this nature were likely to be able to go ahead for the remainder of 2020, we began to hold a number of online meetings and educational events for our specialist working groups, which had the benefit of allowing greater and more diverse attendance than a traditional meeting would have done. A challenge going forward will be how we bring together the positive aspects of both in-person and virtual events to best meet the needs of our membership.
- We produced and updated a number of clinical treatment guidelines, ensuring standardised, high quality and evidence-based treatment for all children, particularly in diseases where there is currently no open clinical trial.
- Following the commissioning of a significant piece of research into the experience and needs of our membership, we developed a strategy for ensuring that our members get the most from their membership, and that we support them in their roles. The strategy includes exciting plans for enhanced member engagement and more opportunities for our members, and while the pandemic meant we were unable to deliver this in 2020, many of the plans will begin in 2021.

Improving diagnosis times by increasing awareness

The significance of a delayed diagnosis presents a challenge for primary health care professionals, who are required to triage symptoms that may point to a cancer diagnosis from those which are not and make appropriate onward referrals. Many symptoms associated with cancer are non-specific and are seen every day in general practice, whilst a cancer diagnosis is seen infrequently. Delays in the diagnostic pathway may well lead to more advanced disease at presentation, with subsequent greater risk of death, greater morbidity, and inevitably, distrust of the medical system. There is evidence that tumours presenting in childhood in the

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

UK are larger, at a more advanced stage and require more therapy than those presenting in other parts of Europe. We work to improve diagnosis times for children and young people with cancer. In 2020:

- We continued working on our Child Cancer Smart project, which will result in a number of clinical referral guidelines, and public and professional awareness tools, on the signs and symptoms of childhood cancer. Some of this activity, which relies on the input and support of a range of health professionals, was delayed due to the pressures on the NHS during the COVID-19 pandemic. We hope to catch up on much of this work during 2021.
- The Child Cancer Diagnosis Study, a research project funded by the National Institute for Health Research (NIHR) and CCLG, and jointly run by CCLG and The University of Nottingham, opened in the majority of Principal Treatment Centres in the UK. This innovative, nationwide research will give us, for the first time, an accurate picture of the routes to diagnosis and where we can develop interventions to drive improvements.
- We continued to work on a referral guide for suspected cancer in children and young people to support general practitioners and other professionals involved in the diagnosis of cancer in this age group. This work will be published in early 2021.

Strengthening our expert information portfolio to support more families of a child with cancer

Looking after a child with cancer can be a scary and lonely experience for families. Our goal is to deliver the right information at the right time and make a positive difference to their daily lives.

We continue to be the leading provider of expert-written, award-winning and quality-assured information about all aspects of childhood cancer, from diagnosis to life when treatment has finished. In 2020:

- We sent more than 20,000 free information booklets and leaflets to hospitals and directly to families during the year. A number of new publications were produced, and further existing publications were reviewed and revised.
- We produced four issues of Contact magazine, a source of information and support for families, with each issue having a circulation in excess of 6,000 copies.
- We continued to add to and improve the health information content of our website, which received over half a million 'hits' during the year.
- Our annual Childhood Cancer Conference, a unique event bringing together parents, professionals and researchers, was unable to take place in 2020. We are currently looking at ways we can deliver this event virtually in 2021.
- Our closed Facebook group for parents and carers of children with cancer, which allows members to seek advice and support from those with similar experiences, and, uniquely, 'ask the experts' through posting questions answered by our clinical membership community, continued to grow, reaching over 1000 members. Much of the activity in the group during the year was driven by the COVID-19 pandemic.
- We achieved the Patient Information Forum (PIF) PIFTick accreditation for our health information. This new quality standard, replacing the former Information Standard which was discontinued, is awarded following rigorous assessment of our information production processes, and demonstrates our commitment to reliable, expert, high-quality health information.

Supporting and funding world-class research

Our aim is to both support and fund world-class research, deepen understanding and foster collaborations across the childhood cancer community. One of our most important areas of work is to offer opportunities for our members to develop scientific networks and belong to a wider research community dedicated to childhood cancer. Our Research Strategy outlines our exciting plans to fund and support innovative world-class research into childhood cancer and recognises the importance of collaboration, both nationally and internationally, to achieve improvements.

- We fund research directly, and work with partner charities to support them to fund the best possible research, using our well-established research funding expertise, experience and infrastructure. In total, between our own research funding and that of the partners we work with, 24 new research projects totalling over £2.9 million were funded in 2020.
- We continued to work in partnership with The Little Princess Trust to support them to fund the best quality research with a focus on finding better, kinder treatments. During the year, the Trust awarded 14 projects just over £2.2 million (included within the £2.9 million above).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

- For the first time, we funded a number of small pilot grants to research projects focusing on the late effects of childhood cancer. We received a large number of high-quality applications, highlighting the paucity of available research funding for this important area, and hope to grow our funding in this area in future years.
- We also worked in partnership to award a research grant on behalf of The Harley Staples Childhood Cancer Trust.
- Work continued on a Priority Setting Partnership for children's cancer during the year, initiated by CCLG and co-funded with the Little Princess Trust, and under the auspices of the James Lind Alliance (JLA). The JLA is a non-profit making initiative established in 2004. It brings patients, carers and clinicians together in Priority Setting Partnerships (PSPs) to identify and prioritise the top 10 unanswered questions or evidence uncertainties that they agree are the most important. The aim of this is to make sure that health research funders are aware of the issues that matter most to the people who need to use the research in their everyday lives. Through virtual meetings, we were able to continue with this work, and the children's cancer PSP will complete its work programme over the next years to define the top 10 research priorities in childhood cancer, which will feed into CCLG's future research strategy.
- COVID-19 also impacted on our research funding programme. With many charities halting or reducing their research funding due to the impact of the pandemic on their income, as one of only a few charities providing funding during the year we received a much larger number of applications to our grant rounds than we would usually expect. Along with reduced availability of expert peer reviewers due to the impact of the pandemic on both healthcare institutions and universities around the world, this meant our research activity during the year, the time taken to make decisions and award grants was extended.

Teenagers and Young Adults with Cancer (TYAC)

Teenagers and Young Adults with Cancer (TYAC) is the professional association for those working in teenage and young adult (TYA) oncology. TYAC merged with CCLG in 2018, and in 2019 we launched a new strategy for the work of TYAC, setting out how we would continue to drive improvements in TYA cancer care, and support the development of professionals working in the field. During the year, the COVID-19 pandemic disrupted the activities of TYAC more than the rest of CCLG's work, primarily due to the disruption to TYA services in the NHS and the impact of this on our members. In 2020, we commissioned a new TYAC website to better support our ambitions to support both the professional members, and TYA with cancer, as well as raising funds under the TYAC brand. We developed a research strategy for TYAC, which will begin to fund and support research into TYA cancer, supported by increased fundraising under the TYAC brand, in 2021.

Fundraising

All of our work is dependent on the generosity of our supporters. A programme of fundraising underpins our ability to fund research, support patients and families, and improve treatment and care for children and young people with cancer. In 2020:

- Our Special Named Fund programme continued to grow. After their cancer experiences, families sometimes consider setting up their own charity. For many, our Special Named Funds may be a great alternative. We support families to achieve their fundraising objectives, while taking away the administrative burden of setting up and running a charity. At the end of the year, there were approximately 60 Special Named Funds at CCLG (2019: 40), each raising funds to support research into a specific type of childhood cancer.
- We began to implement our new fundraising strategy, bringing forward planned activity that could still run during COVID-19 restrictions, such as 'virtual events', as well as laying the foundations for future campaigns around regular giving and legacy giving.
- We invested in new IT solutions to support our fundraising activity, maximise relationships with supporters and prepare for future activity, including implementing a new fundraising CRM database across the organisation, and launching new online platforms for both our Special Named Funds and virtual events programmes.

COVID-19

In response to the COVID-19 pandemic, we undertook a number of activities during the year to support the families of children and young people with cancer during the unprecedented circumstances:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

- We produced ongoing guidance, interpreting the national generic guidance, for families of a child with cancer during the pandemic, which was revised multiple times during the year by a core working group of CCLG experts. The guidance covered: whether children with specific diseases or at specific times during their treatment were clinically extremely vulnerable or clinically vulnerable to severe COVID-19 disease, and what this meant in terms of restrictions including shielding and school attendance; responses to various questions and issues as they arose including increased susceptibility for BAME communities, emerging complications of the disease, changes to hospital procedures etc; various research projects and their results; responding to news and media stories; and vaccination questions once vaccines were approved. The guidance received almost 80,000 website views during the year.
- Alongside the University of Birmingham, we launched the UK Paediatric Oncology Coronavirus Monitoring Project, registering all cases of COVID-19 in children with cancer and recording their outcomes. We published the data from this study in a format accessible to parents, and were able to conclude from this study that, in most cases, the risk of severe COVID-19 disease for children with cancer was lower than first thought – and comparable to ‘well’ children – and were able to update our advice on shielding, enabling many families to release themselves from isolation and improve their mental health and wellbeing.
- Alongside colleagues from the Universities of Southampton and York, and with funding from CCLG, we initiated the SHARE Study, which researched families’ experiences of lockdown, their worries and concerns, at various timepoints during the pandemic. The results supported us to tailor the advice we gave, as well as inform other charities about the need for support services and the specific needs our families of children with cancer. The success of the study saw it replicated for families of children with other diseases, supported by other relevant charities.
- We funded an online programme (iHope programme) for families to learn to better cope with the stresses of the pandemic, including coping with isolation. Alongside running the programme, we evaluated how well it worked and fed back recommendations for future development to the organisers.
- Our Facebook Group for parents and carers of children with cancer grew in membership to over 1000 members during the year. We offered the opportunity for parents and carers to ‘ask the expert’ their questions around childhood cancer and especially questions relating to COVID-19, as well as share experiences with others in the group and to ask them for advice. During the year we answered a large number of questions and feedback indicates this was a hugely valued opportunity, particularly as the government general advice around COVID was not tailored enough for children with illnesses.

Fundraising policy

We are reliant on donations to fund our vital work. Without the generosity of the public, we would not be able to continue providing support to children and young people diagnosed with cancer, and their families, nor fund research into childhood cancer.

We believe that it is essential that we are clear and open about how we raise our funds and about the range of ways people can get involved and support our work.

People raise money for us in many different ways, including through taking part in sporting events, organising events in their local community, or fundraising at their place of work. We also provide opportunities for people to fundraise through providing access to places in key events, such as the London Marathon, and through providing fundraising materials.

Our supporters can sign up to make regular donations, or to play our lottery which we launched in 2018.

We work with a number of corporate partners, and have received support from charitable trusts and foundations, and through grants from other charities. We do not carry out door-to-door fundraising, nor do we use street fundraising to sign up supporters to regular donations. Currently, none of our fundraising activities are conducted on our behalf by professional fundraising agencies.

CCLG is registered with the Fundraising Regulator. We are committed to adhering to the Code of Fundraising Practice. During the year, we received no complaints about our fundraising activities. Regular updates are provided to our board of trustees to ensure that they have a good oversight of our activities.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

FINANCIAL REVIEW

Transactions for the year ended 31 December 2020 fall into roughly the same categories as in previous years. Income generally consists of donations and fundraising income, subscriptions (comprising individual membership subscriptions and hospital subscriptions for health information), registration fees for meetings and events, funding from partner charities such as The Little Princess Trust to support research projects awarded through strategic partnerships, legacy income, and this year income from the Coronavirus Job Retention Scheme. We are grateful to CLIC Sargent and Teenage Cancer Trust for their continued support of TYAC activity.

The major items of expenditure for CCLG remain staff salaries, professional meeting and event costs, the costs associated with the production of health information, and the awarding of research grants.

Staffing costs represent a significant financial commitment, but our small, expert staff team is also responsible for the achievement of the majority of our charitable objectives. Staffing levels are kept under review, with the small, efficient team carrying out and coordinating the considerable activities of the charity.

Our overall income fell by £2,381,008 during 2020, compared with the year ending December 2019. Primarily this was due to the impact of the COVID-19 pandemic, which saw a fall in the number of rounds of grant funding offered by partner charities such as the Little Princess Trust, a reduction in fundraising income, and a fall in income from meetings and events which were unable to take place.

CCLG has a number of restricted funds. Internal records are kept according to requirements for restriction, i.e. tumour specific donations or donations for a specific piece of work. The restricted funds are ring-fenced to support specific projects or areas of activity and cannot be used to support the general running costs of the organisation.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation. Expenditure decreased in 2020 by £2,283,561 compared to 2019. The primary reason for this increase was the awarding of fewer research grants, and not holding meetings and events due to the COVID-19 pandemic.

Early in the year, we re-forecasted our budget based on assumptions about the pandemic and its impact. At this point it looked likely we would need to call on our reserves during the year to ensure the charity was able to meet its commitments. During the year, thanks to implementing cost-saving measures, a natural reduction in some expenditure (e.g. staff and member travel) as a result of pandemic restrictions, use of the coronavirus job retention scheme, and unexpected significant income from legacies, we ended the year with a surplus of £173,050 in unrestricted income and expenditure, which covered the majority of our core costs. Overall, we ended the year on a deficit of £157,367 and did not need to call on our free reserves, with the deficit in restricted income and planned expenditure being £330,417. However, our overall income was significantly lower than 2019.

Reserves Policy

The trustees continue to consider the appropriate balance of financial stability and investment in charitable activity. The COVID-19 pandemic has highlighted the importance of an appropriate reserves policy. Given the ongoing uncertainty around the pandemic and the length of time likely until we recover fully, it is important we continue to hold a level of reserves which can sustain our activity until we have a better picture of what post-pandemic fundraising might look like, both in the short- and medium-term. We have plans in place to ensure CCLG is 'fit for the future' and our reserves policy will ensure we are able to meet those plans.

At the end of the year, we have reviewed our reserves policy for CCLG and aim to hold a target level of free reserves (unrestricted funds less tangible fixed assets) of £400,000, which the trustees consider to be approximately six months of core expenditure, including staff salaries, accommodation costs and general running costs.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

Total reserves at 31 December 2020 were £1,653,937 of which £975,322 are restricted and £678,615 are unrestricted. As at 31 December 2020 the charity's free reserves totalled £637,092, which is in excess of the reserves policy due to the notification of legacies at the year-end. The trustees consider that this ensures that CCLG is 'fit for the future'.

The financial impact of the COVID-19 pandemic

As highlighted throughout this report, the COVID-19 pandemic in 2020 has had a huge impact on CCLG, both in our operations and our income generation. With many major fundraising events – notably the London Marathon – cancelled, as well as the varying lockdowns and other restrictions during the year preventing many types of fundraising events from being organised, our fundraising income was significantly reduced during the year. The inability to hold 'in-person' meetings and events meant that the majority of our education and scientific meetings and conferences – another key source of income – were cancelled, although this was mitigated to some extent by the corresponding decrease in expenditure on the cost of holding such events.

The Trustees and the Chief Executive have considered various scenarios for our finances during the coming year, which are unlikely to recover fully to pre-pandemic levels until at least 2022. We have taken the opportunity to review our activities and strategy, and ensure we have the right team in place to deliver on the charity's priorities for the coming year, including in fundraising. This includes a restructuring of the staff team in early 2021, which may sadly include some redundancies, but will also include the creation of some new staff posts.

As well as focusing on mitigating the impact on the charity as much as possible, to secure the future of our work, The Trustees and the Chief Executive have liaised closely during this year to ensure the wellbeing of staff. We have used the government's Coronavirus Job Retention Scheme ("furlough scheme"), taking the difficult decision to furlough a number of our staff team, and then bring them back on reduced hours under the 'flexible furlough' scheme from July, to support the costs of employing staff during the crisis. This necessitated focusing our work on the most important projects. Supporting our staff throughout this period has been a key priority for the Trustees and Senior Leadership Team. Our staff team is at the heart of what we do and are passionate about the impact CCLG has on children with cancer and their families. We recognise that our committed staff team also have lives outside of their work for CCLG which will have also been affected. The Trustees and Senior Leadership Team are extremely grateful for the dedication of the team, and how they have adapted to the current situation to ensure our vital work continues. We asked all staff to work from home, where possible, from early March, and offered flexible work patterns to suit the new circumstances of our team members. We offered regular online 'social catch-ups' for team members as well as ensuring regular updates were provided directly in team meetings, and through our internal social media platform.

Investment policy

The Trustees previously reviewed our plans for investments to consider the most appropriate way of managing these, balancing cashflow, risk and reward. Given the uncertainty of the financial impact of the UK leaving the European Union, and the COVID-19 pandemic, no further action has been taken on investments. Management accounts are produced for the trustees, and a cashflow forecast considerably facilitates management and prediction of charity income.

Risk Management

CCLG is also aware of the requirement to carry out a risk review of its activities. The trustees reviewed the risks the charity faces during the year. A Risk Register is in operation, documenting the systems in place to mitigate those risks, and is kept under review by the trustees.

FUTURE ACTIVITIES

All future activities planned are designed to ensure that CCLG continues to fulfil its objectives for children and young people with cancer, and their families, as the ultimate beneficiaries.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

As the membership of CCLG continues to grow, so does the activity our members are involved in. Our specialist network groups continue to be increasingly active, supporting our activities and providing specialist advice to commissioners of healthcare services and others. The CCLG Executive continues to consider that CCLG can advance education and professional development, and share and guide best practice.

The CCLG executive is a committee comprised of elected members of the CCLG professional body, along with the CEO, who have delegated authority from the Trustees for deciding and implementing the strategy of the organisation as it relates to the clinical, research and professional elements of our work.

At the end of 2020, as an AMRC member we participated in their 5-yearly peer review audit, which gave us the opportunity to review our research strategy and associated processes. We concluded that our current research strategy remains appropriate and plan to launch a new research strategy once the ongoing Children's Cancer Priority Setting Partnership has concluded and published the top ten research priorities in this field.

We plan to continue to develop our range of patient/parent information products in response to demand and specific needs identified by both end-users and professionals. In 2021, we will launch an updated and revised version of our Parents' Guide, our key publication which is given to all families upon diagnosis.

We also aim to continue raising awareness of CCLG and its activities, with a view to continuing to increase the income and resources available to us to meet our objectives.

In January 2021, the Trustees and Chief Executive began reviewing the staffing structure of the Charity, recognising the likelihood of reduced financial resources in the short to medium term as a result of the COVID-19 pandemic, and to ensure that the right staffing is in place to deliver on our strategic plan.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Children's Cancer and Leukaemia Group (CCLG) was established in 1977 and became a registered charity (number 286669) in 1983. In 2019, a new CIO (registration number 1182637) was formed, with the activities, assets and liabilities of the previous charity transferred to the CIO. The charity's governing instrument is the Constitution and the CIO was first registered in February 2019.

The board of trustees is independent of the CCLG membership. The board of trustees is responsible for managing the charity finances in support of the objectives defined by the CCLG Executive. There are a minimum of two and a maximum of eight trustees. One of the trustees will be the CCLG Treasurer, an elected member of the CCLG Executive, providing a link between these two groups.

If a vacancy arises, the trustees may appoint any eligible person as a trustee. In selecting individuals for appointment as trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity.

Upon appointment, trustees are provided with an induction to the charity. This consists of a briefing paper, as well as meetings with the Chair, CEO, and others as deemed appropriate. Regard is given to the training and development needs of any trustees that may arise.

The board of trustees meets quarterly and is supported by key management personnel. Four meetings were held in 2020.

The trustees come from a range of professional backgrounds, and bring new skills and highly relevant experience.

Trustees serving during the year were:

David Oxnam
Dr Daniel Saunders
Gayle Routledge
Rachel Wilcox

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

The Chief Executive is responsible for the day-to-day operation of the charity on behalf of the trustees. The remuneration of key management is reviewed annually by the board and is set against established pay scales, benchmarked in comparison with similar sized entities including both charities and medical professional associations. The trustees give their time freely and no remuneration was paid in the year. Details of trustee expenses are disclosed in note 12 to the accounts.

Key Management Personnel during the year were:

Ashley Gamble (Chief Executive)
Gill Smitherman (Head of Fundraising)
Claire Shinfield (Head of Engagement)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales and Scotland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities (Accounts and Reports) Regulations 2008, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

David Oxnam
Chair of the board of trustees

Dated: 12 July 2021

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Opinion

We have audited the financial statements of The Children's Cancer and Leukaemia Group (the 'charity') for the year ended 31 December 2020 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2020 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the trustees' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- the charity has not kept adequate and proper accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on 10, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under these acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charity.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- obtaining an understanding of the legal and regulatory framework applicable to the charity by considering the nature of the industry in which the charity operates and enquiring of management; and
- identifying the key laws and regulations considered to have a direct impact on the financial statements including the UK Companies Act 2006, UK Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, UK Generally Accepted Accounting Practice and UK tax legislation; and
- assessing how the charity is complying with the applicable legal and regulatory framework by making further enquiries of management and observing the charity's control environment regarding compliance with regulations and fraud prevention; and

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

- assessing the susceptibility of the charity's financial statements to material misstatement, including how fraud might occur, by considering the effectiveness of the charity's accounting systems and controls and how these were monitored by management. Where the risk of material misstatement was considered to be higher in certain areas, further audit procedures were designed to address this increased risk; and
- discussing amongst the engagement team how and where fraud might occur in the financial statements and any potential indicators of fraud.

Audit response to risks of irregularities identified

Our procedures to respond to risks identified included the following:

- reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations; and
- enquiry of charity staff responsible for compliance to identify any instances of non-compliance with laws and regulations; and
- enquiry of management, those charged with governance and other relevant parties around actual and potential litigation claims; and
- reviewing supporting documentation regarding actual and potential litigation claims; and
- reviewing minutes of meetings of those charged with governance; and
- performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias; and
- communicating identified laws and regulations and potential fraud risks to all engagement team members and assessing whether there are any indications of fraud or non-compliance with laws and regulations throughout the audit.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008, and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Newby Castleman LLP

Chartered Accountants
Statutory Auditor
West Walk Building
110 Regent Road
Leicester
LE1 7LT

2 August 2021

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Total 2019 £
Income from:					
Donations and legacies	3	797,572	504,215	1,301,787	1,131,259
Charitable activities	4	284,190	2,302,758	2,586,948	5,131,664
Investments	5	2,021	-	2,021	8,841
Total		1,083,783	2,806,973	3,890,756	6,271,764
Expenditure on:					
Raising funds	6	207,508	-	207,508	253,005
Charitable activities	7	703,225	3,065,633	3,768,858	6,078,679
Other	11	-	71,757	71,757	-
Total		910,733	3,137,390	4,048,123	6,331,684
Net income/(expenditure) for the year/ Net movement in funds		173,050	(330,417)	(157,367)	(59,920)
Reconciliation of funds					
Total funds brought forward		505,565	1,305,739	1,811,304	1,871,224
Total funds carried forward		678,615	975,322	1,653,937	1,811,304

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

BALANCE SHEET

AS AT 31 DECEMBER 2020

	Notes	2020		2019	
		£	£	£	£
Fixed assets					
Tangible assets	14		41,523		51,150
Current assets					
Stocks	15	38,697		30,514	
Debtors	16	3,105,582		2,781,938	
Cash at bank and in hand		3,926,525		2,776,343	
		<u>7,070,804</u>		<u>5,588,795</u>	
Liabilities					
Creditors: amounts falling due within one year	17	(3,053,855)		(1,743,072)	
Net current assets			4,016,949		3,845,723
Total assets less current liabilities			<u>4,058,472</u>		<u>3,896,873</u>
Creditors: amounts falling due after more than one year	18		(2,404,535)		(2,085,569)
Total net assets			<u>1,653,937</u>		<u>1,811,304</u>
The funds of the charity					
Restricted funds	21		975,322		1,305,739
Unrestricted funds	22		678,615		505,565
Total charity funds			<u>1,653,937</u>		<u>1,811,304</u>

The financial statements were approved and authorised for issue by the board of trustees on 12 July 2021 and are signed on its behalf by:

David Oxnam (Chair of Board of Trustees)

Trustee

The notes on pages 17 - 33 form part of these financial statements.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	2020 £	£	2019 £	£
Cash flows from operating activities					
Cash generated from operations	27	1,148,161		278,848	
Investing activities					
Purchase of tangible fixed assets		-		(53,151)	
Investment income received		2,021		8,841	
Net cash generated from/(used in) investing activities			2,021		(44,310)
Net cash used in financing activities			-		-
Net increase in cash and cash equivalents		1,150,182		234,538	
Cash and cash equivalents at beginning of year		2,776,343		2,541,805	
Cash and cash equivalents at end of year		<u>3,926,525</u>		<u>2,776,343</u>	

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

1 Accounting policies

Charity information

The Children's Cancer and Leukaemia Group is governed by its Constitution.

1.1 Basis of preparation

The charity is a public benefit entity as defined by FRS102. These financial statements have been prepared in accordance with: The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Designated funds are unrestricted funds of the charity that the trustees have decided at their discretion to set aside for specific purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

For legacies, income is recognised and included in the financial statements when all of the following criteria are met:

- the charity has entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Where legacies have been notified to the charity but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

1 Accounting policies

(Continued)

Donated facilities and donated services are recognised as income at their fair value when their economic benefit is probable, it can be measured reliably and the charity has control over the item. Fair value is determined on the basis of the value of the gift to the charity. For example the amount the charity would be willing to pay in the open market for such facilities and services. A corresponding amount is recognised in expenditure.

Government grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Income from charitable activities includes income received from grants, registration fees for meetings, member subscriptions and publication payments. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Investment income is earned through holding assets for investment purposes. It comprises bank interest and is recognised on an accruals basis.

1.5 Expenditure recognition

All expenditure, including the awarding of grants, is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Costs of raising funds includes costs incurred in seeking donations, grants and legacies, website costs and advertising.
- Expenditure on charitable activities includes research, educational activities and professional association activities to further the delivery of the objectives of the charity.
- Other expenditure includes wages and salaries covered by income from the Coronavirus Job Retention Scheme.

1.6 Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure in line with the objectives of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 10.

1.7 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Computer equipment, furniture and fixtures 5-10 years

1.8 Stocks

Stocks include merchandise stock and educational literature. Stocks that are held for resale are stated at the lower of cost and estimated selling price. Stocks held for distribution as part of the charity's activities are valued at their service potential, which the charity considers to be the cost of the materials.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

1 Accounting policies

(Continued)

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.10 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities.

1.11 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any key sources of estimates or uncertainty that have a significant effect on the amounts recognised in the financial statements.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

3 Income from donations and legacies

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Unrestricted funds 2019 £	Restricted funds 2019 £	Total 2019 £
Donations	372,572	432,458	805,030	445,686	545,144	990,830
Legacies	425,000	-	425,000	117,452	-	117,452
Government grants	-	71,757	71,757	-	-	-
Donated goods and services	-	-	-	22,977	-	22,977
	<u>797,572</u>	<u>504,215</u>	<u>1,301,787</u>	<u>586,115</u>	<u>545,144</u>	<u>1,131,259</u>

4 Income from charitable activities

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Unrestricted funds 2019 £	Restricted funds 2019 £	Total 2019 £
Registration fees for meetings	64,709	7,119	71,828	152,486	13,723	166,209
Member subscriptions and publication payments	159,481	-	159,481	149,190	-	149,190
Grant income for research and operations	60,000	2,295,639	2,355,639	73,000	4,743,265	4,816,265
	<u>284,190</u>	<u>2,302,758</u>	<u>2,586,948</u>	<u>374,676</u>	<u>4,756,988</u>	<u>5,131,664</u>

5 Income from investments

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Unrestricted funds 2019 £	Restricted funds 2019 £	Total 2019 £
Interest	2,021	-	2,021	8,841	-	8,841
	<u>2,021</u>	<u>-</u>	<u>2,021</u>	<u>8,841</u>	<u>-</u>	<u>8,841</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

6 Expenditure on raising funds

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Unrestricted funds 2019 £	Restricted funds 2019 £	Total 2019 £
<u>Costs of raising funds</u>						
Virgin Money Giving deductions	11,703	-	11,703	11,195	-	11,195
Website	3,792	-	3,792	2,588	-	2,588
Fundraising, marketing and publicity costs	59,035	-	59,035	112,868	-	112,868
Support costs (note 10)	132,978	-	132,978	126,354	-	126,354
	<u>207,508</u>	<u>-</u>	<u>207,508</u>	<u>253,005</u>	<u>-</u>	<u>253,005</u>

7 Expenditure on charitable activities

	Activities undertaken directly Note 8 £	Grant funding Note 9 £	Support Costs Note 10 £	Total 2020 £	Total 2019 £
Support for research	36,541	3,025,744	137,930	3,200,215	5,399,284
Information for patients and families	36,853	-	205,874	242,727	240,810
Improving treatment and care	108,683	-	217,233	325,916	438,585
	<u>182,077</u>	<u>3,025,744</u>	<u>561,037</u>	<u>3,768,858</u>	<u>6,078,679</u>
Unrestricted funds				703,225	836,231
Restricted funds				3,065,633	5,242,448
				<u>3,768,858</u>	<u>6,078,679</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

8 Expenditure on activities undertaken directly

	Support for research	Information for patients and families	Improving treatment and care	Total 2020	Total 2019
	£	£	£	£	£
Staff costs	17,020	-	-	17,020	3,466
Other tumour specific expenditure	15,729	-	-	15,729	59,795
Contact magazine expenses	-	18,680	-	18,680	9,760
Other publication expenses	-	12,484	-	12,484	35,587
Website	3,792	5,689	5,688	15,169	10,124
Cost of meetings	-	-	81,017	81,017	193,660
Travel expenses	-	-	4,870	4,870	17,887
Other expenses	-	-	17,108	17,108	27,311
	<u>36,541</u>	<u>36,853</u>	<u>108,683</u>	<u>182,077</u>	<u>357,590</u>

9 Expenditure on grant funding

	Support for research	Information for patients and families	Improving treatment and care	Total 2020	Total 2019
	£	£	£	£	£
Grants to institutions:					
University of Birmingham	166,952	-	-	166,952	481,477
University of Surrey	9,844	-	-	9,844	50,286
Newcastle University	74,582	-	-	74,582	500,944
UCL Institute of Child Health	424,623	-	-	424,623	562,149
University of Sheffield	206,625	-	-	206,625	72,656
University of Nottingham	255,841	-	-	255,841	1,302,800
University of Ulster	216,108	-	-	216,108	74,933
University of Bristol	-	-	-	-	198,557
Queen's University Belfast	-	-	-	-	74,997
Great Ormond Street	14,954	-	-	14,954	170,366
University of Southampton	245,079	-	-	245,079	111,236
University Hospital of Wales	-	-	-	-	71,490
Genome Research Limited	-	-	-	-	950,820
University of Glasgow	439,610	-	-	439,610	98,793
University of York	105,027	-	-	105,027	-
University of Cambridge	136,392	-	-	136,392	-
Institute of Cancer Research	299,236	-	-	299,236	275,103
University of Leeds	110,775	-	-	110,775	205,715
University of Manchester	-	-	-	-	3,000
University of Portsmouth	100,901	-	-	100,901	-
University of Oxford	219,195	-	-	219,195	-
	<u>3,025,744</u>	<u>-</u>	<u>-</u>	<u>3,025,744</u>	<u>5,205,322</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

9 Expenditure on grant funding (Continued)

The charity awards grants for specific research projects to various institutions, as part of their charitable activities.

10 Expenditure on support costs

	Basis of allocation	2020 £	2019 £
Staff costs	*1	505,149	456,598
Depreciation & loss on disposal	*1	9,627	39,760
Occupancy expenses	*1	131,841	97,589
Postage	*1	12,275	20,265
Staff training	*1	6,000	6,985
Professional fees	*1 / *2	29,123	20,924
		<u>694,015</u>	<u>642,121</u>
Analysed between			
Trading		132,978	126,354
Charitable activities		561,037	515,767
		<u>694,015</u>	<u>642,121</u>

*1 Support costs, excluding governance costs, have been allocated as follows:

<i>Cost of raising funds</i>	20% (2019 - 20%)
<i>Charitable activities</i>	
Support for research	20% (2019 - 20%)
Information for patients and families	30% (2019 - 30%)
Improving treatment and care	30% (2019 - 30%)

*2 Professional fees include governance costs of £29,123 (2019 - £10,352). Governance costs have been allocated as follows:

<i>Charitable activities</i>	
Support for research	17% (2019 - 17%)
Information for patients and families	22% (2019 - 22%)
Improving treatment and care	61% (2019 - 61%)

The amount charged to the SOFA in respect of auditor's remuneration was:

- Statutory audit £8,580 (2019 - £8,580),
- Preparation of cessation accounts for old unincorporated charity, prior to re-registering as a CIO £5,820.

11 Other expenditure

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Unrestricted funds 2019 £	Restricted funds 2019 £	Total 2019 £
Wages	-	71,757	71,757	-	-	-
	<u>-</u>	<u>71,757</u>	<u>71,757</u>	<u>-</u>	<u>-</u>	<u>-</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

12 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits during the year. 1 of the trustees was reimbursed for travel expenses amounting to £63 (2019 - 3 trustees were reimbursed for travel expenses of £1,757).

13 Employees

The average monthly number of employees during the year was:

	2020	2019
	Number	Number
Total	18	15
	<u> </u>	<u> </u>
Employment costs	2020	2019
	£	£
Wages and salaries	499,229	176,828
Social security costs	45,200	16,621
Other pension costs	49,497	17,613
Recharges from the University of Leicester	-	249,002
	<u> </u>	<u> </u>
	<u>593,926</u>	<u>460,064</u>

Staff working for the charity were employed directly by the University of Leicester until 1 August 2019. Their gross salary and pension costs were recharged to the charity.

The number of employees whose annual remuneration was £60,000 or more were:

	2020	2019
	Number	Number
£60,001 - £70,000	-	1
£80,001 - £90,000	1	-
	<u> </u>	<u> </u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

14 Tangible fixed assets

	Computer equipment, furniture and fixtures £	Total £
Cost		
At 1 January 2020	63,202	63,202
At 31 December 2020	63,202	63,202
Depreciation and impairment		
At 1 January 2020	12,052	12,052
Depreciation charged in the year	9,627	9,627
At 31 December 2020	21,679	21,679
Carrying amount		
At 31 December 2020	41,523	41,523
At 31 December 2019	51,150	51,150

15 Stocks

	2020 £	2019 £
Merchandise stock	23,564	10,659
Educational literature	15,133	19,855
	38,697	30,514

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

16 Debtors

	2020	2019
	£	£
Amounts falling due within one year:		
Trade debtors	10,152	81,352
Grant debtors	1,661,876	1,045,933
Rent deposit	16,200	16,200
Prepayments and accrued income	140,633	200,511
Accrued legacy income	445,000	65,000
	<u>2,273,861</u>	<u>1,408,996</u>

	2020	2019
	£	£
Amounts falling due after more than one year:		
Grant debtors	<u>831,721</u>	<u>1,372,942</u>
Total debtors	<u>3,105,582</u>	<u>2,781,938</u>

17 Creditors: amounts falling due within one year

	Notes	2020	2019
		£	£
Deferred income	19	-	19,095
Trade creditors		20,902	23,115
Grant creditors		2,987,921	1,681,177
Accruals		45,032	19,685
		<u>3,053,855</u>	<u>1,743,072</u>

18 Creditors: amounts falling due after more than one year

	2020	2019
	£	£
Grant creditors	<u>2,404,535</u>	<u>2,085,569</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

19 Deferred income

	2020 £	2019 £
Total deferred income at 1 January 2020	19,095	7,410
Amounts released into incoming resources	(19,095)	(7,410)
Amounts deferred in year	-	19,095
	<hr/>	<hr/>
Total deferred income at 31 December 2020	-	19,095
	<hr/> <hr/>	<hr/> <hr/>

Deferred income comprises advanced registration fees for meetings.

20 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees.

The amount recognised in unrestricted expenditure was £49,497 (2019 - £24,231).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

21 Restricted funds

The income funds of the charity include restricted funds which comprise the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at 1 January 2020 £	Movement in funds		Balance at 31 December 2020 £
		Income £	Expenditure £	
Tumour specific funds	930,227	425,593	(611,172)	744,648
CCLG Prize	304	-	(250)	54
General research fund	2,982	6,387	(5,429)	3,940
Adam Hay fund	11,861	120	(999)	10,982
CCLG Senior Members Group	7	-	-	7
PODC	3,317	1,462	(1,441)	3,338
POTG	2,139	-	-	2,139
The Little Princess Trust fund	6,200	2,248,667	(2,248,667)	6,200
Treatment Guidelines fund	18,661	-	(226)	18,435
TYAC Lisa Thaxter	45,412	-	-	45,412
Child Cancer Smart	174,944	-	(101,444)	73,500
PORT	200	200	-	400
CCLG Research Network Partner Charity	72,656	46,972	(83,300)	36,328
CYP Coalition Activity	9,034	-	(9,034)	-
Neuroblastoma Nursing Group	6,000	4,500	-	10,500
Childhood Cancer Priority Setting Partnership	21,580	-	(3,671)	17,909
PODC - Iraq Fund	215	1,315	-	1,530
Coronavirus Job Retention Scheme	-	71,757	(71,757)	-
	<u>1,305,739</u>	<u>2,806,973</u>	<u>(3,137,390)</u>	<u>975,322</u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

21 Restricted funds

(Continued)

	Balance at 1 January 2019 £	Movement in funds		Balance at 31 December 2019 £
		Income £	Expenditure £	
Tumour specific funds	985,978	543,783	(599,534)	930,227
CCLG Prize	354	-	(50)	304
General research fund	2,122	860	-	2,982
Adam Hay fund	11,776	220	(135)	11,861
CCLG Senior Members Group	7	-	-	7
PODC	3,562	1,851	(2,096)	3,317
POTG	6,231	6,679	(10,771)	2,139
The Little Princess Trust fund	6,165	4,507,368	(4,507,333)	6,200
Treatment Guidelines fund	18,948	-	(287)	18,661
TYAC Lisa Thaxter	45,712	-	(300)	45,412
Child Cancer Smart	165,000	20,000	(10,056)	174,944
PORT	200	-	-	200
CCLG Research Network Partner Charity	-	152,656	(80,000)	72,656
CYP Coalition Activity	-	12,500	(3,466)	9,034
Neuroblastoma Nursing Group	-	6,000	-	6,000
Childhood Cancer Priority Setting Partnership	-	50,000	(28,420)	21,580
PODC - Iraq Fund	-	215	-	215
	<u>1,246,055</u>	<u>5,302,132</u>	<u>(5,242,448)</u>	<u>1,305,739</u>

Tumour specific funds

Represents income received from donors with a specific request that the funds are used in support of grants for a particular tumour type.

CCLG Prize

Represents income received from donors to fund the CCLG Prize.

General research fund

Represents income received from donors with a specific request that the funds are used for research purposes.

Adam Hay fund

This fund has been established to continue work done by the Adam Hat's charity (which merged with CCLG in 2011) in neuroblastoma research and psychological support for children and families.

CCLG Senior Members Group

Represents income received from the Senior Members' Group to be used for their activities.

PODC

Represents income received from donors to be used for the Paediatric Oncology in Developing Countries (PODC).

POTG

Represents income received from donors to be used for the Paediatric Oncology Trainees' Group (POTG).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

21 Restricted funds

(Continued)

The Little Princess Trust fund

Represents income received from The Little Princess Trust to fund future instalments of research grants awarded.

Treatment Guidelines fund

Represents a grant received for the development of rare endocrine tumour guidelines.

TYAC Lisa Thaxter

Represents income received for providing and supporting education and training to professionals working in the field of teenage and young adult cancer. This was previously a restricted fund in TYAC and has transferred to CCLG as part of the closure of TYAC, with the same restrictions maintained.

Child Cancer Smart

Represents income received for a research programme, guideline development and awareness raising focusing on earlier diagnosis of childhood cancer.

PORT

Represents income received for the Paediatric Oncology Reference Team, a group of parents of children with cancer who review clinical trial and other research information to ensure it is appropriate for children with cancer and their families.

CCLG Research Network Partner Charity

Represents income research from other charities to fund research projects.

CYP Coalition Activity

Represents income received from charity members of the Children and Young People's Cancer Coalition for the costs of providing the Coalition secretariat.

Neuroblastoma Nursing Group

Represents income received to support the costs of running the national neuroblastoma nursing group, a group of CCLG member nurses with a special interest in neuroblastoma.

Childhood Cancer Priority Setting Partnership

Represents grant income received to support the James Lind Alliance supported Childhood Cancer Priority Setting Partnership being led by CCLG.

PODC - Iraq Fund

Represents donations received to specifically support work to improve the treatment and care of children with cancer in Iraq.

Coronavirus Job Retention Scheme

Represents amounts received from the Government to cover staff costs during the Covid-19 pandemic.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

22 Unrestricted funds

The unrestricted funds of the charity include general funds and designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	Balance at 1 January 2020 £	Movement in funds			Balance at 31 December 2020 £
		Income £	Expenditure £	Transfers £	
General funds	505,565	1,083,783	(910,733)	-	678,615

	Balance at 1 January 2019 £	Movement in funds			Balance at 31 December 2019 £
		Income £	Expenditure £	Transfers £	
General funds	622,964	969,632	(1,089,236)	2,205	505,565
Treatment Guidelines fund	2,205	-	-	(2,205)	-
	625,169	969,632	(1,089,236)	-	505,565

Treatment Guidelines fund

Represents a sum set aside by the trustees for the development of rare endocrine tumour guidelines.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

23 Analysis of net assets between funds

	Unrestricted Funds 2020 £	Restricted Funds 2020 £	Total 2020 £
Fund balances at 31 December 2020 are represented by:			
Tangible assets	41,523	-	41,523
Current assets/(liabilities)	637,092	3,379,857	4,016,949
Long term liabilities	-	(2,404,535)	(2,404,535)
	<u>678,615</u>	<u>975,322</u>	<u>1,653,937</u>
	<u><u>678,615</u></u>	<u><u>975,322</u></u>	<u><u>1,653,937</u></u>
	Unrestricted Funds 2019 £	Restricted Funds 2019 £	Total 2019 £
Fund balances at 31 December 2019 are represented by:			
Tangible assets	51,150	-	51,150
Current assets/(liabilities)	454,415	3,391,308	3,845,723
Long term liabilities	-	(2,085,569)	(2,085,569)
	<u>505,565</u>	<u>1,305,739</u>	<u>1,811,304</u>
	<u><u>505,565</u></u>	<u><u>1,305,739</u></u>	<u><u>1,811,304</u></u>

24 Events after the reporting date

Legacy income

Legacy income amounting to £172,000 was notified and received after 31 December 2020 and has not been recognised in these accounts.

COVID-19

The ongoing COVID-19 pandemic resulted in another national lockdown in January 2021. Therefore income from fundraising events, meetings and conferences has remained lower than pre-pandemic levels. The charity has continued to use the coronavirus job retention scheme during the period. More detail is included in the trustees report on how COVID-19 has impacted the charity and the measures the trustees have taken to try and mitigate its impact.

25 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2020 £	2019 £
Within one year	27,530	27,530
Between two and five years	75,707	103,237
	<u>103,237</u>	<u>130,767</u>
	<u><u>103,237</u></u>	<u><u>130,767</u></u>

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

25 Operating lease commitments

(Continued)

Amounts recognised in the SOFA as an expense during the period in respect of operating lease arrangements are £27,530 (2019 - £6,882).

26 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel, is as follows.

	2020 £	2019 £
Aggregate compensation	161,873	99,697

There have been no other related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 12 to the financial statements.

27 Cash generated from operations

	2020 £	2019 £
Deficit for the year	(157,367)	(59,920)
Adjustments for:		
Investment income recognised in statement of financial activities	(2,021)	(8,841)
(Gain)/loss on disposal of tangible fixed assets	-	30,133
Depreciation and impairment of tangible fixed assets	9,627	9,627
Movements in working capital:		
(Increase)/decrease in stocks	(8,183)	24,915
(Increase) in debtors	(323,644)	(2,671,531)
Increase in creditors	1,648,844	2,942,780
(Decrease)/increase in deferred income	(19,095)	11,685
Cash generated from operations	1,148,161	278,848

28 Analysis of changes in net funds

During the year the charity had no borrowings or obligations under finance leases. The changes in net funds of the charity therefore solely comprise of cash and cash equivalents.